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Abstract 
High-grade serous (HGS) carcinoma, the most prevalent and most deadly subtype of 
epithelial ovarian cancer (EOC), presents unique therapeutic challenges since the majority of 
cases are diagnosed at advanced, metastatic stage. At this point widespread intraperitoneal 
metastatic lesions are numerous, which is why models that recapitulate disease dissemination 
are critical to uncover novel therapeutic targets. One of the initiating events in ovarian cancer 
metastasis is shedding from the primary tumour into the peritoneal cavity where cells must 
survive in suspension in order to seed secondary tumours. This non-adherent population of 
cells exists as multicellular aggregates, or spheroids; data from our lab has demonstrated that 
cells within spheroids are dormant, yet are readily alter their phenotype upon reattachment to 
an adherent substratum. To further explore the pathobiology of ovarian cancer spheroids, my 
thesis work describes the functional characterization of two different signalling pathways—
bone morphogenetic protein (BMP), and the liver kinase B1 (LKB1)/AMP-activated protein 
kinase (AMPK)—which mediate distinct and important aspects of spheroid formation and 
reattachment. Activated BMP signalling resulted in smaller, loosely-aggregated spheroids, 
which were more readily able to reattach and disperse. These phenotypic alterations observed 
as a result of active BMP signalling were mediated, at least in part, by cooperation with the 
AKT signalling pathway. These studies implicate inhibition of BMP and AKT signalling as 
potential strategies for therapeutic targeting of reattaching spheroids, which is critical for the 
formation of secondary metastatic lesions. Other work in our lab implicated the 
downregulation of AKT signalling in spheroid formation-induced dormancy. In an attempt to 
uncover additional pathways promoting the dormant phenotype of ovarian cancer spheroids, I 
investigated the LKB1/AMPK signalling cascade given its ability to alter cellular metabolism 
in response to nutrient and energy availability. Despite a dramatic enhancement in AMPK 
activity observed in ovarian cancer spheroids, targeted knockdown had no effect on viability 
of cells in this context. However, knockdown of its upstream kinase, LKB1, revealed a 
dramatic decrease in ovarian cancer spheroid viability, suggesting a role for this kinase in 
mediating anoikis-resistance in an AMPK-independent manner. Taken together, my results 
have uncovered two distinct and important signalling pathways that regulate unique aspects 
of spheroid formation, cell survival, and reattachment. By understanding the molecular 
mechanisms used by ovarian cancer spheroids to survive during dissemination and promote 
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secondary metastasis, my work has uncovered additional therapeutic targets for the potential 
treatment of advanced-stage ovarian cancer. 
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Chapter 1  
1 Introduction 
1.1  Overview of Chapter 1 
This thesis focuses on examining signalling pathways, which we believe mediate 
important aspects of ovarian cancer spheroid formation and survival. This chapter begins 
with a description of ovarian cancer (Section 1.2) specifically focusing on the origins, 
classification, and mortality associated with this very complex disease. The next section 
(Section 1.3) focuses on the multicellular spheroid as an in vitro model of ovarian cancer 
metastasis and the unique properties that spheroid cells acquire to avoid anoikis, 
including induction of cellular quiescence, altered cellular metabolism, and altered 
adhesion characteristics. The bone morphogenetic (BMP) (Section 1.4) and adenosine 
monophosphate-activated protein kinase (AMPK) (Section 1.5) signalling pathways will 
be described, and their relevance to ovarian cancer given my data in Chapters 2 and 3 
showing that these pathways are important to the formation and survival of ovarian 
cancer spheroids. The final section provides rationale for our studies (Section 1.6) and 
outlines the studies presented in this thesis.  
1.2  Ovarian Cancer 
1.2.1  Ovarian Cancer Classification and Genetics  
 Ovarian cancers can be broadly characterized as epithelial and non-epithelial. 
Non-epithelial ovarian cancers, which are not the subject of my research, include 
granulosa cell tumours, fibrothecomas, teratomas and yolk sac tumours1. The most 
common form of ovarian cancer however is epithelial, comprising over 90% of cases2.  
Epithelial Ovarian Cancer (EOC) is not a single entity but rather consists of 
several subtypes that are distinguishable by unique histology and molecular 
aberrations3,4. The four main subtypes of ovarian cancer (mucinous, endometrioid, clear-
cell and serous) can be further characterized as benign, malignant or borderline and 
classified as low or high-grade5. Each of these histologic subtypes has distinct clinical 
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characteristics and rates of occurrence. Serous carcinomas are the most common subtype 
and are typically high-grade neoplasms, which initially respond well to treatment with 
platinum/taxane-based chemotherapy but recur in the majority of cases6,7. Endometrioid 
and mucinous carcinomas are much less common (10% and 3-4% respectively) and are 
typically low-grade lesions with a relatively indolent course of progression, allowing 
them to be diagnosed at early stage8,9. Clear-cell carcinomas account for 10% of all cases 
of ovarian cancer and typically do not respond to conventional chemotherapeutics, 
resulting in a poor outcome for most patients10,11. 
In 2004, a dualistic model for the classification of ovarian cancer was proposed, 
which incorporated histopathological discoveries, clinical and molecular genetic findings 
12. In this model, the various types of ovarian cancer are broadly separated into two 
categories. Type I tumours include all of the major histotypes (serous, endometrioid, 
mucinous and clear-cell) but are low-grade and typically slow growing10,13. These 
tumours are associated with mutations in v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), 
phosphatase and tensin homolog (PTEN), phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA), catenin (cadherin-associated protein), beta 1 
(CTNNB1), and AT-rich interactive domain-containing protein 1A (ARID1A)12,14. Type 
II tumours, on the other hand, are comprised almost exclusively of high-grade serous 
carcinomas but also include high-grade endometrioid, undifferentiated carcinomas and 
carcinosarcomas13. These tumours are aggressive in nature and often present at an 
advanced, metastatic stage, owing to their relatively poor prognosis15. Type II tumours 
display a high degree of chromosomal aberrations and genomic instability unlike type I 
tumours which are relatively genetically stable13. An overwhelming proportion of these 
type II tumours (~95%) have mutated TP5316-19(Table 1.1). This new classification takes 
into account the idea that low and high-grade ovarian tumours of the same subtype are 
not a spectrum of disease, but rather, two distinct entities with different origins, mutations 
and clinical course1,20,21.  
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Table 1.1: Classification of type I and type II ovarian carcinomas 
 
 
 
 
 
 
 
 
 
!
! Subtype! Precursor! Frequent!
Mutation(s)!
Level!of!genomic!
instability!
!
!
!
!
!
Type!I!
Low?grade!
serous!
Serous!borderline!
tumour!
KRAS,&BRAF& low!
Low?grade!
endometrioid!
Endometriosis! CTNNB1,&
PTEN,&
ARID1A&
low!
Clear?cell! Endometriosis! PIK3CA,&
ARID1A,&
FBXW74&
low!
Mucinous! Mucinous!
borderline!tumour!
(Gastrointestinal)!
KRAS& low!
!
!
Type!II!
High?grade!
serous!
Fallopian!tube! TP53,&
BRCA1/2&
High!
High?grade!
endometrioid!
Unknown! TP53& High!
Undifferentiated! Unknown! Unknown! Unknown!
Carcinosarcoma! Unknown! TP53& Unknown!*adapted!from!Nik!et.!al.!(2013)!and!references!therein!
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1.2.2  Origins of Ovarian Cancer  
Many epithelial malignancies have well-defined precursor lesions and cells of 
origin1. This is not the case for EOC where until recently the origin and pathogenesis of 
this disease remained elusive13. The traditional view assumed that all ovarian cancer 
subtypes share a common site of origin within the ovarian surface epithelium (OSE). This 
is interesting, given the fact that the OSE is not a well-differentiated epithelium, but 
rather a mesothelial layer that originates embryonically from the mesodermally-derived 
coelomic epithelium2. This theory postulates that the process of damage and repair of the 
ovarian surface that occurs as a result of multiple ovulations throughout a woman’s 
reproductive life increases the susceptibility of the OSE to transformation. In addition, 
multiple invaginations of the ovarian surface are also common as women age. These 
invaginations can pinch off over time and become entrapped within the ovarian stroma 
where they form cortical inclusion cysts (CICs). It is hypothesized that the epithelial cells 
lining these cysts undergo metaplasia in response to the hormone-rich environment 
within the ovary, differentiating into a Müllerian-like epithelium that eventually becomes 
dysplastic leading to ovarian carcinoma2,5.  Although this model is consistent with 
epidemiologic evidence demonstrating that decreased ovulation is significantly correlated 
with a decreased risk of developing ovarian cancer, it does have many limitations22. One 
of the major drawbacks to this model is it does not address the significantly divergent 
phenotypes and genotypes that exist between tumour subtypes5.   
As technology has improved, so has our understanding of ovarian cancer where it 
is now established that it is a complex and heterogeneous disease without a single cell of 
origin1. Many studies have provided strong evidence indicating that endometriosis is the 
precursor lesion for clear-cell and endometrioid carcinomas23-30. Additionally, mucinous 
carcinomas have been shown to originate from appendicekal and other gastrointestinal 
origins1. In the late 1990s to early 2000s, pathologists identified occult non-invasive and 
invasive carcinomas in the fimbria of fallopian tubes collected from prophylactic 
salpingo-oophorectomy specimens in BRCA1/2 mutation carriers31-36. Based on this, Piek 
and colleagues37 proposed a model whereby occult tubal carcinomas shed malignant cells 
that implant and grow on the ovary, mimicking primary ovarian cancer. The hypothesis 
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that the fallopian tube is the primary site of high-grade serous carcinomas has since been 
supported by multiple studies38-41. In 2007, for example, a study performed on women 
with high-grade serous carcinomas (HGSCs) who did not harbor a BRCA mutation 
reported the presence of serous tubal intraepithelial carcinomas (STICs) in 48% of 
patients41. Additionally, studies matching STICs and HGSCs from the same patient not 
only reveal TP53 mutations in 92% of STICs but also show that these mutations match 
the mutation found in the ovarian carcinoma13. Most recently, the Drapkin and Dinulescu 
labs reported the development of an HGSC murine tumour model emanating specifically 
from the murine fallopian tube (oviduct) even after hysterectomy and oophorectomy42. 
This study provides additional support for the fallopian tube and STICs as the origin of 
HGSC. This new model defining the origin of high-grade serous ovarian cancer will open 
up new avenues for early detection and intervention as we gain a better understanding of 
STICs and their role in carcinogenesis. In fact, it may no longer be appropriate to 
categorize HGSCs as ‘ovarian cancer’ since it seems as though the ovary is simply a 
favourable microenvironment for these cancer cells to spread and grow.  
1.2.3  Ovarian cancer treatment and prognosis 
Ovarian cancer is the most lethal gynecologic malignancy in the western world, 
the overall survival of which has remained unchanged for more than 50 years13,43. 
Ovarian cancers that are diagnosed at an early-stage, before they have spread beyond the 
ovary (stage I) have a 90% cure rate through surgical resection. Unfortunately, the 
majority of cases (>75%) are diagnosed once the disease has metastasized to the pelvic 
organs, abdomen (stage III) or to distant sites (stage IV), at which point the chance of 
cure decreases substantially44.  
The high mortality rate associated with this disease is not only due to the lack of 
screening methods for early detection but also to the lack of effective therapies for 
advanced stage disease. Despite the high degree of heterogeneity associated with ovarian 
tumours, the majority of ovarian cancer patients are treated with cytoreductive surgery 
followed by platinum and taxane-based chemotherapy5. Although most tumours initially 
respond to chemotherapeutics, approximately 70% will develop platinum resistance and 
succumb to recurrent disease45. This results in a dismal five-year survival rate for 
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advanced-stage ovarian cancer patients of only 30%46. It is becoming obvious as we gain 
a better understanding of the molecular underpinnings of this complex disease that a 
“blanket approach” to treatment is not going be enough. Rather, we must use our 
knowledge of the molecular genetic characteristics of individual tumours to focus our 
efforts into developing more targeted therapeutics5.  
1.2.4  Ovarian cancer metastasis 
 Ovarian cancer metastasis is unique in that it rarely occurs through the 
bloodstream as is common for other solid tumours3. Instead, single cells or small clusters 
of cells are shed into the peritoneal cavity where they subsequently adhere to mesothelial 
cells of various abdominal organs to establish secondary lesions47-49. Since there is no 
anatomical barrier to prevent metastasis, tumour implants become widespread, blocking 
lymphatic vessels, and allowing ascites fluid to accumulate from leaky vasculature 44. 
This peritoneal ascites fluid is a relatively unique environment in which tumour cells 
must survive in suspension4. The composition of ascites fluid from ovarian cancer 
patients has been shown to vary considerably; in fact, one study showed higher 
proportions of red blood cells when the fluid had rapidly accumulated50. A typical 
distribution of the cellular components of ascites fluid consists of 37% lymphocytes, 29% 
mesothelial cells, 32% macrophages, and <0.1% adenocarcinoma cells51. This fluid is a 
convenient source of tumour cells because it is routinely removed by paracentesis and is 
often of high volume facilitating isolation of tumour cells for study into the unique 
biological characteristics of cancer cells from different patients.   
1.3  Multicellular spheroids 
1.3.1  Spheroids as an in vitro model of metastasis 
Multicellular spheroids have been recognized as a valuable tool in the fields of 
cell and developmental biology for over 50 years52-55. It wasn’t until the 1970s, however, 
that Sutherland and colleagues established multicellular spheroids as a valuable in vitro 
model with which to study tumour biology56-58. Since then, tumour spheroids have been 
widely used to recapitulate the functional and microenvironmental features of human 
tumour tissue in order to study biological processes such as proliferation, metabolism, 
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differentiation, cell death, invasion, angiogenesis and immune response in an in vitro 
setting59-66. Spheroids exhibit many histologic similarities to their solid tumour 
counterparts including areas of necrosis as well as expression of ECM components67.  
1.3.1.1  ECM and cell adhesion 
 The ECM is a complex network made up of several proteins and polysaccharides 
such as fibronectin, collagen, laminin, hyaluronate, heparin sulfate, and elastin. These 
components are produced and secreted by cells, the combination of which depends on the 
functional requirements of a particular tissue68.  
The link between cell survival and adhesion to the extracellular matrix (ECM) has 
been well-established in the literature69-72. Anoikis, from the Greek word meaning 
“homelessness”, refers to apoptosis induced by loss of cell adhesion to ECM73. This is an 
important physiological process as it prevents cells from reattaching to new matrices and 
growing in a dysplastic manner74. The ability to overcome anoikis has important 
implications for metastatic cancer. In fact, cancer cell lines are significantly less sensitive 
to anoikis than normal epithelial cells and in many cases have developed anchorage-
independence, meaning they are able to survive and proliferate without attachment to 
ECM75-78. Integrins are important mediators of anchorage-independent survival that 
through their interaction with the ECM, stimulate numerous signalling pathways capable 
of modulating organization of the cytoskeleton, cell motility, and cell growth79-81. In 
addition to integrin-associated signalling molecules, many cancer cells also have 
alterations in cell-cell adhesion molecules, protein kinases, and cell cycle regulators. This 
also contributes to anoikis-resistance, allowing these cells to disseminate and become 
metastatic77,78,82-84. Epithelial cadherin (E-Cadherin), for example, has been shown to be a 
crucial mediator of cell-cell adhesion in multicellular spheroids. Oral squamous 
carcinoma cells, as well as mammary and prostate epithelial cells require E-cadherin in 
order to avoid anoikis in suspension85,86. These studies as well as others have shown that 
part of the pro-survival function of E-cadherin involves the induction of quiescence, or 
reversible exit from the cell cycle. When E-cadherin is overexpressed in the EMT/6 
breast cancer cell line, which lacks endogenous E-cadherin expression, cells form 
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compact spheroids and the proportion of dividing cells is greatly reduced. This exit from 
the cell cycle is mediated by induction of p27Kip1 activity in E-cadherin expressing cells87. 
 Many tumour cells are not able to survive under anchorage-independent 
conditions if they remain as single cells. Rather, single cells must aggregate in order to 
avoid anoikis. In this context, survival signals arising from cell-cell contact substitute 
signals that normally come from matrix adhesion. Understanding the complex 
relationship between ECM components and cell-cell contact in multicellular spheroids is 
relevant in the field of tumour biology as they may more closely recapitulate the in vivo 
situation when tumour cells are detached from their tissue of origin68. In fact, the ECM 
profile and organization of glioma, osteosarcoma and melanoma spheroids have been 
shown to more closely resemble in vivo tumours than that of conventional monolayer 
cultures88-90. Additional studies in human epidermoid and colorectal carcinoma spheroids 
revealed a similar pattern with respect to integrin expression, whereby the expression 
pattern of various integrins observed in multicellular spheroids closely resembled that of 
solid tumours91,92. These results provide support for the use of multicellular spheroids as 
in vitro models with which to study the contribution of cell-matrix and cell-cell contacts 
in anoikis resistance.  
1.3.1.2  Response to cytotoxic drugs 
 Many studies on multicellular spheroids have focused on the response of these 
structures to various tumour therapies93-108. The most extensively studied phenomenon is 
the response of spheroids to ionizing radiation. One of the most interesting findings from 
these studies was the observation that cells within multicellular spheroids are more 
resistant to ionizing radiation than monolayer cultures109-111. This was some of the first 
evidence to support the idea that spheroids mimic the in vivo response of cancer cells to 
treatment more closely than conventional monolayer cell cultures67.  
 Multicellular spheroids remain an attractive model with which to examine the role 
of the tumour microenvironment on response to various therapeutic strategies. These 
structures maintain many of the metabolic and proliferative gradients that occur as a 
result of cellular interactions in a 3D context112. In fact, spatial variations in cellular 
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proliferation are quite common in solid tumours, where cellular proliferation is highest in 
areas adjacent to microvessels113-116. Decreased proliferation in areas with lower oxygen 
and nutrient concentrations is often associated with quiescence, reversible exit from the 
cell cycle114,117. These proliferation gradients common to solid tumours have not been 
demonstrated in monolayer cultures, but have been well-documented in multicellular 
spheroids67,118. In fact, cells toward the center of the spheroid exhibit prolonged cell-cycle 
times and often enter a non-proliferating or quiescent state119. Given the fact that the vast 
majority of therapeutics aimed at cancer cells target rapidly dividing cells, it is not 
surprising that multicellular spheroids are generally more resistant to cytotoxic drugs than 
the same cells in monolayer culture58,120.  
1.3.2  Multicellular spheroids in ovarian cancer 
 Multicellular spheroids are valuable tools for the study of ovarian cancer because, 
as described above, they more closely mimic the characteristics of solid tumours, but also 
because of the unique way ovarian cancer metastasizes. One of the early events in 
ovarian cancer metastasis is the proteinase-mediated shedding of cells from the primary 
tumour into the peritoneal cavity, which has now been elegantly demonstrated in a 
murine model of HGSC4,42,121-123. It is here, suspended within peritoneal ascites fluid, that 
this unique non-adherent population of ovarian cancer cells must respond to a series of 
unique environmental cues in order to survive and metastasize4. It is believed that in 
order to maintain cell-cell contact and avoid anoikis, cells under these conditions 
aggregate to form multicellular spheroids124 (Figure 1.1). When forced into suspension, 
cells spontaneously aggregate as part of their natural survival response. Spheroid 
compaction is mediated by the interaction of key cell adhesion molecules such as 
integrins and cadherins124.  E-cadherin expression, for example, has been shown to be 
lower in cells suspended within ascites fluid as compared to the primary tumour125. This 
loss of E-cadherin is part of a global “cadherin switch” whereby Neural Cadherin (N-
Cadherin) and Placental cadherin (P-cadherin) are upregulated to compensate121,126. This 
switch in cadherin expression is indicative of an epithelial-to-mesenchymal transition 
(EMT), which has been shown to allow cells to survive under hypoxic conditions when 
cells are crowded together127. Integrins have also been shown to be important mediators 
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of survival when cells are in suspension. Ovarian cancer spheroid formation is greatly 
inhibited, for example, when cells are treated with a blocking antibody against β1 
integrin128. Another important attribute of ovarian cancer spheroids is their ability to 
implant on mesothelial-lined peritoneal surfaces such as the peritoneum, omentum and 
pleural surface49. Skubitz and colleagues were the first to model this in vitro, 
demonstrating that ovarian cancer spheroids had the ability to reattach and invade live 
mesothelial cell monolayers48. More recently, the Brugge lab has shown that ovarian 
cancer spheroids use myosin-generated force in order to displace the mesothelial layer of 
cells and gain access to the underlying ECM to promote invasion129.  
 These studies have taken the first steps towards gaining a better understanding of 
ovarian cancer spheroid biology, however, the stresses associated with ECM-detachment 
puts cells under a significant selection pressure. The cells that are able to survive within 
the peritoneal cavity and subsequently metastasize have likely altered many key 
signalling pathways. We have just begun to scratch the surface when it comes to 
understanding the adaptations of cells in this unique environment where they must exist 
in suspension. Since ovarian cancer mortality can be directly attributed to disseminated 
peritoneal mestastasis, it is critical that we identify signalling pathways which are 
important for spheroid formation, survival and reattachment4 
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Figure 1.1: Mechanism of high-grade serous ovarian cancer metastasis. 
During the process of ovarian cancer metastasis, malignant cells are shed from the 
primary tumour into the peritoneal cavity. It is here, suspended within ascites fluid, that 
single-cells and multicellular aggregates (spheroids) disperse throughout the peritoneal 
cavity. Widespread secondary metastatic lesions are formed when cells re-attach to 
mesothelial surfaces throughout the peritoneal cavity. 
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1.4  BMP/TGF-β signalling 
1.4.1  Overview 
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-β 
(TGF-β) superfamily and, as their name suggests, were originally identified based on 
their ability to induce bone and cartilage formation at extraskeletal sites130-132. These 
powerful cytokines have since become recognized for their role in other cellular 
processes such as, differentiation, apoptosis and migration133-180. Given the importance of 
BMP signalling in controlling proliferation and differentiation during development and in 
maintaining and regenerating tissue during adulthood, it is not surprising that this 
pathway has also been shown to play an important role in many types of cancer157,180-187. 
This section will discuss TGF-β/BMP signal transduction, how this pathway is regulated 
as well as its role in various different cancers, including ovarian cancer. 
1.4.2  Pathway activation 
BMP dimers are secreted to the extracellular environment, where they initiate 
signalling by cooperatively binding to two types of serine/threonine kinase receptors 
(type I and type II)188,189. These receptors are separated in the plasma membrane until a 
ligand binds and increases oligomerization, essentially acting as a bridge between the two 
receptors. Both types of receptors are structurally similar consisting of an extracellular 
domain, a single transmembrane-spanning domain, and an intracellular domain with 
serine/threonine kinase activity190. The type II receptors are constitutively active and are 
responsible for transphosphorylating the type I receptors when a signal is present191. This 
phosphorylation occurs on the GS domain (glycine and serine rich domain) which is 
located N-terminal to the serine/threonine kinase domain on the type I receptor (Figure 
1.2). The activated type I receptor is responsible for binding and activating the 
downstream signalling mediators for this pathway, the Smads190,191. 
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Figure 1.2: Activation of Bone Morphogenetic Protein (BMP) signalling. 
Dimeric BMP ligands transduce their signal through a heterotetrameric complex 
composed of type I and type II transmembrane receptors. Following phosphorylation by 
the type II receptor, the type I receptor phosphorylates and  activates Smads 1,5,8, 
allowing them to complex with Smad 4 and translocate to the nucleus to regulate target 
gene expression. Negative regulation of this pathway can occur through extracellular 
antagonists as well as intracellular inhibitory Smads. 
 
 
14 
 
1.4.2.1  Smad protein family 
Eight different Smad proteins have been identified in mammals, each of which 
can be separated into three categories: Receptor-regulated Smads (R-Smads), Common-
mediator Smad, or Inhibitory Smads (I-Smads)192-194.  
The Receptor-regulated Smads or R-Smads are those that interact with the type I 
receptor and are activated by phosphorylation. This interaction with the receptor is 
transient and once phosphorylation occurs, the R-Smad is released to the cytoplasm 
where it is free to form a complex with co-Smad190. The particular Smad that interacts 
with the receptor depends on the type of receptor as well as the ligand that triggers the 
signal. Smad2 and Smad3 transmit the signal from TGF-β, Nodal and activin 
ligands195,196, whereas Smad1, 5 and 8 transduce the signal from BMP ligands197-199. 
The common-mediator Smad, of which there is only one, Smad4, has the ability 
to interact with any R-Smad, forming a heteromeric complex that can translocate to the 
nucleus to affect the expression of target genes191. This complex can be composed of one 
R-Smad bound to Smad4 or two R-Smads, depending on the target gene200. 
The third group of Smads, the inhibitory Smads (I-Smads), is comprised of 
Smad6 and Smad7. These Smads have the ability to modulate signalling by competing 
with R-Smads for binding to either the receptor or Smad4201,202.  
1.4.2.2. TGF-β/BMP receptors 
Seven different type I receptors for the TGF-β family have been identified in 
mammals (activin receptor-like kinases 1-7; Alk 1-7). Of these, type I BMP receptors 
BMPR1A (Alk3) and BMPR1B (Alk6), as well as, type I activin receptor Acvr1 (Alk2) 
activate Smad 1,5, and 8 in response to BMP ligands. The remaining type I receptors 
activate Smad 2 or 3 and are responsible for transducing signal from TGF-β, Activin, or 
Nodal ligands190. Table 1.2 describes the various type I receptors and summarizes their 
expression patterns, their ligand-affinity and downstream signalling targets. 
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The binding preferences of a particular ligand for a type I receptor is determined 
by the presence of the type II receptor203. There are three type II receptors used by BMPs 
in mammals. BMPR-II is specific for BMPs, whereas, ActR-II and ActR-IIB are also 
used by activins and myostatin190.  
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Table 1.2: Type I BMP receptors. 
 
 
 
!
Receptors) Cell)type) Ligands) Smads) References)
BMPR91A)(Alk93)) Ubiquitously!expressed! BMP2,4! 1,5,8! (ten!Dijke,!Yamashita!et!al.!1994;!Dewulf,!Verschueren!et!al.!1995;!Miyazono,!Kamiya!et!al.!2010)!
BMPR91B)(Alk96)) Brain! BMP2,4,6,7! 1,5,8! (ten!Dijke,!Yamashita!et!al.!1994;!Dewulf,!Verschueren!et!al.!1995;!Miyazono,!Kamiya!et!al.!2010)!
Alk91) Endothelial!cells,!chondrocytes! TGF-β, BMP9 ! 2,3!1,5,8! (Goumans!and!Mummery!2000;!Oh,!Seki!et!al.!2000;!Seki,!Hong!et!al.!2006;!Finnson,!Parker!et!al.!2008;!Luo,!Tang!et!al.!2010;!Miyazono,!Kamiya!et!al.!2010)!
Alk92) Ubiquitously!expressed! BMP6,7,9! 1,5,8! (Zhang,!Schwarz!et!al.!2003;!Luo,!Tang!et!al.!2010;!Miyazono,!Kamiya!et!al.!2010)!
ActR91B))
(Alk94))
Blood! TGF-β, Nodal! 2,3! (Reissmann,!Jornvall!et!al.!2001;!Bianco,!Adkins!et!al.!2002;!Miyazono,!Kamiya!et!al.!2010)!
TβR9I))
(Alk95))
Endothelial!cells,!chondrocytes! TGF-β! 2,3! (Seki,!Hong!et!al.!2006;!Finnson,!Parker!et!al.!2008;!Miyazono,!Kamiya!et!al.!2010)!
ActR9IC))
(Alk97))
Adipose!tissue! Nodal! 2,3! (Carlsson,!Jacobson!et!al.!2009;!Miyazono,!Kamiya!et!al.!2010)!
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1.4.3  Pathway attenuation 
Both BMP and TGF-β signalling are modulated at many different levels: outside 
the cell, inside the cell as well as at the membrane. In many instances, the expression of 
these inhibitory signals is controlled by the TGF-β/BMP signalling cascade, which 
creates a negative-feedback loop204.  
1.4.3.1  Extracellular modulation 
At the extracellular level, secreted antagonists are capable of sequestering BMP 
ligands and preventing them from binding to the receptor. In vertebrates, more than seven 
of these antagonists have been identified191,204. These proteins are not redundant 
inhibitory signals as each antagonist displays a unique affinity for different ligands. Table 
1.3 describes a number of BMP ligands and their antagonists in addition to knockout 
mouse models demonstrating their important embryonic functions. 
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Table 1.3: Knockout mouse models of BMP ligands and antagonists. 
 
!
 
All knockout mouse models described above are homozygous for gene of interest 
 Gene Embryonic 
lethal? 
Phenotype Reference(s) 
 
 
 
 
 
 
 
 
 
BMP ligands 
 
 
 
  
BMP2 Yes Amnion/chorion 
malformation 
Defects in cardiac 
development 
(Zhang and Bradley 
1996) 
BMP3 No Increased tranbecular bone 
density 
(Daluiski, Engstrand et al. 
2001) 
BMP4 Yes Defects in extraembryonic 
and posterior/ventral 
mesoderm formation 
(Winnier, Blessing et al. 
1995) 
BMP5 No Abnormal skull and axial 
part of skeleton 
(Green 1958; Kingsley, 
Bland et al. 1992) 
BMP6 No Mild delay of sternum 
ossification in late gestation 
(Solloway, Dudley et al. 
1998) 
BMP7 Postnatal lethal Holes in the basisphenoid 
bone and the xyphoid 
cartilage, retarded 
ossification of bones, fused 
ribs and vertebrae, 
underdeveloped neural 
arches of the lumbar and 
sacral vertebrae 
(Jena, Martin-Seisdedos 
et al. 1997) 
!
!
!
!
!
!
!
!
!
!
!
BMP!
Antagonists!
!
Noggin&(highest!affinity!for!BMP!2,4)! Yes! Failure of neural tube closure, broad club-shaped limbs, loss of caudal 
vertebrae, shortened body 
axis and retention of small 
vestigial tail 
(Brunet,!McMahon!et!al.!1998;!McMahon,!Takada!et!al.!1998;!Choi,!Stottmann!et!al.!2007)!
Chordin&&(highest!affinity!for!BMP2,4)! Still!born! Normal!early!development!and!Neural!induction,!defects!in!inner!and!outer!ear!development,!pharyngeal!and!cardiovascular!organization!at!later!stages!of!embryogenesis!
(Bachiller,!Klingensmith!et!al.!2000)!
Follistatin&(highest!affinity!for!BMP7)! Postnatal!lethal!! Smaller!than!heterozygotes,!less!muscle,!fail!to!breath!after!birth! (Matzuk,!Lu!et!al.!1995)!
DAN&(highest!affinity!for!BMP2)! No! No!defects!in!head,!mesoderm,!somites,!facial!structures!and!limbs,!normal!neural!tube!development,!viable!and!fertile!
(Dionne,!Skarnes!et!al.!2001)!
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1.4.3.2  Intracellular modulation 
 As mentioned above, inhibitory Smads or I-Smads (Smad 6 & 7) function within 
the cell to antagonize TGF-β/BMP signalling. These Smads have the ability to interact 
with type I receptors but are never released and thus prevent R-Smads from interacting 
with these same receptors190. Smad7 has the ability to inhibit TGF-β and BMP signalling, 
whereas Smad6 has been shown to preferentially inhibit BMP signalling205. I-Smads have 
also been shown to have activity within the nucleus. Smad7, for example, is able to bind 
to Smad-responsive DNA elements and disrupt the formation of a functional Smad-DNA 
complex206. On the other hand, Smad6, functions by recruiting transcriptional 
corepressors, such as histone deacetylases and C-terminal binding proteins (CtBP)207,208. 
 Another way that Smad activity is regulated is through ubiquitin-mediated 
degradation. Smad ubiquitin regulatory factors 1 & 2 (Smurfs 1 & 2) are E3 ubiquitin 
ligases that selectively target R-Smads as well as activated type I receptors for 
degradation209,210. Smurf1 specifically interacts with Smads 1 and 5 to inhibit BMP 
signalling, whereas, Smurf2 acts more broadly to inhibit Smads 1 and 2 in order to 
repress both BMP and TGF-β signalling188,204. Smurf1 is also able to enhance the 
interaction between I-Smads and type I receptors in order to inhibit BMP signalling211. 
1.4.4  Smad-independent signalling 
 Smads are not only phosphorylated at the C-terminus by type I receptors in a 
ligand-dependent manner, but can also be phosphorylated within their linker region by 
kinases from other pathways (ie: MAPKs, ERKs, JNK, p38)204. The Smad linker region 
is easily accessed by a number of kinases since it is loosely organized and highly flexible. 
Specifically, epidermal growth factor (EGF) treatment, which activates Ras/MAPK 
signalling, results in phosphorylation of the Smad1 linker region. This phosphorylation 
blocks the nuclear translocation of Smad1, inhibiting BMP signalling212. Additionally, 
expression of a dominant negative mutant of Ras or treatment of intestinal epithelial cells 
with a MAP and ERK kinase (MEK) inhibitor decreased the ability of the BMP pathway 
in induce Smad1 phosphorylation213. From this it was proposed that these two pathways 
converge on Smad1 by phosphorylation of the C-terminus (BMP pathway) and the linker 
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region (Ras/MAPK pathway). It is the balance of these two inputs that determines Smad1 
activation and nuclear translocation214. The crosstalk between BMP signalling and other 
signalling pathways could have important implications not only in development but also 
in cancer. 
1.4.5  BMP signalling in cancer 
The BMP signalling pathway can exhibit both tumour suppressive and oncogenic 
functions depending not only on the type of cancer but also the stage. In some cancers, 
BMP signaling is growth inhibitory and induces apoptosis153,215-220 via activation of 
downstream Smad-dependent pathways that promote apoptosis or inhibition of pathways 
that prevent apoptosis. Alternatively, the BMP signaling pathway can also increase 
metastatic potential221,222 and tumour angiogenesis223. In fact, it has been reported in 
different cancers that BMPs serve a dual role, acting as a tumour suppressor at early 
stages of carcinogenesis and as a promoter of tumour metastasis at later stages224,225.  
1.4.5.1  Cancer promoting activities 
The BMP signalling pathway has been shown to increase metastatic 
potential221,222 and tumour angiogenesis223 in a number of different cancers. For example, 
BMP2 is expressed in non-small-cell lung carcinoma (NSCLC) and has the ability to 
enhance the growth of lung cancer cell lines in vitro and in vivo226. In addition to 
enhancing tumour growth, BMP2 has also been shown to play an important role in 
angiogenesis. Four days following injection of recombinant BMP2 a large increase in the 
size and number of blood vessels was observed in a NSCLC tumour xenograft model223. 
In addition to this, BMP7 has been shown to enhance vascular endothelial growth factor 
(VEGF) expression in metastatic prostate cancer cells227. The tumour-promoting 
properties of various components of the BMP signalling pathway have been illustrated in 
a number of other cancer sites including osteosarcoma, prostate, breast and colorectal228-
231.  
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1.4.5.2  Anti-cancer activities 
The potential tumour suppressive function of the BMP signalling pathway was 
highlighted in the early 2000s with the discovery of germline mutations in the type I 
BMP receptor, BMPR1A (Alk3), and Smad4 in up to 40% of juvenile polyposis 
patients232-237. This is an autosomal dominant syndrome characterized by multiple 
hamartomatous polyps and predisposition for gastrointestinal cancers233. A role for the 
BMP signaling pathway in this inherited syndrome was further supported by a transgenic 
mouse model expressing the BMP inhibitor noggin. At two to three months of age, these 
mice displayed a phenotype similar to that observed in juvenile polyposis patients. At a 
later age (6 to 8 months), adenomatous polyps could be observed in these mice, 
resembling the syndrome in humans 238. In addition to this, recent studies have suggested 
that the BMP signalling pathway may in fact be inactivated in a number of cases of 
sporadic colorectal cancer239. 
1.4.6  BMP signalling in ovarian cancer 
BMPs serve critical functions in the normal ovary, controlling processes such as 
steroidogenesis, follicle formation, and apoptosis240-244. In addition to this, double 
knockout mouse models for either Smad 1 & 5 or BMPRIA & BMPRIB develop 
granulosa cell tumours by three and eight months of age respectively245,246. Given the 
importance of BMP signalling pathway in maintaining normal ovarian function, it is not 
surprising to that it may play a role in the development of ovarian cancer. 
Human EOC cells have been reported to possess an autocrine BMP4 signalling 
loop247 and treatment of EOC cells with exogenous BMP4 or constitutively-active type I 
BMP receptor (Alk3QD) resulted in an increase in cell adhesion and invasion, as well as a 
cell spreading response indicative of enhanced cell motility187,247. Additionally, BMP2 
expression has been shown to be elevated in malignant ascites cells and solid tumour 
samples with expression positively correlating with tumour grade184. Perhaps some of the 
most convincing evidence for the cancer promoting functions of the BMP signalling 
pathway in ovarian cancer came from the Buckanovich lab in 2011. They demonstrated 
that activation of BMP signalling significantly increased the proportion of ovarian cancer 
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stem cells. Additionally, inhibiting BMP signalling in vivo resulted in a decreased 
proportion of ovarian cancer stem cells and decreased tumour growth248. Taken together 
these results indicate a cellular response which could contribute to EOC progression in 
response to BMP signalling, however, given the complexity of this pathway, it is likely 
that it serves different functions throughout ovarian cancer pathogenesis. The use of 
relevant models to dissect the role of this pathway during ovarian cancer metastasis could 
provide additional insight into the therapeutic potential for targeting this pathway for 
treatment of ovarian cancer. 
1.5 LKB1/AMPK signalling 
1.5.1  Overview 
As mentioned previously, the objective of my research was to identify signalling 
pathways that potentially interact and have a pro-survival effect on spheroid cells in 
ovarian cancer. In this vein, recent work uncovered a unique connection between the 
TGF-β/BMP signalling pathway and a tumour suppressor protein that plays an important 
role in the metabolic reprogramming of cancer cells, liver kinase B1 (LKB1). In this 
study they found that LKB1 is able to phosphorylate Smad4 and prevent it from binding 
to DNA, thus inhibiting both TGF- β/BMP signalling pathways249. 
Metabolic reprogramming of tumour cells is an important disease driver that 
allows cells to survive in unfavourable conditions where oxygen and nutrients are 
scarce250-253.  This is especially relevant to the ovarian cancer environment where cancer 
cells are released into the ascites fluid an environment where oxygen and nutrient access 
is severely compromised which necessitates a unique metabolic response for survival.  In 
this context, Adenosine monophosphate-activated protein kinase (AMPK) is important in 
that it functions as a sensor of cellular energy and allows cells to cope with various forms 
of metabolic stress, such as nutrient and energy deprivation254. AMPK is the only kinase 
that has the ability to respond to adenosine nucleotide levels within a cell and is thus one 
of the most important mediators of metabolic reprogramming. This section will discuss 
how the LKB1/AMPK signalling pathway is activated, how each of these kinases 
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contributes to oncogenesis, and the potential contribution of this pathway to ovarian 
cancer pathogenesis.  
1.5.2  Pathway activation and attenuation 
1.5.2.1  AMPK structure and activity 
AMPK was originally discovered in 1987 as the protein kinase responsible for 
phosphorylating and inactivating acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR), enzymes crucial for fatty acid and sterol 
biosynthesis, respectively255. In response to cellular stress that results in ATP depletion 
either by inhibiting its production or accelerating its consumption, AMPK switches off 
ATP-consuming anabolic processes and turns on ATP-producing catabolic pathways in 
order to restore energy homeostasis256. This prevents cells from proliferating in situations 
where nutrients are scarce and allows them to survive periods of stress, an important 
attribute that many cancer cells have adapted especially ovarian cancer cells in ascites 
fluid. 
AMPK is a highly conserved sensor of intracellular adenosine nucleotide levels 
that exists as a heterotrimeric complex consisting of catalytic α subunits and regulatory β 
and γ subunits257. In mammals, there are two isoforms of the α subunit (α1 and α2), two 
of the β (β1 and β2), and three of the γ subunit (γ1, γ2, and γ3), each of which is encoded 
by a distinct gene258. The α subunits contain a serine/threonine kinase domain in the N-
terminus and are activated by phosphorylation of Threonine (Thr) 172 within the 
activation loop of this domain259,260. The γ subunits contain four tandem repeats known as 
CBS motifs. These repeats are arranged in a pseudo-symmetrical manner, yielding four 
potential adenosine nucleotide-binding clefts256. Site 4 binds only to AMP, site 2 appears 
to remain unoccupied while sites 1 and 3 competitively bind ADP, ATP or AMP261,262. 
The β subunits link the C-terminus of the α subunit to the N-terminal domain of the γ 
subunit262-264. In a cell that is not stressed and ATP:ADP ratios are high, sites 1 and 3 of 
the γ subunit are occupied primarily by ATP. However, when cells are exposed to 
metabolic stress and levels of ADP and AMP increase, ATP is gradually replaced at these 
sites256. When AMP or ADP is bound to the γ subunit a conformational change occurs in 
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the complex that promotes phosphorylation of the α subunit, which is required for its 
activation257. 
For many years the upstream kinase responsible for activating AMPK remained 
elusive. In 2003, after over 20 years of work and the combination of studies in yeast and 
mammals, three different groups published consecutive papers identifying liver kinase B1 
(LKB1) as the primary kinase responsible for phosphorylating AMPK265-267. Since this 
time, calmodulin-dependent protein kinase β (CAMKKβ) has also been shown to 
phosphorylate AMPK at Thr172 in response to calcium flux268-270 (Figure 1.3). 
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Figure 1.3: Activation of the LKB1/AMPK signalling cascade. 
AMPK is activated when AMP or ADP levels increase due to a number of physiological 
stresses. It can also be activated pharmacologically (AICAR, A-769662). LKB1, in 
complex with STRAD and MO25, is the major upstream kinase that phosphorylates 
Thr172 on the α-subunit of AMPK in response to a rise in AMP or ADP. AMPK can also 
be phosphorylated by CAMKK2 in response to calcium flux. Activated AMPK directly 
phosphorylates a number of substrates to affect cellular metabolism and growth. 
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1.5.2.2  LKB1 structure and activity 
The human LKB1 gene also referred to as serine threonine kinase 11 (STK11), 
spans 23kb with ten exons, nine of which are coding. LKB1 is phosphorylated on at least 
eight different residues, 4 of which are phosphorylated by upstream kinases (Ser31, 
Ser325, Thr366 and Ser428), while the other 4 are autophosphorylation sites (Thr185, 
Thr189, Thr336, and Ser 404)271. Mutation of these sites to an alanine (Ala) or glutamic 
acid (Glu) does not appear to have any effect on the catalytic activity or subcellular 
localization of LKB1272-274. However, mutation of Ser428 rendered LKB1 unable to 
suppress cell growth in vitro, suggesting that phosphorylation of this residue may 
contribute to LKB1 tumour suppressor function274. This particular site can be 
phosphorylated by the p90 ribosomal S6 protein kinase (RSK) as well as Protein kinase A 
(PKA), suggesting that phosphorylation of LKB1 may be an avenue through which these 
kinases can regulate cell growth274,275.  
LKB1 exists in mammalian cells in a complex with STE20-related adaptor 
(STRAD) and mouse protein 25 (MO25)276-278. STRADα and STRADβ are referred to as 
pseudokinases because although they exhibit high sequence homology to the STE20 
family of protein kinases, they lack several key catalytic residues, rendering them 
inactive276. MO25α and MO25β are closely related to each other but don’t appear to 
resemble any other protein. They were originally identified as genes expressed at the 
early cleavage stage during mouse embryogenesis279. STRAD and MO25 are required not 
only to enhance the activity of LKB1 but also to ensure proper localization within the 
cell. 
LKB1 on its own is located predominantly in the nucleus, with only a small 
proportion in the cytoplasm280,281. This nuclear retention is mediated by a nuclear 
localization signal (NLS) located within the N-terminal non-catalytic region of 
LKB1271,280,282-284. When the NLS is mutated, LKB1 becomes distributed throughout the 
cell but retains its ability to suppress cell growth285. This suggests that the cytosolic pool 
of LKB1 may be the primary mediator of its tumour suppressive function271.  When 
STRAD and MO25 are present LKB1 is relocalized to the cytoplasm where the catalytic 
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activity towards its substrates is 10-fold higher. When a mutant of LKB1 that is unable to 
bind STRAD is introduced into the G361 melanoma cell line, it is unable to induce cell 
cycle arrest. Thus, MO25/STRAD/LKB1 complex is essential for the tumour suppressive 
function of LKB1272,276,282.  
1.5.2.3  LKB1-mediated activation of AMPK 
LKB1 does not respond to changes in AMP concentration, rather, it is 
constitutively active, constantly phosphorylating the Thr172 residue within the activation 
loop of AMPK286,287. When cells have an adequate supply of energy and nutrients, this 
site is immediately dephosphorylated, a process mediated by the conformational change 
induced in the γ subunit when adenosine nucleotides bind. This allows the 
phosphorylation state and activity of AMPK to change according to cellular energy 
status288. Specifically, in the presence of ADP or AMP, dephosphorylation of Thr172 by 
protein phosphatase 2C (PP2C) is inhibited289,290, LKB1-mediated phosphorylation of 
Thr172 is promoted291,292, and further activation is achieved by allosteric binding of 
AMP288,293. 
One of the initial papers identifying LKB1 as the upstream kinase for AMPK also 
highlighted the importance of this kinase in mediating AMPK stress responses. They 
showed that LKB1/STK11-null cells failed to activate AMPK in response to metabolic 
stress and that this response could be rescued by re-expression of LKB1265. This has more 
recently also been demonstrated in vivo where mice lacking LKB1 expression in skeletal 
muscle have significantly lower AMPK activity, fatty acid oxidation and glucose uptake 
in response to muscle contraction, a process which normally significantly enhances 
AMPK activation294. This was the first genetic evidence demonstrating the ability of the 
LKB1/AMPK pathway to regulate and maintain cellular energy levels. 
1.5.2.4  LKB1-mediated activation of AMPK-related kinases (ARKs) 
In the early 2000s, as we became more aware of various protein kinases and how 
they interact functionally as well as their sequence similarities, came the development of 
the human kinome dendogram295. It is from this that a group of 12 protein kinases closely 
related to AMPK were discovered and are now referred to as AMPK-related kinases 
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(ARKs; BRSK1/SAD-A, BRSK2/SAD-B, NUAK1/ARK5, NUAK2/SNARK, SIK1, 
OIK/SIK2, SIK3, SNRK, MARK1, MARK2, MARK3 and MARK4)271. LKB1 is the 
master kinase of this entire subfamily of protein kinases, phosphorylating and activating 
the residue equivalent to Thr172 within each AMPK-related kinase. Correspondingly, the 
activity of these kinases is decreased significantly in LKB1-deficient cells286,296. The 
catalytic subunits of the ARK subfamily do not interact with the γ subunits that provide 
AMPK with its ability to respond to changes in AMP/ADP concentrations, therefore, 
these kinases do not appear to be regulated by energy stress256,297. ARKs have been 
shown to play roles in cell polarity (MARK, BRSK/SAD)298-301, cell proliferation 
(NUAKs)271,302 and CREB-regulated gene transcription (SIKs)303,304, although their 
regulation and function is poorly understood in comparison to AMPK256. Further study of 
the ARKs is important in cancer because they may mediate some of the tumour 
suppressor effects previously ascribed to LKB1 (Figure 1.4). 
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Figure 1.4: LKB1 is a master kinase, phosphorylating a number of AMPK-related 
kinases (ARKs). 
LKB1, in a complex with STRAD and MO25, phosphorylates 12 AMPK-related kinases 
(ARKs) in addition to AMPK itself. These ARKs play roles in many important cellular 
processes, including microtubule stability, protein translation, CREB transcription and 
apoptosis. Upstream, LKB1 is phosphorylated by RSK, PKCζ or PKA at Ser428 and 
ATM at Thr 363.  
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1.5.3  LKB1/AMPK signalling in cancer 
1.5.3.1  Peutz-Jeghers syndrome and LKB1 
In 1922, Dr. Johannes Peutz was the first to describe Peutz-Jeghers Sydrome 
(PJS)305. This was followed by additional characterization provided by Dr. Harold 
Jeghers in the 1940s306. PJS is an autosomal dominant disorder characterized by 
development of benign hamartomatous polyps (benign tumour-like growths) within the 
gastrointestinal tract and marked cutaneous pigmentation (discolouration) of mucous 
membranes271. PJS patients also have a significantly greater chance of developing 
malignant tumours in a number of different tissues, including the breast, ovary, and 
pancreas307-309. In fact, 93% of PJS patients develop cancer by the age of 43 with 8% of 
patients developing a gynaecological cancer310,311. 
In 1998, parallel studies from two laboratories identified a number of mutations in 
the LKB1/STK11 gene in PJS families, providing the first evidence for LKB1’s function 
as a tumour suppressor312,313. Since that time, 144 different mutations in the LKB1 gene 
have been identified in PJS families and a limited number of sporadic cancers. The 
majority of which result in significant truncation of the catalytic domain, impairing 
catalytic activity314-326. These findings indicate that the tumour suppressive functions of 
LKB1 are mediated by its downstream targets (AMPK and ARKs). 
1.5.3.2  LKB1/AMPK function as tumour suppressors 
Given the tumour suppressive function LKB1 plays in PJS, its mutation status in a 
number of sporadic cancers has also been examined. Surprisingly, the occurrence of 
somatic LKB1/STK11 mutations in sporadic cancers is relatively rare, except in the case 
of NSCLC and cervical cancers where mutations in this gene have been identified in 30% 
and 20% of tumours, respectively327-329. Additional evidence to support the tumour 
suppressive function of LKB1 was provided by overexpression studies whereby wild-
type LKB1 induced a G1 cell-cycle arrest in the HeLa cervical cancer and G361 
melanoma cell lines330. Mice heterozygous for LKB1+/- are viable with no overt 
phenotype until 45 weeks of age, at which point most animals develop polyps in the 
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gastrointestinal tract. Histology performed on these polyps revealed that they are 
remarkably similar to those found in PJS patients271,331,332. When LKB1/STK11+/-mice 
are aged beyond 50 weeks of age, the majority of animals will develop hepatocellular 
carcinomas. These tumours have no LKB1 mRNA or protein expression, indicating that 
complete loss of LKB1 may be required for carcinogenesis333.  
Prior to the discovery that AMPK activation involves a tumour suppressor 
(LKB1), AMPK had solely been viewed as kinase with important roles in metabolism 
and was not on the radar of many cancer biologists. Although AMPK mediates some of 
the tumour suppressor functions of LKB1, some of these effects are also likely mediated 
by AMPK-related kinases256. A recent publication in which whole-animal knockout of 
AMPKα1 accelerates the development of B cell lymphomas in mice overexpressing c-
myc supports the idea that AMPK may function as a tumour suppressor334.  
As part of its energy sensing capabilities, AMPK has a unique ability to control 
the cell-cycle under conditions of metabolic stress. This can occur through AMPK 
phosphorylation and stabilization of p53, which causes cells to arrest in the G1/S phase of 
the cell-cycle335,336. This effect was mediated by upregulation of cyclin-dependent kinase 
inhibitors p21WAF1/CIP1, which is a transcriptional target of p53, and p27KIP1, which is 
phosphorylated by AMPK337.  
Perhaps the best characterized mechanism through which AMPK controls cell 
growth is by suppressing the mechanistic Target of Rapamycin 1 (mTORC1) pathway. 
mTOR is a crucial hub through which a number of kinases signal, integrating signals 
from nutrient and energy sensors in order to ensure that growth and proliferation are only 
triggered when conditions are favourable338. AMPK is able to directly phosphorylate two 
crucial components of the mTORC1 signalling cascade, Tuberous sclerosis complex2 
(TSC2/Tuberin)339 and regulatory-associated protein of mTOR (RAPTOR)340. AMPK 
phosphorylation of both TSC2 and RAPTOR results in inhibition of mTORC1 signalling, 
thereby decreasing protein translation and inducing prosurvival process such as 
autophagy.  
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1.5.3.3  LKB1/AMPK pathway is tumour-promoting 
Although many of the functions of the LKB1/AMPK pathway discussed above 
seem to support the idea that these kinases function as tumour suppressors, it has also 
been suggested that this may be highly context-dependent, based not only on the type of 
cancer but also the stage of metastasis. In fact, LKB1/AMPK may act as conditional 
tumour suppressors or oncogenes, depending on the magnitude or duration of stress254,341.  
It has also been suggested that LKB1 and AMPK may not always act in concert. 
Interestingly, unlike LKB1, AMPK subunits are more frequently amplified than mutated 
in human cancer and there is no evidence of a germline cancer predisposition syndrome 
involving AMPK subunits254. In addition to this, high levels of AMPK activity are 
observed in NSCLCs, where loss of LKB1 is common342. Given the lack of genetic 
evidence to support loss of AMPK function in cancer, AMPK may in fact be required for 
cancer cell survival in some instances254. In solid tumours, for example, AMPK is 
activated in areas of hypoxia allowing cells to tolerate nutrient starvation253. In this 
context, some of the aforementioned ‘tumour suppressive’ functions of AMPK can 
actually contribute to cell survival during periods of energetic stress. The prosurvival role 
of AMPK is likely mediated at least in part by its ability to inhibit mTORC1 signalling, 
thereby inducing proliferative quiescence and autophagy.  
AMPK is able to induce autophagy, a highly conserved cellular process through 
which cellular content is degraded and recycled through lysosomal machinery. This 
process has been shown to be upregulated during periods of starvation in order to 
generate nutrients essential to maintain basic cellular function. mTORC1 activity 
suppresses autophagy by phosphorylating autophagy-related 13 (ATG 13) and Unc-51 
like autophagy activating kinase 1 (ULK1) and preventing autophagosome 
initiation343,344. AMPK has the ability to indirectly induce autophagy when nutrients are 
scarce through its inhibition of mTORC1 signalling. It has also been reported that AMPK 
has the ability to directly phosphorylate ULK1345,346, another mechanism through which 
AMPK directly promotes autophagy. The protective nature of AMPK activation and 
autophagy induction was illustrated in a recent study by Avivar et al.. In this study 
autophagy-induction mediated by the LKB1/AMPK/mTORC1 signalling axis promoted 
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anoikis-resistance in mammary epithelial cells. This effect was also found to be mediated 
by suspension-induced PERK activation, a member of the unfolded protein response 
(UPR) pathway347.  
1.5.3.4  Therapeutic manipulation of LKB1/AMPK signalling in 
cancer 
Based on the proposed tumour suppressive function of the LKB1/AMPK pathway 
and its ability to suppress mTORC1 activity, it has been proposed that AMPK-activating 
drugs may be useful as cancer therapeutics348. One of the most commonly used AMPK 
agonists is the drug metformin, which is taken by approximately 120 million type 2 
diabetics daily349. This activation, however, is not direct as metformin fails to activate 
AMPK in cell-free assays, rather it has been hypothesized to be through metformin’s 
inhibition of the mitochondrial respiratory chain complex I350. Retrospective studies have 
demonstrated a strong correlation between metformin use and a reduction in cancer risk 
of up to 30%351-353. The most significant risk-reduction was observed for pancreatic and 
hepatocellular carcinomas354. It has been suggested that these associations between 
cancer incidence and metformin use may be due to other effects that metformin has on 
the tumour cells themselves, rather than AMPK activation alone. This provoked studies 
in tumour-prone PTEN+/- mice crossed to mice with decreased LKB1 expression 
(hypomorphic LKB1), in which development of lymphomas was delayed by 
administration of metformin or A-769662 (an allosteric AMPK agonist)355. Since 
metformin and A-769662 have completely different mechanisms through which they 
activate AMPK, it is unlikely that the effects of either of these compounds, is AMPK-
independent356. Therefore, these data strongly suggest that metformin may be used as an 
AMPK-agonist in a therapeutic setting for cancer treatment. 
As discussed above, the role of the LKB1/AMPK pathway largely depends on the 
stage of the tumour in question. In pre-neoplastic lesions, LKB1/AMPK may in fact 
function as a tumour suppressor through its ability to inhibit cell proliferation. Once a 
tumour is established, however, LKB1/AMPK may be needed to allow cells to survive 
periods of metabolic stress256. Before we use AMPK-activators as a cancer therapeutic, 
we need to better understand the unique metabolic requirements of cancer cells during 
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different stages of the carcinogenic process. In some cases, like when cells lose ECM-
attachment or become hypoxic, specific inhibitors of LKB1 or AMPK may in fact be 
more appropriate. 
1.5.4  LKB1/AMPK signalling in ovarian cancer 
The observation that females with PJS have a significantly higher risk of 
developing gynecological cancers lead researchers to suspect that LKB1 may play an 
important role in the female reproductive tract357. In fact, 61% (176/288) of high-grade 
serous ovarian tumours analyzed within The Cancer Genome Atlas (TCGA) exhibit 
deletion of one or more of the alleles of the LKB1/STK11 gene. Correspondingly, 
immunofluorescence performed on 92 human high-grade serous ovarian carcinomas 
revealed complete loss of protein expression in 54% of samples and partial/scattered or 
no loss in the remaining specimens358. The consequences of LKB1 loss in high-grade 
serous ovarian cancer was examined using a conditional knockout mouse model in which 
LKB1 is lost in the OSE and stromal cells of the ovary using the Amhr2-cre driver mouse 
strain. Although adult LKB1cko mice exhibit a high degree of surface papillary 
hyperplasia of the ovary, tumour formation was not observed. Perhaps this was due to the 
fact that it is now well-recognized that the cell of origin of high grade serous cancer is the 
secretory cell of the fimbria in the fallopian tube. When LKB1cko mice are crossed to 
conditional knockout PTEN mice under control of the same promotor, however, adnexal 
(adnexa of uterus; i.e. fallopian tubes or ovaries) tumours were observed with 100% 
penetrance. When these tumours are examined histologically and compared to human 
ovarian cancer specimens, they strongly resemble that of high-grade serous ovarian 
carcinomas358. These studies provided the first evidence that LKB1 loss and its synergy 
with other tumour suppressors may be important for the initiation of high-grade serous 
ovarian cancer. 
Contrary to LKB1, when tumour specimens from ovarian cancer patients were 
examined for expression of the various AMPK subunits, higher levels were observed in 
ovarian carcinomas compared to normal ovarian controls359. Additional studies have 
demonstrated that activation of AMPK by metformin or AMP mimetic, 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICAR) inhibits cell growth and 
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induces apoptosis360,361. The functional consequences of AMPK subunit overexpression 
in ovarian carcinoma specimens have yet to be determined with targeted knockdown 
experiments.   
1.5.5  Summary 
The LKB1/AMPK signalling pathway is unique in that it allows cells to respond 
to various forms of metabolic stress, such as nutrient deprivation, hypoxia, and energy 
depletion. The importance of metabolic reprogramming in allowing cancer cells to 
survive adverse microenvironments has become apparent over the last few years. It is 
clear that LKB1/AMPK may in fact play many context-specific roles throughout 
tumorigenesis and may not simply be classified as oncogenes or tumour suppressors. For 
example, loss of LKB1/AMPK signalling may be necessary during the initial stages of 
tumour development where there is need for rapid proliferation to support tumour 
growth. Subsequent to this, when this growth has stripped many of the available nutrient 
supplies, reactivation of LKB1/AMPK signalling may allow cells to survive until 
nutrients are replenished. Given the studies that have begun to implicate this pathway in 
ovarian carcinogenesis, there is a critical need for a more thorough molecular analysis 
and functional studies to determine the role of the LKB1/AMPK signalling pathway in 
ovarian cancer pathogenesis. This is particularly important given the unique way that 
ovarian cancer metastasizes and the crucial role that LKB1/AMPK signalling plays in 
mediating anoikis-resistance347,362. 
1.6 Scope of Thesis 
 Mechanisms of anoikis-resistance and spheroid formation are of particular 
importance when studying ovarian cancer given the way this disease metastasizes. Cells 
shed into the peritoneal cavity from the primary tumour must survive under non-adherent 
conditions until they reach the serosal surface of various abdominal organs at which point 
they are able to reattach and form secondary metastatic lesions. We developed an in vitro 
system with which to model suspension-induced spheroid formation and re-implantation 
to an adherent substratum. This allowed us to examine two signalling pathways we 
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hypothesized to play important, although not necessarily overlapping roles, in the process 
of ovarian cancer spheroid formation and re-implantation.  
 Our investigations began with the BMP signalling pathway, which we 
demonstrated is autonomously down-regulated during spheroid formation (Chapter 2). 
Correspondingly, over-activation of this pathway has a detrimental effect on the ability of 
cells to aggregate in suspension, resulting in much smaller spheroids. Further to this, we 
also demonstrate that when cells are reattached to an adherent substratum, BMP 
signalling is activated and enhances cell dispersion. Global gene expression analyses 
revealed a number of molecular aberrations associated with activated BMP signalling in 
ovarian cancer cells under both adherent and suspension conditions. Of these, Akt, which 
is also autonomously down-regulated when cells are in suspension, was shown to be 
enhanced in spheroids with activated BMP signalling. We also demonstrate that the BMP 
and Akt signalling pathways have the ability to act in concert to mediate suspension-
induced cell aggregation and subsequent reattachment to an adherent surface.  This study 
highlights the context-dependent role for the BMP signalling pathway throughout the 
various stages of ovarian cancer metastasis and provides a crucial link between this 
pathway and the PI3K/AKT signalling cascade. Given the important role that AKT plays 
in mediating the phenotypic alterations associated with activated BMP signalling in 
spheroids and other studies in our laboratory demonstrating that AKT signalling is a 
crucial mediator of reversible spheroid formation-induced dormancy, we became 
interested in other pathways that may cooperate with the PI3K/AKT pathway in our 
system. 
 AMPK is an important sensor of cellular energy status that converges with the 
PI3K/AKT signalling cascade on mTOR. These kinases have opposing regulatory effects 
on mTOR and therefore, may act in concert to allow ovarian cancer cells to survive in 
suspension. Indeed, in contrast to AKT, the activity of AMPK and its upstream kinase, 
LKB1, are enhanced in ovarian cancer spheroids (Chapter 3). Further pharmacological 
activation of the AMPK pathway is detrimental to adherent cells but much less so when 
cells are in suspension. Interestingly, targeted knockdown experiments demonstrated that 
LKB1 is crucial for suspension-induced spheroid formation and survival and that this 
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effect is AMPK-independent. These studies have begun to uncover the diverse range of 
signalling aberrations that occur when cells form multicellular spheroids and how these 
pathways interact to promote aggregation and survival in suspension. 
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Chapter 2 
2 BMP signalling controls the malignant potential of 
ascites-derived human epithelial ovarian cancer 
spheroids via AKT kinase activation  
2.1 Introduction 
Metastasis of epithelial ovarian cancer (EOC) is unique among most carcinomas 
in that spread occurs by direct dissemination of malignant cells from the primary tumour 
into the peritoneal cavity. EOC cells exist in suspension as single cells or aggregates 
called spheroids, until they adhere to the serosal surfaces of abdominal organs to establish 
and grow as secondary tumours1,2. It is becoming increasingly evident that EOC 
spheroids harbour unique characteristics that render them more resistant to 
chemotherapeutics, and perhaps more aggressive in establishing metastatic implants3. 
From an experimental perspective, we know that the gene expression patterns of cancer 
cells within multicellular spheroids more closely resemble that of the tumour, when 
compared with adherent monolayer cell cultures 4,5. Therefore, cell culture systems that 
better mimic this metastatic program of EOC are favoured because they will more 
accurately reflect the pathophysiology of native EOC spheroids and provide relevant data 
regarding the signalling pathways important for spheroid formation and survival.  
The transforming growth factor beta (TGF-β)/bone morphogenetic protein (BMP) 
signalling superfamily has been implicated in numerous aspects of the pathogenesis of 
many different cancers including EOC 4,5. Both normal human ovarian surface epithelial 
(OSE) cells and EOC cells possess the signalling components necessary for activation of 
this pathway in response to ligands of this superfamily, including TGF-β, BMPs, activin 
and Mullerian inhibiting substance (MIS)6-13. For example, EOC cells respond to 
exogenous TGF-β by inducing growth arrest due to upregulation of p15 expression 14. 
MIS treatment targets EOC-initiating cells of both cell lines and patient ascites cells by 
reducing their stem-like characteristics and thereby blocking their tumour-forming ability 
when injected in mice 15. BMP signalling through BMP4 increases the adhesion, motility 
and invasiveness of ascites-derived primary human EOC cells and induces epithelial-
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mesenchymal transition (EMT); treatment with the BMP2/4 antagonist Noggin blocks 
these activities as well as autocrine BMP4 signalling 13. In addition, BMP2 expression in 
EOC cells from ascites fluid is elevated compared to matched solid tumour samples 7. 
Regulated expression of a constitutively-active BMP2/4 receptor in the human OVCA429 
ovarian cancer cell line recapitulates many of the changes modulated by BMP ligands, 
however, the ability of these cells to form ascites and secondary tumours in immuno-
compromised mice is dramatically reduced 11. Thus, we propose that BMP signalling has 
different effects at specific stages of EOC progression including dissemination from the 
primary tumour, spread through the ascites as spheroids, and reattachment to form 
secondary tumours. Determining the molecular changes controlled by activated BMP 
signalling in an in vitro cell culture system that closely mimics EOC pathogenesis would 
provide additional mechanistic insight into the functional implications of this pathway 
during the disease process in patients. 
Herein, we describe the characterization of activated BMP signalling using a 
three-dimensional cell culture system whereby ascites-derived primary human EOC cells 
are grown in suspension where they naturally and rapidly form viable multicellular 
aggregates that closely resemble those observed directly in the malignant ascites 
collected from patients. Endogenous BMP signalling is decreased during EOC spheroid 
formation yet re-established during the process of spheroid reattachment. Ectopic 
expression of the constitutively-active BMP type I receptor ALK3QD, however, reduces 
the formation of large multicellular spheroids, yet enhances the immediate reattachment 
of EOC spheroids via increased cell motility. In addition, we provide evidence that 
activated BMP signalling in EOC cells and spheroids induces AKT phosphorylation, 
which is a necessary intracellular mediator of activated BMP signalling regulating the 
malignant features of metastatic disease.     
2.2 Materials and Methods 
2.2.1  Cell culture 
Ascitic fluid collected from chemotherapy-naive patients at time of paracentesis 
or debulking surgery was used to generate primary ascites cell cultures from patients with 
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stage III or IV ovarian cancer as described previously 16. Briefly, ascitic fluid containing 
cells was mixed 1:1 with growth medium [MCDB105 (Sigma, St. Louis, MO)/M199 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Wisent, 
St. Bruno, Quebec, Canada) and 50 µg/ml penicillin-streptomycin]. Cells were grown in 
a 37°C humidified atmosphere of 95% air and 5% CO2. All experiments with primary 
EOC cells were performed between passages 3 and 5.   
  
Adherent cells were maintained on tissue culture-treated polystyrene (Sarstedt, 
Newton, NC). Non-adherent cells were maintained on Ultra Low-Attachment (ULA®) 
cultureware (Corning, Corning, NY) which is coated with a hydrophilic, neutrally 
charged hydrogel to prevent cell attachment. Single-cell suspensions of 5 x 104 cells/mL 
were seeded to ULA plates to form spheroids over time.  
2.2.2  Adenovirus vectors and cell transduction 
The virus Ad-ALK3QD, which encodes constitutively-active BMP type IA 
receptor was previously constructed using the AdEasy Vector System (Qbiogene, Irvine, 
CA, USA) 11. Adenovirus expressing green fluorescent protein (Ad-GFP) was a kind gift 
from Dr. B. C. Vanderhyden (Ottawa Health Research Institute). Primary ovarian cancer 
cells were transduced at 80% confluence with a multiplicity of infection of 25 with either 
Ad-ALK3QD or Ad-GFP in a minimal volume of medium containing 10% FBS for 2 
hours with occasional agitation. Following transduction, complete growth medium was 
replenished. ALK3QD is tagged with a hemagglutinin (HA) epitope at the carboxyl-
terminus, therefore expression was detected by western analysis using anti-HA. All 
experiments were performed or initiated 24 hours following transduction. 
2.2.3  RNA expression analysis 
Total RNA was isolated from cells grown either as a monolayer on tissue-culture-
treated polystyrene or as spheroids on ULA® cultureware using Qiagen RNeasy Mini Kit 
(Qiagen, Valencia, CA). Quantity and quality of purified RNA was determined using an 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and Agilent 
2100 bioanalyzer (Agilent Technologies, Santa Clara, CA). Monolayer and spheroid 
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RNA samples from five different primary EOC patient samples that were transduced with 
either Ad-GFP (control) or Ad-ALK3QD (activated BMP signalling) were hybridized to 
Affymetrix® Human Genome U133A GeneChips (Affymetrix, Santa Clara, CA) at 
Precision Biomarker Resources Inc. (Evanston, IL).  
2.2.4  Real-time quantitative RT-PCR 
Reverse transcription was performed using total RNA isolated from five 
independent patient samples (adherent & spheroid, Ad-GFP & Ad-ALK3QD-transduced) 
and Superscript II reverse transcriptase (Invitrogen) as per manufacturer’s instructions. 
PCR reactions were carried out using Brilliant® SYBR® Green QPCR Master Mix (Agilent 
Technologies/Stratagene) and a Stratagene Mx3000P machine with data exported to 
Microsoft® Excel for data analysis. Human-specific primers sequences and annealing 
temperatures used for CDH1, SNAI1, SNAI2, TWIST1, TWIST2, ZEB2, SMAD6, NOG, 
MSX2, TBX3, HEY1 and DLX2 are available upon request. GAPDH served as an internal 
control for RNA input using previously published primer sequences 11.  
2.2.5  Cell number a viability assays 
Primary EOC cells were transduced in complete growth medium with either Ad-
GFP or Ad-ALK3QD. Twenty-four hours following transduction, cells were seeded to 
either tissue-culture treated or ULA cultureware. Adherent cells were exposed to 0.25% 
trypsin-EDTA for 3 minutes and, following detachment, trypsin was inactivated using 
complete growth medium. Spheroids were exposed to 0.25% trypsin-EDTA for 10 
minutes with vortexing and trituration to disaggregate spheroids. Trypsin was then 
inactivated using a small volume of FBS. To evaluate total cell number, single-cell 
suspensions were counted in a hemacytometer. To assess cell viability, single-cell 
suspensions were first diluted 1:1 in Trypan Blue reagent (Invitrogen, Carlsbad, CA) and 
all dye-excluding, viable cells counted in a hemacytometer. All treatments were 
performed in triplicate and two hemacytometer counts were performed per replicate. 
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2.2.6  Spheroid formation and reattachment assays 
Primary EOC cells were transduced at 80% confluence with either Ad-GFP or 
Ad-ALK3QD. Twenty four hours later, spheroids were formed on ULA cultureware for 
three days at which point phase contrast images were captured of each well  containing 
spheroids using an Olympus IX70 inverted microscope and ImagePro image capture 
software. The size of each of the spheroids was quantified for each image using the area 
measurement tool in the ImageJ image processing program (NIH, Bethesda, MD). In 
some cases, instead of transduction with virus, cells were incubated in media with 
minimal serum (0.5%-1%) for 24 hours prior to seeding to ULA culture ware, at which 
point, cells were treated with either Fc-Noggin or LDN-193189.  
Spheroids were collected and re-plated to: (i) 18 mm diameter round glass 
coverslips placed in 22 mm diameter culture dishes for subsequent BrdU 
immunocytochemical analysis (see below), or (ii) directly to tissue-culture-treated 24-
well polystyrene plates to quantify spheroid reattachment and dispersion. Phase contrast 
images were captured using an Olympus IX70 inverted microscope and ImagePro 
software of individual reattaching spheroids at initial point of attachment prior to 
dispersion (3 hours) and 24 hours following re-attachment. At this point, the experiment 
was terminated and re-attached spheroids were fixed and stained with using Hema-3 
Stain kit (Fisher, Kalamazoo, MI). Spheroid dispersion was quantified using the area 
measurement tool in ImageJ (NIH, Bethesda, MD). Dispersion area at 24 hours was 
calculated as a percentage of the original spheroid size at 3 hours of attachment.  
2.2.7  Spheroid disaggregation assay 
Primary EOC cells were transduced as described above with either virus (Ad-GFP 
or Ad-ALK3QD) and 24 hours later plated to ULA cultureware to form spheroids. 
Spheroids that had formed for 3 days were then exposed to 0.25% trypsin-EDTA for 
specified periods of time (i.e., 2-30mins) at which point the trypsin was inactivated with a 
small volume of FBS and single cells were counted in a hemacytometer. All treatments 
were performed in triplicate and two hemacytometer counts were performed per replicate. 
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2.2.8  Flow cytometry 
Primary EOC cells were transduced with Ad-GFP or Ad-ALK3QD and 24 hours 
later plated to ULA culture ware to form spheroids or to standard tissue culture plastic for 
adherent culture. After three days in culture, adherent cells and spheroids were detached 
and disaggregated, respectively, using 0.25% trypsin-EDTA. Cells were rinsed with PBS 
and fixed for 5 minutes using 10% neutral-buffered formalin. Cells were then rinsed with 
PBS/1% BSA and incubated with primary anti-E-cadherin antibody (#3195; Cell 
Signalling) for 1 hour, rinsed in PBS/1% BSA, and incubated with AlexaFluor 488-
conjugated anti-rabbit secondary antibody (#4412; Cell Signalling).  The proportion of E-
cadherin-positive cells was determined using a Beckman Coulter Epics XL-MCL flow 
cytometer with at least 10,000 events counted per test. Four independent patient samples 
were tested in triplicate and included cells-only and secondary antibody-only controls for 
each. 
2.2.9  BrdU cytochemistry 
Spheroids formed over a 3 day period were allowed to re-attach and disperse on 
glass coverslips for 24 hours at which point they were pulse labelled overnight with 
10µM bromodeoxyuridine (BrdU; GE Healthcare, Buckinghamshire, UK). Spheroids on 
coverslips were then fixed in a buffered 10% formalin solution, washed with PBS, and 
permeabilized with 0.1% TritonX-100 in PBS. This was followed by sequential washes 
and incubations in 2N HCl/0.5% TritonX-100 for DNA denaturation, 0.1M NaB4O4 pH 
8.5 for neutralization, mouse anti-BrdU primary antibody (1:100; Becton Dickinson), 
anti-Mouse FITC-conjugated secondary antibody (1:100; Vector Laboratories), and 4',6-
diamidino-2-phenylindole (DAPI; 1:5000; Sigma). Stained coverslips were washed in 
PBS, inverted and mounted on glass slides with VectaShield mounting medium (Vector 
Laboratories). Fluorescence images were captured using an Olympus AX70 upright 
microscope and ImagePro image capture software.  
2.2.10  Western blotting 
Total cellular protein was isolated from adherent and non-adherent EOC cells. 
Cells were washed once briefly in ice-cold PBS, dissolved in lysis buffer [50 mM HEPES 
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pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 mM sodium 
orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1X protease inhibitor cocktail (Roche, 
Laval, Quebec, Canada)], clarified by centrifugation (20 min at 15,000 x g), and 
quantified by Bradford analysis (Bio-Rad Laboratories, Mississauga, Ontario, Canada). 
Thirty to fifty micrograms of protein extract per lane were separated by SDS-PAGE in 
the presence of 1% β-mercaptoethanol using 8% or 12% gels. Proteins were then 
transferred to a polyvinylidene difluoride membrane (PVDF; Roche, Laval, Quebec, 
Canada), blocked with 5% skim milk in Tris-buffered saline with Tween-20 [TBST; 10 
mM Tris.HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20]. Membranes were washed in 
TBST and incubated (overnight, 4°C) with appropriate antibodies (1:1000 in 5% skim 
milk/TBST or 5% BSA/TBST). Immunoreactive bands were visualized by incubating 
(1h, room temperature) with a peroxidase-conjugated anti-rabbit (1:10,000 in 1% skim 
milk/TBST; GE Healthcare) followed by exposure to enhanced chemiluminescence 
reagent (ECL Plus; GE Healthcare). 
2.2.11  Antibodies and other reagents 
Antibodies against phospho-Smad1/5/8 (#9511), phospho-Smad2 (#3108), phospho-
Smad3 (#9520), total Smad1 (#9743), total Smad2 (#3122), total Smad3 (#9528), Smurf1 
(#2174), and E-cadherin (#3195) were purchased from Cell Signaling Technologies 
(Danvers, MA). HA-probe (Y-11; sc-805) and Smad4 (H-552; sc-7154) antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The antibody against ID1 
was purchased from Biocheck (Foster City, CA). Antibody to detect phosphorylated 
AKT (Ser473) was purchased from Cell Signaling Technology (#9271; Danvers, MA), 
and for total AKT1/2/3 from Santa Cruz Biotechnology (H-136 sc-8312; Santa Cruz, 
CA). Anti-actin antibody (A 2066) was purchased from Sigma (Mississauga, ON).  
Recombinant human Noggin (Fc-NG; 6057-NG) was purchased from R&D systems 
(Minneapolis, MN) and used at 50 or 100 ng/mL, as indicated. The BMP type I receptor 
inhibitor LDN-193189 was purchased from Stemgent (San Diego, CA) and prepared in 
DMSO: chloroform (3:1) according to manufacturer’s instructions, and used at a 
concentration of 10 or 100 nM, as indicated. Akt inhibitor VIII (Akti-1/2) was purchased 
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from EMD/Calbiochem (Merck, Darmstadt, Germany), prepared in DMSO according to 
manufacturer’s instructions, and used at a concentration of 5 mM. The PI3K inhibitor 
LY294002 was purchased from (Cell Signaling)) and used at a concentration of 50 mM. 
Mammalian target of rapamycin inhibitors were used at a concentration of 20 nM for 
rapamycin (Sigma) and 500 nM for temsirolimus (Torisel®; Pfizer). 
2.2.12  Statistical analysis 
Statistical analysis was performed using GraphPad Prism® software. Data were 
expressed as mean ± SEM. Statistical analysis was performed using two-tailed Student’s 
t-tests or one-way ANOVA and Tukey’s post-hoc test with significances set at *p < 0.05, 
** p < 0.01 and *** p < 0.001 as indicated.  
2.3 Results 
2.3.1  Reduced BMP signalling activity in primary human EOC 
spheroids 
We have previously reported that primary human EOC cells possess an intact BMP 
signalling pathway 11,12,17. To determine whether the critical BMP signalling components 
are present in EOC spheroids we prepared protein extracts from several independent 
primary human EOC cells that were grown as suspension cultures for three days. We 
have selected this time point because primary EOC cells will autonomously form multi-
cellular aggregates or spheroids with morphological characteristics mimicking those 
observed directly in patient ascites within this time frame. Western blotting using protein 
lysates isolated from EOC spheroids and matched adherent cultures demonstrated 
expression of phosphorylated Smad1/5/8 levels. Interestingly, total Smad1/5 protein was 
significantly increased in all primary EOC spheroids as compared with their adherent cell 
counterparts (Figure 2.1A). Thus, when BMP-activated R-Smad levels are normalized to 
total Smad1/5 protein, endogenous BMP signalling activity is in effect decreased by 
>50% upon spheroid formation.  
To follow this observation, we performed quantitative RT-PCR on RNA isolated 
from primary EOC adherent cells and spheroids and directly measured the expression of  
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Figure 2.1: BMP signalling is decreased during EOC spheroid formation. 
(A) Western blot analysis of phosphorylated and total Smad1/5/8 in adherent [A] and 
spheroid [S] samples in two independent EOC patient samples. Densitometric 
quantification of phosphorylated and total Smad1/5/8 (n=8) levels from Western blots. 
(B) Quantitative RT-PCR analysis of BMP2, BMP4, BMP6 and ID3 mRNA in adherent 
and spheroid samples in four independent EOC patient samples. (C, D) Western blot and 
densitometric quantification of  ID3 and SMURF1 levels respectively in spheroids 
compared to adherent EOC cells (n=6). *p<0.05; **p<0.01;***p<0.001 as determined by 
Student’s t-test. 
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ligands BMP 2, 4 and 6, known to be present in EOC cells 7,9,17. The mRNA levels of all 
three of these BMP ligands were significantly reduced in EOC spheroids compared with 
matched adherent cells (Figure 2.1B). Quantitative RT-PCR analysis of BMP7, however, 
did not yield a consistently detectable product in all samples analyzed (data not shown). 
In addition, the expression of the BMP signalling target gene ID3 12,17 was significantly 
reduced in EOC spheroids (Figure 2.1C). To address the potential mechanism by which 
EOC spheroids exhibit increased Smad1/5 protein, we assessed the expression level of 
the E3 ubiquitin-protein ligase SMURF1. SMURF1 is a Smad1/5-specific ubiquitin 
ligase and functions to target the degradation of R-Smad1/5/8 as a form of negative 
feedback regulation 18,19. Indeed, SMURF1 protein levels were significantly decreased in 
EOC spheroids as compared to adherent cells from multiple patient samples (Figure 
2.1D), which could account for the observed increase in total Smad1/5 in EOC spheroids.  
To determine whether this phenomenon of downregulated signalling could be applied 
broadly to the TGFβ superfamily, we also assessed the levels of the related R-Smad2/3. 
Phosphorylated Smad2 and Smad3 were detectable in both adherent EOC cells and 
spheroids, but there was no statistically significant difference in expression between 
culture conditions (Figure 2.2). Additionally, levels of the common-mediator Smad4 
were not significantly altered in EOC spheroids (data not shown). Thus, it appears that 
differential R-Smad expression and activity in three-dimensional EOC spheroids is 
specific to the BMP pathway, with the net result being a downregulation of its 
endogenous signalling capacity in EOC spheroids. 
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Figure 2.2: TGF-β signalling is not altered during EOC spheroid formation. 
(A) Western blot and densitometric analysis of Smad2 and Smad3 levels in adherent [A] 
and spheroid [S] EOC cells (n=4).  
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2.3.2  Forced BMP activity in EOC spheroids alters cell adhesion 
Given that endogenous BMP signalling activity was decreased in EOC spheroids, we 
postulated that this change was important for the optimal formation of spheroids. To 
examine this further, we tested the effect of ectopic re-activation of BMP signalling 
within these structures. To accomplish this, we transduced primary human EOC cells 
grown as adherent monolayer with adenovirus constructs expressing an HA-tagged 
constitutively-active mutant of the BMP type I receptor ALK3 (Ad-ALK3QD), or control 
virus expressing green fluorescent protein (Ad-GFP). We chose this method to sustain 
BMP signalling during spheroid formation and reattachment experiments to ensure cell 
autonomous BMP signalling without the limitation of BMP ligand access to all cells 
within the three-dimensional multicellular aggregate during the time course of the 
experiment. Transducing cells as adherent cultures ensured homogeneous and efficient 
transduction and resultant expression of ALK3QD (Figure 2.3A); direct transduction of 
established spheroids yielded uptake of virus into surface cells only, as visualized by Ad-
GFP (data not shown). To confirm that ALK3QD expression resulted in activation of BMP 
signalling in transduced EOC cells, western immunoblotting was performed to detect 
downstream targets of the pathway. As predicted, forced ALK3QD expression resulted in 
increased phosphorylated Smad1/5/8 and ID1 protein levels as compared with EOC cells 
transduced with Ad-GFP (Figure 2.3B). 
Since endogenous BMP signalling is naturally reduced in EOC spheroids, we 
hypothesized that sustained BMP signalling activity via ALK3QD would abrogate their 
formation and resultant morphological phenotype. Indeed, primary human EOC cells 
expressing ALK3QD generates EOC spheroids that are much smaller in size as compared 
with Ad-GFP transduced control spheroids (Figure 2.3C&D). This result is consistent 
with previous results using OVCA429 cells expressing ALK3QD 11.  
In addition, we noted that ALK3QD-expressing spheroids consist of cells that are 
much more loosely-aggregated than the compact spheroids observed from control cells 
(Figure 2.3C). To verify that this phenotype is not just due to decreased cell viability 
from overexpression of ALK3QD, we performed viable cell counting of Trypan blue-
excluding cells over 72 hours of spheroid formation. ALK3QD signalling had no effect on  
71 
 
 
Figure 2.3: Activated BMP signalling results in smaller EOC spheroids that are 
more loosely aggregated. 
(A) ALK3QD expression was achieved by adenoviral transduction of primary EOC cells 
using Ad-ALK3QD [A] and compared to Ad-GFP [G] control vector. (B) ALK3QD 
expression results in activation of BMP signalling pathway as confirmed by increased 
phosphorylated Smad1/5/8 and ID1 protein levels 24 hours following transduction. (C) 
ALK3QD dramatically reduces the ability of primary EOC cells to form large multicellular 
spheroids as compared with Ad-GFP transduced controls. Scale bar = 200 µm. (D) 
ALK3QD reduces the size of EOC spheroids as quantified using ImageJ software and 
averaged among seven experiments using independent patient samples. (E) ALK3QD 
expression in EOC cells has no effect on cell viability within the first 72 hours of seeding 
to non-adherent culture as determined by Trypan blue exclusion. (F) ALK3QD-expressing 
primary EOC spheroids (5 out of 8 individual patient samples) are more readily 
disaggregated compared to Ad-GFP controls, as determined by single-cell counting after 
a 2-minute trypsinization. *p<0.05; **p<0.01 as determined by Student’s t-test. 
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EOC cell viability in suspension culture, indicating that enhanced anoikis is not triggered 
by elevated BMP signalling during spheroid formation (Figure 2.2E). To assay cell 
cohesion directly, spheroid disaggregation experiments were performed on several patient 
samples (n=8) expressing ALK3QD, or Ad-GFP controls. Timed exposure to trypsin 
followed by quantification of single cells demonstrated that activated BMP signalling 
caused decreased cell cohesion of spheroids in 5 of 8 independent primary EOC samples 
(Figure 2.3F).  
Activated BMP signalling in adherent EOC cells induces epithelial-mesenchymal 
transition (EMT), a hallmark of which is the downregulation of E-cadherin 11,13. Since E-
cadherin may be involved in mediating cell-cell interactions in 3D spheroids 2,20, we 
sought to determine if ALK3QD was downregulating E-cadherin expression via inducing 
EMT in EOC spheroids, thereby resulting in decreased cell cohesion. Using real-time 
quantitative RT-PCR analysis of several EMT markers, we observed that EOC cells 
naturally undergo an EMT response during spheroid formation with an upregulation of 
Snail, Slug, ZEB2, Twist1 and Twist2 transcriptional repressors and concomitant 
downregulation of E-cadherin (CDH1) expression (Figure 2.4A). In contrast, we 
observed that spheroid cells expressing ALK3QD possess increased E-cadherin mRNA 
expression compared with control cells, and this correlated with an increase in the 
proportion of cells that were E-cadherin positive as determined by flow cytometry 
(Figure 2.4B). Therefore, constitutively active BMP signalling appeared to counteract the 
natural dynamics of transitions between epithelial and mesenchymal cell phenotypes in 
EOC spheroids.  
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Figure 2.4: EMT is induced during EOC spheroid formation. 
(A) EMT is induced in EOC spheroids, both in the absence or presence of activated 
ALK3QD signalling, as determined by real-time quantitative RT-PCR of E-cadherin 
(CDH1), Snail (SNAI1), Slug (SNAI2), TWIST1, TWIST2 and ZEB2. Fold expression was 
quantified against adherent cultures (set to 1) using pooled data from 5 independent 
patient samples performed in duplicate; GAPDH served as an internal control. (B) Flow 
cytometry for E-cadherin protein expression across 5 independent patient samples in the 
presence or absence of Alk3QD signalling. *p<0.05; ***p<0.001 as determined by 
Student’s t-test. 
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The capacity of EOC spheroids for reattachment, growth and motility defines 
their ability to form secondary metastases2. Since activated BMP signalling consistently 
reduces cell-cell cohesion within EOC spheroids, we next sought to determine whether 
activated BMP signalling affects the ability of EOC spheroid cells to reattach and 
migrate. ALK3QD-expressing EOC spheroids and GFP controls were plated for 
reattachment using standard tissue culture-treated plastic by directly transferring 
spheroids into new dishes with fresh growth medium. We observed an increased cell 
dispersion area and number of motile cells emanating from ALK3QD-expressing EOC 
spheroids within the first 24 hours of replating, as compared with controls (Figure 
2.5A&B). This was not due to cell proliferation since there was no significant difference 
in BrdU-incorporated cytochemistry in dispersing cells of ALK3QD-expressing spheroids 
compared to GFP controls (data not shown). This observed effect on EOC cell motility 
upon spheroid reattachment was consistent with our previous results of increased motility 
in adherent primary human EOC cells using recombinant human BMP4 and ALK3QD 
expression in conventional scratch wound assays 11,13. 
2.3.3  Inhibition of endogenous BMP signalling affects EOC 
spheroid adhesion 
Given the enhanced effect of activated BMP signalling during EOC spheroid 
reattachment, we wanted to determine if the reduction in endogenous BMP signalling, 
which was observed during EOC spheroid formation, would be restored during 
reattachment. Indeed, there is a significant increase in the levels of phosphorylated 
Smad1/5/8 when normalized to total protein levels in a number of different EOC patient 
samples (Figure 2.5C). These results indicate that the activity of the BMP signalling 
pathway is restored during EOC spheroid reattachment. 
  
75 
 
 
Figure 2.5: Alk3QD expression enhances the movement of EOC cells from spheroids 
after reattachment. 
(A) ALK3QD enhances the ability of EOC spheroids to migrate from the spheroid. (B) 
ALK3QD increases the dispersion area generated by reattached EOC spheroids as 
quantified using ImageJ software and averaged among six experiments using independent 
patient samples. Dispersion area was calculated 24 hours after spheroids have been 
replated to standard tissue culture plastic and normalized to the size of original spheroid. 
ALK3QD increases the number of dispersed cells 24 hours following spheroid 
reattachment as determined by counting DAPI-stained nuclei. (C) Western blot and 
densitometric analysis of phosphorylated and total Smad1/5/8 in adherent, spheroid and 
reattached EOC spheroid cells (n=7). (*p<0.05;** p<0.001;***p<0.001 as determined by 
Student’s t-test). Scale Bar: 200µm. 
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Given our results in EOC spheroids thus far, we postulated that blocking 
endogenous BMP activity may further facilitate spheroid formation yet decrease 
subsequent reattachment and dispersion. Primary human EOC cells express several BMP 
ligands, chiefly BMP2, BMP4 and BMP6 (Figure 2.1B) and their ability to promote 
signalling in EOC cells can be efficiently blocked using natural antagonists such as 
Noggin (NG) and Chordin 9,13. Additionally, LDN-193189 is a small molecule that 
selectively inhibits BMP type I receptors and can be used to block this pathway 21,22. 
Treatment of EOC cells with a single bolus of 50 ng/mL Fc-NG or with a range of 
concentrations of LDN-193189 resulted in a rapid and sustained reduction in 
phosphorylated BMP R-Smad1/5/8 over 72 hours (Figure 2.6A). Primary EOC cells were 
seeded to Ultra-Low Attachment dishes and treatment with Fc-NG (50 ng/mL) or LDN-
193189 (10 nM and 100 nM) was initiated immediately. From this, we observed a 
statistically significant increase in the average size of EOC spheroids as compared with 
control cultures (Figure 2.6B&C). In addition to this, when EOC spheroids were treated 
with either Fc-NG or LDN-193189 upon reattachment, dispersion areas were 
significantly reduced. A reduction in the number of dispersing cells was observed at 100 
nM of LDN-193189, but no difference in the number of cells arising from the attached 
spheroids by treatment with Fc-NG. Taken together, these results suggest a functional 
requirement for differential regulation of EOC spheroid formation and subsequent 
motility of EOC cells upon spheroid reattachment by BMP signalling.  
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Figure 2.6: Inhibition of BMP signalling enhances EOC spheroid formation and 
decreases reattachment. 
(A) Treatment of primary EOC cells with extracellular antagonist of BMP signalling Fc-
Noggin (Fc-NG, 50 ng/mL) and small molecule inhibitor LDN-193189 results in potent 
inhibition of BMP signalling as visualized by Western blot analysis of pSmad1/5/8. (B) 
Treatment with Fc-NG (50 ng/mL) or LDN-193189 (100 nM) increases the ability of 
EOC cells to form large multicellular spheroids and a subsequent decreased ability to 
disperse on tissue culture plastic. Scale bar=50 µm. (C) Quantification of spheroid size 
and dispersion area following treatment with Fc-NG or LDN-193189 using ImageJ 
software (n=3; n=7 respectively). (**p<0.01; ***p<0.001 using Student’s t-test). 
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2.3.4  BMP signalling activates the AKT pathway in EOC cells & 
spheroids 
The phenotypic changes in EOC spheroid adhesion and motility due to ALK3QD 
signalling likely result from a combination of both direct and indirect alterations in 
expression of many genes and their products. Activation of BMP signalling leads to the 
regulation of target gene expression primarily via Smad-dependent mechanisms. Several 
genes are direct targets of BMP signalling in EOC cells, including genes encoding the 
inhibitory Smad6/7 and the helix-loop-helix negative regulatory transcription factors ID1 
and ID312,17. Thus, to uncover many potential targets on a genome-wide scale, we 
performed an expression microarray using Ad-ALK3QD- and Ad-GFP-transduced cells of 
five independent EOC patient samples, and compared mRNA expression between 
adherent and spheroid cultures as well. We selected primary human EOC cells from 
patients with high-grade serous adenocarcinoma since they represent the most common 
histologic subtype of EOC and also to minimize potential experimental variability among 
patient samples. Using Affymetrix® Human U133A 2.0 plus arrays, we uncovered a 
plethora of altered gene expression characteristics which were consistent among all five 
patient samples (p<0.05): 444 annotated genes were elevated in expression due to 
ALK3QD in EOC spheroids compared to GFP controls, and 314 annotated genes were 
reduced (Table S2.1). The subset of genes that were commonly-regulated by ALK3QD in 
both adherent EOC cells and spheroids, comprising 96 up-regulated and 45 down-
regulated genes (Tables 2.1 & 2.2 and Figure 2.7A) were used to focus our analysis. 
Some known BMP target genes were identified in this subset, namely the transcription 
factors SMAD6 and SMAD7, MSX2, DLX2, and JUND. In addition, the BMP signalling 
antagonists NOG (Noggin) and GREM2 (Gremlin 2) were also increased due to ALK3QD 
signalling in both adherent cells and spheroids. We have since validated the expression of 
several of these genes, with SMAD6, NOG, MSX2, HEY1 and TBX3 demonstrating 
reproducible upregulation by ALK3QD signalling as determined by qRT-PCR (Figure 
S2.1).  
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Table 2.1: Up-regulated genes in response to Alk3QD expression and common 
between adherent and spheroid EOC cells. 
 
 
Gene Name Gene Description Probe Set Adherent 
Fold 
Change 
Spheroid 
Fold 
Change 
BMP signalling & target genes   
DLX2* distal-less homeobox 2 207147_at 8.543 20.206 
SMAD6* SMAD family member 6 207069_s_at 5.782 10.538 
SMAD7 SMAD family member 7 204790_at 2.078 2.813 
GREM2 gremlin 2 235504_at 5.071 2.982 
  240509_s_at 4.665 2.535 
NOG* noggin 231798_at 3.683 10.343 
MSX2* msh homeobox 2 210319_x_at 2.581 4.527 
  205555_s_at 2.118 4.689 
JUND jun D proto-oncogene 203751_x_at 2.146 2.291 
ECM & cell adhesion   
GJD3 gap junction protein, delta 3, 31.9kDa 230025_at 7.533 10.917 
HAS2 hyaluronan synthase 2 206432_at 4.122 2.696 
CD24 CD24 molecule 209772_s_at 4.078 39.195 
  208650_s_at 3.376 24.444 
  266_s_at 2.927 37.327 
  208651_x_at 2.861 21.376 
LRRC4 leucine rich repeat containing 4 223552_at 4.043 6.963 
PCDH10 protocadherin 10 1552925_at 3.641 2.624 
CD300LG CD300 molecule-like family member g 1552509_a_at 3.316 6.675 
SSX2IP synovial sarcoma, X breakpoint 2 interacting 
protein 
203018_s_at 2.858 3.122 
  210871_x_at 2.788 3.153 
  203016_s_at 2.759 3.056 
  203015_s_at 2.675 3.625 
  203019_x_at 2.655 3.195 
  203017_s_at 2.19 2.175 
FBLN2 fibulin 2 203886_s_at 2.542 2.905 
CDH24 cadherin-like 24 1553166_at 2.321 2.181 
CNTNAP2 contactin associated protein-like 2 219301_s_at 2.309 25.559 
Ligands     
TNFSF9 tumor necrosis factor, member 9 206907_at 4.802 8.53 
CCL26 chemokine (C-C motif) ligand 26 223710_at 4.725 11.408 
CCK cholecystokinin 205827_at 7.97 3.831 
JAG1 jagged 1 231183_s_at 3.146 2.306 
  209098_s_at 2.639 2.546 
PGF placental growth factor 209652_s_at 2.84 3.963 
INSL3 insulin-like 3 1553594_a_at 2.472 2.875 
Receptors & membrane proteins   
FOLR3 folate receptor 3 206371_at 6.787 12.253 
SYT15 synaptotagmin XV 1560879_a_at 6.497 6.516 
  1560878_at 3.835 2.825 
FIBCD1 fibrinogen C domain containing 1 240042_at 4.27 4.389 
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SEMA7A semaphorin 7A 230345_at 4.226 2.382 
TMEM132E transmembrane protein 132E 243708_at 4.196 3.56 
MALL mal, T-cell differentiation protein-like 209373_at 3.705 4.481 
SLC25A15 solute carrier family 25, member 15 222705_s_at 3.524 2.879 
KCNQ5 potassium voltage-gated channel, member 5 244623_at 3.489 6.034 
STRA6 stimulated by retinoic acid gene 6 221701_s_at 3.465 3.08 
PLXNA2 plexin A2 213030_s_at 2.758 4.575 
  227032_at 2.413 2.938 
PAQR9 progestin and adipoQ receptor family member 
IX 
1558322_a_at 2.7 2.681 
LIN7B lin-7 homolog B 241957_x_at 2.583 4.773 
FZD8 frizzled homolog 8 227405_s_at 2.513 3.713 
PITPNM2 phosphatidylinositol transfer protein, 
membrane-associated 2 
1552924_a_at 2.476 2.579 
TRPC3 transient receptor potential cation channel, 
subfamily C, member 3 
210814_at 2.223 4.341 
TRPV2 transient receptor potential cation channel, 
subfamily V, member 2 
219282_s_at 2.1 2.149 
FGFR3 fibroblast growth factor receptor 3 204379_s_at 2.184 2.227 
Intracellular signalling proteins 
DUSP5P dual specificity phosphatase 5 1553299_at 2.305 3.296 
DUSP26 dual specificity phosphatase 26 219144_at 4.234 2.56 
SPRY2 sprouty homolog 2 204011_at 2.598 2.061 
SOCS2 suppressor of cytokine signaling 2 203372_s_at 2.473 6.416 
  203373_at 2.065 4.938 
SHC4 SHC family, member 4 230538_at 2.132 2.765 
NCLN nicalin 222206_s_at 2.007 2.055 
Structural proteins    
LOR loricrin 207720_at 63.124 49.49 
IVL involucrin 214599_at 4.612 14.951 
KRTAP2-4 keratin associated protein 2-4 1555673_at 4.146 3.112 
KIF7 kinesin family member 7 229405_at 4.102 2.224 
EML1 echinoderm microtubule associated protein 
like 1 
204797_s_at 3.853 2.712 
ACTC1 actin, alpha, cardiac muscle 1 205132_at 3.766 40.174 
DCDC5 doublecortin domain containing 5 232603_at 3.346 4.783 
TUBB2A /// 
TUBB2B 
tubulin, beta 2A /// tubulin, beta 2B 209372_x_at 2.684 2.546 
TPM1 tropomyosin 1 206117_at 2.454 3.223 
SPTBN1 spectrin, beta, non-erythrocytic 1 226342_at 2.437 2.422 
TLN2 talin 2 212701_at 2.239 3.438 
MAP1B microtubule-associated protein 1B 212233_at 2.193 3.056 
Transcription factors    
FEZF2 FEZ family zinc finger 2 233972_s_at 5.611 16.35 
MYB v-myb myeloblastosis viral oncogene 204798_at 3.721 3.094 
ATOH8 atonal homolog 8 1558706_a_at 3.716 4.353 
  228890_at 2.873 4.266 
KLF4 Kruppel-like factor 4 220266_s_at 3.638 3.033 
  221841_s_at 2.701 2.962 
LMO2 LIM domain only 2 204249_s_at 3.592 4.971 
AFF2 AF4/FMR2 family, member 2 206105_at 3.356 3.267 
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TBX3* T-box 3 225544_at 2.737 2.183  
  229576_s_at 2.707 2.416  
GATA2 GATA binding protein 2 209710_at 2.422 2.501  
GATA3 GATA binding protein 3 209604_s_at 2.123 2.301  
HEY1* hairy/enhancer-of-split related with 
YRPW motif 1 
44783_s_at 2.053 3.736 
 
  218839_at 2.047 3.216  
PRRX2 paired related homeobox 2 219729_at 2.037 4.659  
Other      
AKR1C1 aldo-keto reductase family 1, member 
C1  
204151_x_at 4.2 4.254 
 
  216594_x_at 3.321 3.725  
AKR1C2 aldo-keto reductase family 1, member 
C2  
211653_x_at 5.339 4.759 
 
  209699_x_at 3.62 3.771  
CCDC68 coiled-coil domain containing 68 220180_at 2.022 2.067  
CCDC85A coiled-coil domain containing 85A 235228_at 3.596 5.131  
TRNP1 TMF1-regulated nuclear protein 1 227862_at 3.268 4.095  
CRYAB crystallin, alpha B 209283_at 3.058 4.708  
GPX3 glutathione peroxidase 3 214091_s_at 3.03 4.534  
THAP2 THAP domain containing, apoptosis 
associated protein 2 
230380_at 2.893 4.04 
 
DNAJA4 DnaJ homolog, subfamily A, member 4 1554334_a_at 2.89 3.921  
PEG10 paternally expressed 10 212092_at 2.875 2.108  
RPA4 replication protein A4 221143_at 2.733 4.239  
KANK4 KN motif and ankyrin repeat domains 4 229125_at 2.522 2.414  
DCBLD2 discoidin, CUB and LCCL domain 
containing 2 
213873_at 2.497 3.841 
 
  213865_at 2.323 2.769  
NHEDC2 Na+/H+ exchanger domain containing 2 1564746_at 2.438 3.347  
  229491_at 2.358 4.648  
ALAS2 aminolevulinate synthase 2 244205_at 2.355 2.621  
HSPD1 /// 
HSPD1P4 
heat shock 60kDa protein 1 /// 
pseudogene 4 
243372_at 2.34 2.642 
 
HSPA1A /// 
HSPA1B 
heat shock 70kDa protein 1A /// 1B 200800_s_at 2.145 7.074 
 
MEX3C mex-3 homolog C 1556874_a_at 2.326 2.37  
CASQ1 calsequestrin 1 219645_at 2.285 3.64  
PSG6 pregnancy specific beta-1-glycoprotein 6 208106_x_at 2.195 2.017  
YWHAH tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase activation 
protein, eta polypeptide 
201020_at 2.188 2.704 
 
ME2 malic enzyme 2 210154_at 2.068 2.187  
HECW2 HECT, C2 and WW domain containing 
E3 ubiquitin protein ligase 2 
232080_at 2.04 3.641  
ATP13A3 ATPase type 13A3 219558_at 2.018 3.262  
            
*- Expression was validated by real-time quantitative RT-PCR as described in Materials & Methods. 
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Table 2.2: Down-regulated genes in response to Alk3QD expression common 
between adherent and spheroid EOC cells. 
 
 
 
Gene Name Gene Description Probe Sets Adherent 
Fold Change 
Spheroid 
Fold 
Change 
ECM & cell adhesion   
CHI3L1 chitinase 3-like 1 209396_s_at 23.81 4.35 
  209395_at 14.08 3.25 
VCAM1 vascular cell adhesion molecule 1 203868_s_at 3.82 3.38 
CCDC80 coiled-coil domain containing 80 225241_at 3 3.27 
  225242_s_at 2.38 2.72 
Ligands     
PDGFD platelet derived growth factor D 219304_s_at 4.55 3.3 
CXCL16 chemokine (C-X-C motif) ligand 16 223454_at 3.57 2.85 
Receptors & membrane proteins   
PDPN podoplanin 221898_at 5.88 3.64 
  204879_at 3.46 2.72 
KCNH2 potassium voltage-gated channel, subfamily H, 
member 2 
210036_s_at 4.37 3.21 
KCNJ12 potassium inwardly-rectifying channel, 
subfamily J, member 12 
232289_at 2.51 2 
  207110_at 2.5 2.01 
VNN1 vanin 1 205844_at 3.48 3.72 
PLSCR4 phospholipid scramblase 4 218901_at 3.17 2.43 
EPHB3 EPH receptor B3 204600_at 2.91 5.95 
PLSCR1 phospholipid scramblase 1 202430_s_at 2.81 2.1 
PTGFRN prostaglandin F2 receptor negative regulator 224937_at 2.66 2.43 
TNFRSF21 tumor necrosis factor receptor superfamily, 
member 21 
218856_at 2.39 2.72 
ITGB8 integrin, beta 8 226189_at 2.21 2.41 
SORT1 sortilin 1 224818_at 2.17 2.57 
PGRMC2 progesterone receptor membrane component 2 213227_at 2.04 2.32 
Intracellular signalling proteins   
RAP1A RAP1A, member of RAS oncogene family 1555340_x_at 1000 333.33 
  1555339_at 333.33 333.33 
PKIB protein kinase inhibitor beta 231120_x_at 18.18 3.23 
REPS2 RALBP1 associated Eps domain containing 2 227425_at 6.21 5.08 
  205645_at 4.61 3.19 
CASP10 caspase 10 205467_at 2.43 2.28 
ELMO1 engulfment and cell motility 1 204513_s_at 2.22 2.15 
ARHGEF3 Rho guanine nucleotide exchange factor 3 218501_at 2.19 2.01 
Structural proteins    
PPL periplakin 203407_at 15.15 4.42 
MYO5B myosin VB 225299_at 3.04 3.1 
  225301_s_at 3.04 3.7 
MBP myelin basic protein 210136_at 2.97 2.51 
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  1554544_a_at 2.56 3.15  
MAP7 microtubule-associated protein 7 202890_at 2.5 2.39  
Transcription factors     
NFE2L3 nuclear factor (erythroid-derived 2)-like 3 204702_s_at 3.06 2.19  
KAT2B lysine acetyltransferase 2B 203845_at 2.39 2.75  
BNC1 basonuclin 1 1552487_a_at 2.1 2.2  
Other      
LRIG3 leucine-rich repeats and immunoglobulin-
like domains 3 
226908_at 4.31 3.65 
 
SLC46A3 solute carrier family 46, member 3 214719_at 3.77 2.22  
ALDH6A1 aldehyde dehydrogenase 6 family, member 
A1 
221589_s_at 3.68 2.86 
 
ALDH6A1  221588_x_at 2.84 2.39  
ALDH6A1  204290_s_at 2.51 2.31  
CYP7B1 cytochrome P450, family 7, subfamily B, 
polypeptide 1 
207386_at 3.64 2.67 
 
CYP39A1 cytochrome P450, family 39, subfamily A, 
polypeptide 1 
1553977_a_at 2.73 2.12 
 
IFIT1 interferon-induced protein with 
tetratricopeptide repeats 1 
203153_at 3.19 2.7 
 
ERO1LB ERO1-like beta 231944_at 2.69 2.06  
FTH1 ferritin, heavy polypeptide 1 214211_at 2.59 2.16  
FTH1      
FTH1      
CMBL carboxymethylenebutenolidase 227522_at 2.46 2.74  
AOX1 aldehyde oxidase 1 205083_at 2.28 6.25  
SLC27A1 solute carrier family 27, member 1 226728_at 2.2 2.15  
ZFYVE16 zinc finger, FYVE domain containing 16 1555982_at 2.14 2.14  
B3GNT1 beta-1,3-N-acetylglucosaminyl-transferase 1 203188_at 2.07 2.92  
PS1TP4 HBV preS1-transactivated protein 4 226381_at 2.06 2.04  
FUCA1 fucosidase, alpha-L-1, tissue 202838_at 2.02 2.06  
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Uncovering potential novel mechanisms of disease hidden within a gene expression 
signature is more readily attainable when compared to the large number of published 
datasets available. One such useful resource is Connectivity Map (CMAP) that was 
established and made available by the Broad Institute and MIT 
(http://www.broadinstitute.org/cmap) 23-25. CMAP facilitates the discovery of connections 
among human diseases, chiefly cancer, with gene expression changes and drug action. By 
uploading the up-regulated and down-regulated probe set lists (i.e. 96 up- and 45 down-
regulated genes) from our microarray study to CMAP (Figure 2.7A), we identified that 
three of the top ten drugs are inhibitors targeting the phosphatidylinositol 3-kinase 
(PI3K)-mammalian target of rapamycin (mTOR) pathway (Figure 2.7B). The PI3K 
inhibitors LY294002 and wortmannin were ranked first and seventh respectively, and the 
mTOR inhibitor sirolimus, also known as rapamycin, was ranked second. Interestingly, 
the compiled data of these three drugs from CMAP had a strong negative correlation with 
our ALK3QD gene expression signature.  Given that the ALK3QD gene expression dataset 
was negatively-correlated with those from all three of the PI3K-mTOR pathway 
inhibitors, we reasoned that activated BMP signalling induces the PI3K-mTOR pathway 
in primary EOC cells. To determine if this was the case, we performed western blotting 
to detect phosphorylated AKT levels as a direct readout of PI3K-mTOR pathway activity 
in EOC cells and spheroids expressing the constitutively-active BMP receptor. Indeed, 
ALK3QD expression significantly increased phospho-AKT in EOC cells (Figure 2.8C).  
We and others have demonstrated that active PI3K-mTOR signalling is vital to 
promoting the metastatic potential of EOC cells and spheroids26-29 26-29. Indeed, treatment 
of reattaching primary EOC spheroids with any of three different inhibitors of the PI3K-
mTOR pathway, LY294002, rapamycin and temsirolimus (Torisel®), resulted in a 
significant reduction in cell dispersion (Figure S2.2). To address whether this pathway is 
required for the phenotypic changes imparted by active BMP signalling, we targeted its 
central mediator AKT directly and specifically using the AKT inhibitor, Akti-1/2. 
Reattaching EOC spheroids transduced with either Ad-ALK3QD or Ad-GFP were treated 
with 5 µM AKTi-1/2, or DMSO as a vehicle control. As early as 24 hours after treatment 
with Akti-1/2, the dispersion area of ALK3QD spheroids was reduced, although not  
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Figure 2.7: The PI3K-AKT-mTOR pathway is activated by BMP signalling in EOC 
cells and spheroids. 
(A) Venn diagrams (based on Genespring analysis of microarray data using Affymetrix 
Human U133 plus 2.0 arrays) representing a total of 96 genes which are increased and 45 
genes which are decreased in expression in response to ALK3QD in both EOC cells and 
spheroids. The up-regulated and down-regulated probe set lists from the microarray study 
were uploaded to Connectivity Map (CMAP) which was established and made available 
by the Broad Institute and MIT (http://www.broadinstitute.org/cmap).  (B) The top ten 
drugs with gene expression signatures correlating with the ALK3QD gene expression 
signatures. Inhibitors targeting the PI3K-AKT-mTOR pathway, specifically LY294002, 
sirolimus, and wortmannin, result in gene expression patterns exhibiting a negative 
correlation with the ALK3QD gene expression signature.   
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completely down to levels observed in Ad-GFP control spheroids (Figure 2.8D). This 
suggests that enhanced AKT activity is required, at least in part, for the enhanced 
reattachment and dispersion of EOC cells observed as a result of active BMP signalling. 
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Figure 2.8: BMP-enhanced spheroid reattachment is partially mediated by AKT 
signalling. 
(A) ALK3QD results in increased levels of phosphorylated AKT (at residue Ser473) in 
EOC cells. (B, C) Enhanced EOC spheroid dispersion due to ALK3QD is decreased by 
treatment with the AKT inhibitor, Akti-1/2 (5 mM). 
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2.4 Discussion 
The multicellular spheroids found in EOC malignant ascites possess distinct 
biological properties due to their 3D architecture and downstream signalling afforded by 
the tumour sphere structure2,30. For example, the formation of EOC multi-cellular clusters 
provides protection against anoikis allowing these cancer cells to survive in ascites and 
seed metastatic tumours31. Therefore, identifying signalling pathways that contribute to 
the formation or disruption of EOC spheroids will provide new potential therapeutic 
targets that may also facilitate killing of solid tumour cells given their common 3D 
structure. We have shown previously that EOC cells express an intact and functional 
BMP signalling pathway, which directly impacts several key characteristics of a 
transformed cell phenotype12,13. Here we have exploited the in vitro EOC spheroid model 
system, to uncover novel actions of the BMP signalling pathway in EOC pathobiology 
(Figure 2.9). Interestingly, we have found that endogenous BMP signalling in EOC cells 
is down-regulated during spheroid formation. To determine whether this reduction in 
BMP signalling has functional implications for the formation of EOC spheroids we 
generated cells with constitutive activation of the pathway. Indeed, expression of the 
constitutively-active BMP type I receptor ALK3QD caused a decrease in EOC cell 
cohesion during spheroid formation. Additionally, enhanced BMP signalling activity 
subsequently resulted in increased motility of EOC cells dispersing from spheroids that 
attached to the culture dish. At the protein level we determined that activated BMP 
signalling resulted in activation of the AKT signalling pathway in human EOC cells. 
Therefore, the phenotypic changes induced by BMP signalling in EOC spheroids may, in 
part, be mediated by its effects on AKT signalling.   
The process of forming multi-cellular aggregates in suspension, akin to what occurs 
in malignant ascites, results in the down-regulation of endogenous BMP signalling. The 
genes encoding several BMP ligands showed significantly reduced expression during 
spheroid formation when compared to proliferating adherent monolayer cells, which was 
directly correlated with reduced levels of phosphorylated BMP R-Smad protein, thus 
implying that autocrine activation of the pathway is reduced in spheroid EOC cells. The 
downregulation of BMP signalling in EOC spheroid cells could occur through several 
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mechanisms. Several extracellular antagonists exist for BMP signalling, including 
Noggin, Chordin and Gremlin and other related proteins 32. Moreover, BMP signalling 
induces the transcriptional activation of target genes encoding inhibitory Smad proteins, 
Smad6 and Smad7. Smad6/7 function at several points in the pathway, namely to inhibit 
R-Smad phosphorylation, and Smad complex formation and its transcriptional activity33-
35. This mechanism is likely not operational in EOC spheroid cells because Smad6/7 
mRNA expression does not change in EOC spheroids, and Smad6 protein levels are not 
consistent among EOC cells and spheroids generated from patient samples (data not 
shown). We also demonstrate that increased turnover of R-Smads by SMURF1-mediated 
ubiquitinylation is not a likely mechanism, since SMURF1 levels are in fact decreased in 
expression in EOC spheroids. This indicates that turnover of Smads is reduced in 
spheroids leading to the subsequent accumulation of Smad1/5 as we observed. This 
increase in BMP R-Smad protein levels may represent a compensatory response to the 
decrease in endogenous BMP signalling during EOC cell spheroid formation. 
Consequently, the reduction in expression of the major BMP ligands expressed in EOC 
cells, i.e. BMP4, BMP2, and BMP6, likely represents the mechanism for downregulated 
BMP signalling in EOC spheroids. This is the first time that decreased endogenous BMP 
signalling has been observed during spheroid formation. This is in contrast to the data 
demonstrating that BMP signalling is elevated in primary EOC cells and in solid tumour 
samples compared to normal ovarian surface epithelial cells7,12,17. Thus, our results 
provide new insight about the dynamics of BMP signalling within EOC spheroids, which 
represent a unique transitional step for malignant cells between the primary tumour and 
secondary metastases2.   
The process of multicellular spheroid formation is complex and involves the 
coordinated action of different cell adhesion molecules. During the initial stages of 
spheroid formation, cell-cell adhesion is primarily mediated by the actions of integrins 
and cadherins20,36,37. By analysing several markers for EMT, we observed that EOC cells 
induce an EMT phenotype during spheroid formation, defined by a substantial decrease 
in the gene expression of the cell-cell adhesion molecule E-cadherin. This implies that 
EOC spheroid compaction likely depends on additional molecules or processes, such as 
fibronectin, vimentin or actomyosin-mediated contractility as seen in other spheroid 
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systems2,37-39. Since endogenous BMP signalling is reduced during spheroid formation, 
we propose that induction of the EMT phenotype in EOC spheroid cells does not require 
activation of BMP signalling. We noted, however, that the general induction of EMT in 
EOC spheroids is sustained in the presence of ectopic activated BMP signalling, a result 
which is supported by previous studies showing that BMP stimulation can induce 
EMT11,13,40. We also observed an unexpected slight but significantly greater increase in 
the induction of E-cadherin expression in ALK3QD expressing patient derived EOC 
spheroid cells relative to GFP transduced cells. This up regulation may be related to the 
unique microenvironment of the spheroid counteracting the EMT inducing properties of 
activated BMP signalling to maintain cell-cell contacts.  The decreased spheroid integrity 
that occurs as a result of activated BMP signalling may be due to the lack of typical late-
step spheroid compaction. In fact, the reduction in EOC spheroid compaction in the 
presence of activated BMP signalling may provide cells with an increased propensity to 
attach and disperse during secondary metastasis formation (as modeled by spheroid re-
attachment and dispersion in vitro). 
Reattachment of EOC spheroids to a hospitable substratum and the subsequent 
dispersion of cells and expansion via cell proliferation and motility are necessary to 
achieve secondary metastasis2,41,42. In response to activated BMP signalling, EOC 
spheroids have a significantly increased ability to reattach and disperse due to increased 
cell adhesion and motility and not cell proliferation. This result conforms to previous data 
indicating that BMP signalling has no effect on EOC cell proliferation, but induces a cell 
spreading phenotype, enhances motility and adhesion to several ECM components13,17.  
The phenotypic response of altered cell motility due to BMP signalling usually occurs 
in a Smad-independent manner utilizing other converging intracellular signalling 
pathways43,44. In this report, we determined that levels of phosphorylated AKT were 
significantly elevated in EOC cells and spheroids in response to activated BMP 
signalling, thus providing a further mechanism for BMP-mediated changes in cell 
adhesion and motility. There has been growing evidence for crosstalk between the BMP 
and PI3K-AKT-mTOR signalling pathways. For example, AKT kinase is activated by 
BMP2 stimulation of mouse myoblast C2C12 cells, an effect that is inhibited by the BMP 
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type I receptor specific inhibitor LDN-193189 21. Stimulation of vascular smooth muscle 
cells with BMP2 induces cell motility in a phospho-AKT dependent manner via the 
action of Rac1 and RhoA GTPases45. In addition, activated BMP signalling enhances cell 
motility, invasion and EMT via the PI3K-AKT pathway in other cancer cell types 46-50. 
Thus, it will be important to identify whether BMP activation of AKT employs common 
or different mechanisms in EOC cells and spheroids, as well as the functional 
implications of this signalling on the malignant characteristics of EOC. 
Our laboratory has independent evidence that the PI3K-AKT pathway is down-
regulated endogenously during EOC spheroid formation, yet its activation is required 
again during spheroid reattachment and cell dispersion. Taken together, AKT and BMP 
signalling are co-ordinately down-regulated during EOC spheroid formation. Perhaps 
sustained AKT activity due to enforced BMP signalling leads to less-cohesive spheroid 
formation yet enhances cell dispersion after re-attachment (Figure 2.9). This idea is 
supported by our studies in which treatment of ALK3QD-expressing spheroids with an 
Akt1/2 inhibitor results in a partial restoration of spheroid dispersion area to that of 
controls.  Thus, we believe that activation of the AKT pathway is functionally required 
and plays an important role in BMP-induced changes in spheroid behaviour and 
ultimately EOC metastasis. As mentioned previously, the presence of BMP signalling in 
EOC is correlated with significantly shorter survival periods for patients with advanced 
stage disease7. One mechanism for the deleterious effects of active BMP signalling in 
EOC may be downstream activation of the AKT pathway, another established marker for 
poor patient prognosis51,52. Thus, further exploration of the interaction between these two 
pathways is currently underway and may determine the therapeutic potential of targeting 
BMP signalling or AKT activity during EOC metastasis. 
Our previous and current studies implicate disparate roles for BMP signalling during 
different steps of the metastatic cascade in EOC pathogenesis. Overall, the data supports 
the notion that BMP signalling has bi-phasic influences: reduced activity may be required 
for EOC spheroid formation during dissemination of cells from the primary tumour, yet 
reactivation is required for more efficient establishment of secondary metastases (Figure 
2.9). As such, the conflicting roles for BMP signalling during EOC progression are 
92 
 
similar to the multifaceted effects of the related TGFβ pathway at early and late stages of 
multiple human cancers53. Collectively our data indicates the critical necessity to assess 
the effects of signalling systems at each step of the EOC metastatic process to assess the 
overall therapeutic potential of targeting a particular pathway.  
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Figure 2.9: Proposed model of BMP signalling in EOC metastasis. 
Metastatic EOC cells disseminating from the primary tumour naturally aggregate to form 
multicellular spheroids while in suspension in ascites in the peritoneal cavity. EOC 
spheroids endogenously down-regulate both BMP and AKT signalling, which may be 
required for tight cell-cell cohesion. Upon reattachment of EOC spheroids, however, cells 
reactivate the BMP and AKT pathways for efficient adhesion and dispersion to establish 
secondary metastases (e.g. on peritoneal wall). Ectopic activation of BMP signalling 
using ALK3QD, with the concomitant increase in AKT activity, alters this dynamic 
process by rendering EOC spheroids more loosely-aggregated while in suspension, which 
ultimately enhances their ability to disperse upon reattachment. 
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Figure S2.1: Validation of microarray results by quantitative RT-PCR analysis of 
specific up-regulated genes. 
SMAD6, NOG, MSX2, TBX3, and HEY1 mRNA expression was detected using human-
specific primers for each and cDNA samples generated from adherent primary human 
EOC cells (A) and spheroids (B) transduced with either Ad-ALK3QD or Ad-GFP control 
virus. Relative expression was normalized to Ad-GFP transduced cells (set to 1) and 
GAPDH mRNA served as an internal control. 
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Figure S2.2: Inhibition of PI3K-mTOR signalling reduces EOC cell dispersion upon 
spheroid reattachment. 
EOC cells from patient ascites samples (EOC30 and EOC67) were seeded to ULA cluster 
plates to generate spheroids over three days. EOC spheroids were individually seeded to 
standard tissue culture plastic and treated with LY294002, rapamycin, or temsirolimus 
(Torisel®) or DMSO vehicle control. Images of spheroids were captured (>40 per 
treatment group) at 24 h post-reattachment and dispersion area was quantified using 
ImageJ software. (**p<0.01; ***p<0.001 using Student’s t-test). 
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Table S2.1: Genes with increased expression due to Alk3QD in adherent EOC cells. 
 
Supplemental Table 1. Genes with increased expression due to ALK3QD in adherent EOC cells
Gene Title Gene Symbol Probe Set ID Fold Change
loricrin LOR 207720_at 63.124
calcitonin-related polypeptide beta CALCB 214636_at 17.708
S100 calcium binding protein P S100P 204351_at 14.716
heat shock 70kDa protein 6 (HSP70B) HSPA6 213418_at 9.249
distal-less homeobox 2 DLX2 207147_at 8.543
cholecystokinin CCK 205827_at 7.97
pregnancy specific beta-1-glycoprotein 5 PSG5 204830_x_at 7.951
FLJ35409 protein FLJ35409 1559506_x_at 7.665
gap junction protein, delta 3, 31.9kDa GJD3 230025_at 7.533
acetoacetyl-CoA synthetase-like AACSL 1570020_at 6.901
pregnancy specific beta-1-glycoprotein 3 PSG3 211741_x_at 6.892
folate receptor 3 (gamma) FOLR3 206371_at 6.787
synaptotagmin XV SYT15 1560879_a_at 6.497
similar to hCG2038656 LOC100129058 1564300_at 6.285
KIT ligand KITLG 211124_s_at 6.282
dual specificity phosphatase 2 DUSP2 204794_at 6.138
podocalyxin-like PODXL 201578_at 6.085
claudin 4 CLDN4 201428_at 6.019
SMAD family member 6 SMAD6 207069_s_at 5.782
FEZ family zinc finger 2 FEZF2 233972_s_at 5.611
keratin associated protein 4-12 KRTAP4-12 224269_at 5.553
chloride intracellular channel 2 CLIC2 213415_at 5.416
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alphAKR1C2 211653_x_at 5.339
glutamate receptor, ionotropic, AMPA 2 GRIA2 241172_at 5.324
solute carrier family 16, member 14 (monocarboxylic acid transporter 14) SLC16A14 238029_s_at 5.109
interleukin 9 IL9 208193_at 5.086
gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 235504_at 5.071
tumor necrosis factor (ligand) superfamily, member 9 TNFSF9 206907_at 4.802
chemokine (C-C motif) ligand 26 CCL26 223710_at 4.725
gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 240509_s_at 4.665
involucrin IVL 214599_at 4.612
hypothetical protein MGC16121 MGC16121 228235_at 4.348
XK, Kell blood group complex subunit-related family, member 6 XKR6 1557436_at 4.344
hemicentin 2 HMCN2 241650_x_at 4.341
ameloblastin (enamel matrix protein) AMBN 221114_at 4.3
fibrinogen C domain containing 1 FIBCD1 240042_at 4.27
dual specificity phosphatase 26 (putative) DUSP26 219144_at 4.234
semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) SEMA7A 230345_at 4.226
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysterAKR1C1 204151_x_at 4.2
transmembrane protein 132E TMEM132E 243708_at 4.196
keratin associated protein 2-4 KRTAP2-4 1555673_at 4.146
hypothetical LOC441052 LOC441052 232443_at 4.131
hyaluronan synthase 2 HAS2 206432_at 4.122
kinesin family member 7 KIF7 229405_at 4.102
keratin associated protein 4-1 KRTAP4-1 234635_at 4.082
CD24 molecule CD24 209772_s_at 4.078
leucine rich repeat containing 4 LRRC4 223552_at 4.043
polymerase (RNA) II (DNA directed) polypeptide A, 220kDa POLR2A 217415_at 4.005
G protein-coupled receptor 56 GPR56 212070_at 3.941
gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 220794_at 3.908
folate receptor 2 (fetal) FOLR2 204829_s_at 3.882
hypothetical protein LOC284542 LOC284542 230920_at 3.88
zinc finger protein 114 ZNF114 1552946_at 3.878
echinoderm microtubule associated protein like 1 EML1 204797_s_at 3.853
neuregulin 1 NRG1 206343_s_at 3.837
synaptotagmin XV SYT15 1560878_at 3.835
hypothetical protein MGC16121 MGC16121 227488_at 3.823
neuronal cell adhesion molecule NRCAM 204105_s_at 3.777
actin, alpha, cardiac muscle 1 ACTC1 205132_at 3.766
zinc finger protein 831 ZNF831 1558826_at 3.752
extra spindle pole bodies homolog 1 (S. cerevisiae) ESPL1 204817_at 3.747
v-myb myeloblastosis viral oncogene homolog (avian) MYB 204798_at 3.721
Atonal homolog 8 (Drosophila) ATOH8 1558706_a_at 3.716
pregnancy specific beta-1-glycoprotein 9 PSG9 209594_x_at 3.712
mal, T-cell differentiation protein-like MALL 209373_at 3.705
synaptopodin SYNPO 235914_at 3.697
noggin NOG 231798_at 3.683
synapsin I SYN1 221914_at 3.657
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protocadherin 10 PCDH10 1552925_at 3.641
Kruppel-like factor 4 (gut) KLF4 220266_s_at 3.638
clusterin CLU 222043_at 3.632
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alphAKR1C2 209699_x_at 3.62
GIPC PDZ domain containing family, member 3 GIPC3 236730_at 3.617
glutathione peroxidase 3 (plasma) GPX3 201348_at 3.601
coiled-coil domain containing 85A CCDC85A 235228_at 3.596
LIM domain only 2 (rhombotin-like 1) LMO2 204249_s_at 3.592
vasoactive intestinal peptide VIP 206577_at 3.532
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 SLC25A15 222705_s_at 3.524
DIRAS family, GTP-binding RAS-like 3 DIRAS3 215506_s_at 3.49
potassium voltage-gated channel, KQT-like subfamily, member 5 KCNQ5 244623_at 3.489
trafficking protein particle complex 2 TRAPPC2 1562349_at 3.483
WD repeat domain 33 WDR33 243832_at 3.466
stimulated by retinoic acid gene 6 homolog (mouse) STRA6 221701_s_at 3.465
acidic (leucine-rich) nuclear phosphoprotein 32 family, member C ANP32C 208538_at 3.454
pappalysin 2 PAPPA2 228237_at 3.404
CD24 molecule CD24 208650_s_at 3.376
hypothetical gene supported by AK026773 LOC440863 234478_at 3.368
myosin binding protein H MYBPH 206304_at 3.363
RASD family, member 2 RASD2 223634_at 3.36
AF4/FMR2 family, member 2 AFF2 206105_at 3.356
doublecortin domain containing 5 DCDC5 232603_at 3.346
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysterAKR1C1 216594_x_at 3.321
CD300 molecule-like family member g CD300LG 1552509_a_at 3.316
pleckstrin homology domain containing, family A member 7 PLEKHA7 228450_at 3.276
TMF1-regulated nuclear protein 1 TRNP1 227862_at 3.268
myosin, heavy chain 13, skeletal muscle MYH13 208208_at 3.243
hypothetical LOC100126784 LOC100126784 240407_at 3.228
hypothetical protein LOC254057 LOC254057 232370_at 3.226
RAB39B, member RAS oncogene family RAB39B 230075_at 3.204
UPF0632 protein A LOC388630 244472_at 3.199
ankyrin repeat domain 20 family, member A pseudogene LOC375010 1566147_a_at 3.182
small nucleolar RNA host gene 4 (non-protein coding) SNHG4 1565325_at 3.172
TIMP metallopeptidase inhibitor 4 TIMP4 206243_at 3.169
similar to Primase, DNA, polypeptide 2 (58kDa) /// primase, DNA, polypeptide 2 (58kDa) LOC100134355 /215709_at 3.162
family with sequence similarity 83, member G FAM83G 228587_at 3.158
Jagged 1 (Alagille syndrome) JAG1 231183_s_at 3.146
neural cell adhesion molecule 1 NCAM1 212843_at 3.145
solute carrier family 6 (neutral amino acid transporter), member 15 SLC6A15 232263_at 3.138
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 210812_at 3.109
breast cancer 1, early onset BRCA1 211851_x_at 3.096
similar to TLK2 protein /// similar to TLK2 protein /// similar to Serine/threonine-protein kinase tousled-likeLOC100128729 /232585_at 3.088
echinoderm microtubule associated protein like 1 EML1 204796_at 3.062
crystallin, alpha B CRYAB 209283_at 3.058
exoribonuclease 2 ERI2 240604_at 3.048
retinoic acid induced 2 RAI2 219440_at 3.039
glutathione peroxidase 3 (plasma) GPX3 214091_s_at 3.03
IGF-like family member 2 IGFL2 231148_at 3.027
retinitis pigmentosa 1 (autosomal dominant) RP1 224021_at 3.013
chromosome 14 open reading frame 145 C14orf145 244033_at 3.01
Hypothetical LOC150538 FLJ32063 235147_at 3.005
ELMO/CED-12 domain containing 1 ELMOD1 231930_at 2.984
jagged 1 (Alagille syndrome) JAG1 216268_s_at 2.974
glycerol-3-phosphate dehydrogenase 2 (mitochondrial) GPD2 211613_s_at 2.971
extra spindle pole bodies homolog 1 (S. cerevisiae) ESPL1 38158_at 2.953
chromosome 14 open reading frame 145 C14orf145 1557755_at 2.936
CD24 molecule CD24 266_s_at 2.927
aurora kinase B AURKB 209464_at 2.912
dynein, axonemal, heavy chain 12 DNAH12 1563097_at 2.91
hypothetical protein LOC283278 LOC283278 242417_at 2.907
fatty acid binding protein 5 (psoriasis-associated) FABP5 202345_s_at 2.898
THAP domain containing, apoptosis associated protein 2 THAP2 230380_at 2.893
DnaJ (Hsp40) homolog, subfamily A, member 4 DNAJA4 1554334_a_at 2.89
formin 2 FMN2 1555471_a_at 2.877
paternally expressed 10 PEG10 212092_at 2.875
atonal homolog 8 (Drosophila) ATOH8 228890_at 2.873
T-box 3 TBX3 219682_s_at 2.871
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 210813_s_at 2.866
CD24 molecule CD24 208651_x_at 2.861
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synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203018_s_at 2.858
RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing RLTPR 227216_at 2.854
placental growth factor PGF 209652_s_at 2.84
transketolase TKT 228205_at 2.83
formin 2 FMN2 223618_at 2.826
cancer susceptibility candidate 4 CASC4 1559635_at 2.798
t-complex 11 homolog (mouse) TCP11 220378_at 2.798
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 210871_x_at 2.788
cholecystokinin A receptor CCKAR 211174_s_at 2.772
Na+/K+ transporting ATPase interacting 2 NKAIN2 242002_at 2.762
matrix metallopeptidase 3 (stromelysin 1, progelatinase) MMP3 205828_at 2.762
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203016_s_at 2.759
plexin A2 PLXNA2 213030_s_at 2.758
ATP-binding cassette, sub-family C (CFTR/MRP), member 9 ABCC9 208561_at 2.758
hypothetical protein LOC144481 LOC144481 1559315_s_at 2.755
T-box 3 TBX3 225544_at 2.737
replication protein A4, 34kDa RPA4 221143_at 2.733
WD repeat domain 4 WDR4 241937_s_at 2.725
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 205071_x_at 2.713
T-box 3 TBX3 229576_s_at 2.707
transient receptor potential cation channel, subfamily C, member 4 TRPC4 224219_s_at 2.703
pyrophosphatase (inorganic) 2 PPA2 1554499_s_at 2.701
Kruppel-like factor 4 (gut) KLF4 221841_s_at 2.701
progestin and adipoQ receptor family member IX PAQR9 1558322_a_at 2.7
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) MAFB 218559_s_at 2.691
tubulin, beta 2A /// tubulin, beta 2B TUBB2A /// TUBB209372_x_at 2.684
cysteine-rich protein 2 CRIP2 208978_at 2.682
pregnancy specific beta-1-glycoprotein 9 PSG9 207733_x_at 2.681
actinin, alpha 2 ACTN2 203861_s_at 2.678
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203015_s_at 2.675
RNA binding motif protein, Y-linked, family 3, member A pseudogene RBMY3AP 1565320_at 2.669
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203019_x_at 2.655
serine/threonine/tyrosine kinase 1 STYK1 220030_at 2.649
transforming growth factor, alpha TGFA 211258_s_at 2.642
jagged 1 (Alagille syndrome) JAG1 209098_s_at 2.639
sperm specific antigen 2 SSFA2 236207_at 2.639
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) MAFB 222670_s_at 2.619
zinc finger and BTB domain containing 45 ZBTB45 240551_at 2.602
regulator of G-protein signaling 4 RGS4 204339_s_at 2.602
sprouty homolog 2 (Drosophila) SPRY2 204011_at 2.598
X-ray repair complementing defective repair in Chinese hamster cells 4 XRCC4 205072_s_at 2.593
E2F transcription factor 7 E2F7 228033_at 2.586
lin-7 homolog B (C. elegans) LIN7B 241957_x_at 2.583
msh homeobox 2 MSX2 210319_x_at 2.581
MAP/microtubule affinity-regulating kinase 2 MARK2 211082_x_at 2.581
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) CFTR 234706_x_at 2.581
solute carrier family 4, sodium bicarbonate cotransporter, member 4 SLC4A4 210738_s_at 2.565
regulator of G-protein signaling 4 RGS4 204338_s_at 2.563
synaptotagmin-like 3 SYTL3 238423_at 2.558
fibulin 2 FBLN2 203886_s_at 2.542
Hypothetical protein LOC100132244 LOC100132244 229438_at 2.538
ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) ELOVL6 204256_at 2.531
Fc receptor-like A FCRLA 235401_s_at 2.527
KN motif and ankyrin repeat domains 4 KANK4 229125_at 2.522
jagged 1 (Alagille syndrome) JAG1 209099_x_at 2.519
Sperm specific antigen 2 SSFA2 229744_at 2.516
chromosome 10 open reading frame 116 C10orf116 203571_s_at 2.516
frizzled homolog 8 (Drosophila) FZD8 227405_s_at 2.513
cerebellin 2 precursor CBLN2 242301_at 2.508
potassium voltage-gated channel, subfamily G, member 1 KCNG1 214595_at 2.507
diacylglycerol kinase, gamma 90kDa DGKG 206395_at 2.504
olfactory receptor, family 2, subfamily J, member 2 OR2J2 208508_s_at 2.502
microtubule-associated protein 1A MAP1A 203151_at 2.502
discoidin, CUB and LCCL domain containing 2 DCBLD2 213873_at 2.497
ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) ELOVL6 210868_s_at 2.493
solute carrier family 29 (nucleoside transporters), member 2 SLC29A2 1560149_at 2.484
ubiquitin-like with PHD and ring finger domains 1 UHRF1 225655_at 2.484
angiotensin II receptor, type 2 AGTR2 222321_at 2.481
phosphatidylinositol transfer protein, membrane-associated 2 PITPNM2 1552924_a_at 2.476
suppressor of cytokine signaling 2 SOCS2 203372_s_at 2.473
103 
 
Table S2.1 cont'd. 
 
insulin-like 3 (Leydig cell) INSL3 1553594_a_at 2.472
peroxisome proliferator-activated receptor gamma PPARG 208510_s_at 2.47
non-protein coding RNA 161 NCRNA00161 1554405_a_at 2.467
phosphatidylinositol-5-phosphate 4-kinase, type II, beta PIP4K2B 1553047_at 2.464
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) ITGA2 205032_at 2.456
tropomyosin 1 (alpha) TPM1 206117_at 2.454
TOX high mobility group box family member 2 TOX2 228737_at 2.446
kelch-like 17 (Drosophila) KLHL17 229792_at 2.44
Na+/H+ exchanger domain containing 2 NHEDC2 1564746_at 2.438
spectrin, beta, non-erythrocytic 1 SPTBN1 226342_at 2.437
TruB pseudouridine (psi) synthase homolog 1 (E. coli) TRUB1 236020_s_at 2.432
p21 protein (Cdc42/Rac)-activated kinase 7 PAK7 213990_s_at 2.428
GATA binding protein 2 GATA2 209710_at 2.422
similar to hCG2042915 LOC100129673 236611_at 2.419
plexin A2 PLXNA2 227032_at 2.413
testis specific, 14 TSGA14 215637_at 2.403
acyl-CoA thioesterase 7 ACOT7 215728_s_at 2.399
Spectrin repeat containing, nuclear envelope 1 SYNE1 232027_at 2.391
hypothetical locus MGC42157 MGC42157 1552987_a_at 2.376
transcription factor 19 TCF19 223274_at 2.369
Na+/H+ exchanger domain containing 2 NHEDC2 229491_at 2.358
aminolevulinate, delta-, synthase 2 ALAS2 244205_at 2.355
claudin domain containing 2 CLDND2 231162_at 2.343
heat shock 60kDa protein 1 (chaperonin) /// heat shock 60kDa protein 1 (chaperonin) pseudogene 4 HSPD1 /// HSPD 243372_at 2.34
purinergic receptor P2Y, G-protein coupled, 8 P2RY8 229686_at 2.336
GINS complex subunit 4 (Sld5 homolog) GINS4 211767_at 2.332
ADAMTS-like 1 ADAMTSL1 229585_at 2.33
mex-3 homolog C (C. elegans) MEX3C 1556874_a_at 2.326
discoidin, CUB and LCCL domain containing 2 DCBLD2 213865_at 2.323
cadherin-like 24 CDH24 1553166_at 2.321
homeobox A4 HOXA4 206289_at 2.321
erythrocyte membrane protein band 4.2 EPB42 210746_s_at 2.315
contactin associated protein-like 2 CNTNAP2 219301_s_at 2.309
dual specificity phosphatase 5 pseudogene DUSP5P 1553299_at 2.305
choroideremia (Rab escort protein 1) CHM 1569183_a_at 2.303
interleukin 21 receptor IL21R 221658_s_at 2.301
FERM domain containing 8 FRMD8 227964_at 2.293
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 NFKBIL2 1558329_at 2.286
calsequestrin 1 (fast-twitch, skeletal muscle) CASQ1 219645_at 2.285
OTU domain, ubiquitin aldehyde binding 2 OTUB2 222878_s_at 2.281
sterile alpha motif domain containing 11 SAMD11 1560477_a_at 2.28
leucine-rich repeats and WD repeat domain containing 1 LRWD1 225680_at 2.28
aquaporin 5 AQP5 213611_at 2.268
high mobility group AT-hook 2 HMGA2 1567224_at 2.267
acyl-Coenzyme A dehydrogenase, long chain ACADL 206068_s_at 2.265
A kinase (PRKA) anchor protein 6 AKAP6 205359_at 2.262
tetraspanin 13 TSPAN13 217979_at 2.262
minichromosome maintenance complex component 5 MCM5 201755_at 2.257
calcium activated nucleotidase 1 CANT1 1554327_a_at 2.252
plexin A2 PLXNA2 207290_at 2.239
talin 2 TLN2 212701_at 2.239
pregnancy specific beta-1-glycoprotein 3 PSG3 203399_x_at 2.233
carbohydrate (chondroitin 6) sulfotransferase 3 CHST3 32094_at 2.228
Janus kinase 2 JAK2 205842_s_at 2.224
pre-B-cell leukemia homeobox 4 PBX4 230536_at 2.223
transient receptor potential cation channel, subfamily C, member 3 TRPC3 210814_at 2.223
poliovirus receptor PVR 214443_at 2.221
retinoic acid receptor, gamma RARG 204188_s_at 2.217
clusterin CLU 208791_at 2.211
ADAM metallopeptidase domain 11 ADAM11 207880_at 2.204
FERM domain containing 8 FRMD8 1554903_at 2.196
pregnancy specific beta-1-glycoprotein 6 PSG6 208106_x_at 2.195
microtubule-associated protein 1B MAP1B 212233_at 2.193
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203017_s_at 2.19
prolactin PRL 205445_at 2.19
connector enhancer of kinase suppressor of Ras 2 CNKSR2 1554607_at 2.189
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide YWHAH 201020_at 2.188
MyoD family inhibitor domain containing MDFIC 1559942_at 2.186
fibroblast growth factor receptor 3 FGFR3 204379_s_at 2.184
cadherin 6, type 2, K-cadherin (fetal kidney) CDH6 205532_s_at 2.183
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annexin A10 ANXA10 210143_at 2.183
intermediate filament family orphan 2 IFFO2 225615_at 2.179
coiled-coil-helix-coiled-coil-helix domain containing 10 CHCHD10 224932_at 2.176
monoglyceride lipase MGLL 211026_s_at 2.175
oxysterol binding protein-like 6 OSBPL6 223805_at 2.169
glycerol-3-phosphate acyltransferase, mitochondrial GPAM 225420_at 2.162
collagen, type XIII, alpha 1 COL13A1 211343_s_at 2.157
SHC (Src homology 2 domain containing) family, member 4 SHC4 235238_at 2.156
FERM domain containing 3 FRMD3 230645_at 2.153
carbonic anhydrase I CA1 205949_at 2.148
small VCP/p97-interacting protein SVIP 230005_at 2.148
jun D proto-oncogene JUND 203751_x_at 2.146
heat shock 70kDa protein 1A /// heat shock 70kDa protein 1B HSPA1A /// HSPA200800_s_at 2.145
Ankyrin-repeat and fibronectin type III domain containing 1 ANKFN1 1559640_at 2.139
arylsulfatase B ARSB 1554032_at 2.139
nucleolar and coiled-body phosphoprotein 1 NOLC1 205895_s_at 2.133
SHC (Src homology 2 domain containing) family, member 4 SHC4 230538_at 2.132
TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) TRMT1 203701_s_at 2.127
GATA binding protein 3 GATA3 209604_s_at 2.123
heme oxygenase (decycling) 1 HMOX1 203665_at 2.123
chromosome 14 open reading frame 34 C14orf34 1555786_s_at 2.123
similar to HSPC047 protein LOC100134722 220692_at 2.122
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 203196_at 2.121
msh homeobox 2 MSX2 205555_s_at 2.118
Insulin receptor substrate 1 IRS1 235392_at 2.112
chondroitin sulfate synthase 3 CHSY3 242100_at 2.106
transient receptor potential cation channel, subfamily V, member 2 TRPV2 219282_s_at 2.1
RGM domain family, member B RGMB 227339_at 2.099
TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) TRMT1 210463_x_at 2.099
BTB (POZ) domain containing 11 BTBD11 238692_at 2.097
ATPase family, AAA domain containing 3A /// ATPase family, AAA domain containing 3B /// similar to AAATAD3A /// ATAD1552641_s_at 2.092
notchless homolog 1 (Drosophila) NLE1 203867_s_at 2.086
FERM domain containing 3 FRMD3 229893_at 2.079
SMAD family member 7 SMAD7 204790_at 2.078
Sp8 transcription factor SP8 239743_at 2.072
clusterin CLU 208792_s_at 2.071
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 1554918_a_at 2.069
malic enzyme 2, NAD(+)-dependent, mitochondrial ME2 210154_at 2.068
thromboxane A2 receptor TBXA2R 336_at 2.068
KIAA1609 KIAA1609 221843_s_at 2.067
suppressor of cytokine signaling 2 SOCS2 203373_at 2.065
myosin VA (heavy chain 12, myoxin) MYO5A 204527_at 2.06
hairy/enhancer-of-split related with YRPW motif 1 HEY1 44783_s_at 2.053
solute carrier family 4, sodium bicarbonate cotransporter, member 4 SLC4A4 1554027_a_at 2.051
YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) YOD1 215150_at 2.049
hairy/enhancer-of-split related with YRPW motif 1 HEY1 218839_at 2.047
glutamate receptor, ionotropic, kainate 2 GRIK2 1560265_at 2.046
smoothelin SMTN 207390_s_at 2.046
BTB (POZ) domain containing 11 BTBD11 228570_at 2.044
protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform PPP3CB 209817_at 2.043
septin 13 13-Sep 230355_at 2.042
potassium inwardly-rectifying channel, subfamily J, member 8 KCNJ8 205304_s_at 2.042
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 232080_at 2.04
Kruppel-like factor 2 (lung) KLF2 226646_at 2.037
paired related homeobox 2 PRRX2 219729_at 2.037
gamma-aminobutyric acid (GABA) A receptor, gamma 1 GABRG1 241805_at 2.032
acyl-CoA thioesterase 7 ACOT7 208002_s_at 2.026
coiled-coil domain containing 68 CCDC68 220180_at 2.022
SET domain and mariner transposase fusion gene SETMAR 1554060_s_at 2.021
ATPase type 13A3 ATP13A3 219558_at 2.018
glycerol-3-phosphate acyltransferase, mitochondrial GPAM 225424_at 2.018
KIAA1609 KIAA1609 65438_at 2.013
zinc finger protein 175 ZNF175 205497_at 2.01
prominin 2 PROM2 1552797_s_at 2.009
nicalin homolog (zebrafish) NCLN 222206_s_at 2.007
BAI1-associated protein 2 BAIAP2 205293_x_at 2.005
P antigen family, member 1 (prostate associated) PAGE1 206897_at 2.004
monoglyceride lipase MGLL 225102_at 2
collagen, type IV, alpha 6 COL4A6 210945_at 2
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Supplemental Table 2. Genes with increased expression due to ALK3QD in EOC spheroids
Gene Title Gene Symbol Probe Set ID Fold Change
lipopolysaccharide binding protein LBP 214461_at 72.27
loricrin LOR 207720_at 49.49
hairy/enhancer-of-split related with YRPW motif 2 HEY2 222921_s_at 48.379
actin, alpha, cardiac muscle 1 ACTC1 205132_at 40.174
CD24 molecule CD24 209772_s_at 39.195
CD24 molecule CD24 266_s_at 37.327
CD24 molecule CD24 209771_x_at 34.274
CD24 molecule CD24 216379_x_at 30.311
contactin associated protein-like 2 CNTNAP2 219301_s_at 25.559
CD24 molecule CD24 208650_s_at 24.444
cut-like homeobox 2 CUX2 213920_at 24.245
CD24 molecule CD24 208651_x_at 21.376
distal-less homeobox 2 DLX2 207147_at 20.206
FEZ family zinc finger 2 FEZF2 233972_s_at 16.35
involucrin IVL 214599_at 14.951
dickkopf homolog 1 (Xenopus laevis) DKK1 204602_at 13.536
cannabinoid receptor 1 (brain) CNR1 213436_at 13.412
gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2 209990_s_at 12.811
folate receptor 3 (gamma) FOLR3 206371_at 12.253
chromosome 5 open reading frame 23 C5orf23 219054_at 11.902
chemokine (C-C motif) ligand 26 CCL26 223710_at 11.408
gap junction protein, delta 3, 31.9kDa GJD3 230025_at 10.917
SMAD family member 9 SMAD9 206320_s_at 10.709
SMAD family member 6 SMAD6 207069_s_at 10.538
noggin NOG 231798_at 10.343
chromosome 2 open reading frame 88 C2orf88 223754_at 10.294
guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 GNGT1 207166_at 9.878
lipopolysaccharide binding protein LBP 211652_s_at 9.867
keratin 81 KRT81 213711_at 9.186
Interleukin 1 receptor-like 1 IL1RL1 234066_at 9.109
distal-less homeobox 1 DLX1 242138_at 8.579
tumor necrosis factor (ligand) superfamily, member 9 TNFSF9 206907_at 8.53
chemokine (C-C motif) ligand 2 CCL2 216598_s_at 8.503
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2 SLC25A2 224166_at 8.37
hypothetical protein LOC90246 LOC90246 233835_at 7.669
neural cell adhesion molecule 1 NCAM1 227394_at 7.19
Inhibitor of growth family, member 2 ING2 213544_at 7.105
heat shock 70kDa protein 1A /// heat shock 70kDa protein 1B HSPA1A /// HSP200800_s_at 7.074
hypothetical gene supported by BC011527; BC021928; BC011527; BC021928 LOC284260 1570208_at 7.018
leucine rich repeat containing 4 LRRC4 223552_at 6.963
protocadherin 9 PCDH9 219738_s_at 6.945
neutrophil cytosolic factor 2 NCF2 209949_at 6.843
tubulin, beta 2B TUBB2B 214023_x_at 6.831
hypothetical LOC100127940 LOC1001279401564299_at 6.828
calcitonin-related polypeptide alpha CALCA 217561_at 6.805
CD300 molecule-like family member g CD300LG 1552509_a_at 6.675
FEZ family zinc finger 2 FEZF2 221086_s_at 6.65
chromosome 2 open reading frame 88 C2orf88 228195_at 6.64
Tropomyosin 4 TPM4 1559989_at 6.591
neurofilament, medium polypeptide NEFM 205113_at 6.543
synaptotagmin XV SYT15 1560879_a_at 6.516
heparan sulfate 6-O-sulfotransferase 3 HS6ST3 232275_s_at 6.499
myozenin 2 MYOZ2 207148_x_at 6.44
suppressor of cytokine signaling 2 SOCS2 203372_s_at 6.416
UPF0632 protein A LOC388630 244472_at 6.388
hypothetical protein LOC254057 LOC254057 232370_at 6.369
hypothetical protein LOC284542 LOC284542 230920_at 6.349
collagen, type XXIII, alpha 1 COL23A1 229168_at 6.304
hypothetical LOC84983 MGC14436 1553811_at 6.267
contactin associated protein-like 2 CNTNAP2 219302_s_at 6.263
sterile alpha motif domain containing 4A SAMD4A 215120_s_at 6.246
A kinase (PRKA) anchor protein 5 AKAP5 230846_at 6.169
myozenin 2 MYOZ2 213782_s_at 6.144
potassium voltage-gated channel, KQT-like subfamily, member 5 KCNQ5 244623_at 6.034
solute carrier family 37 (glycerol-3-phosphate transporter), member 1 SLC37A1 218928_s_at 6.029
pyruvate dehydrogenase kinase, isozyme 4 PDK4 225207_at 5.985
matrix metallopeptidase 24 (membrane-inserted) MMP24 213171_s_at 5.825
NEL-like 1 (chicken) NELL1 206089_at 5.742
cartilage oligomeric matrix protein COMP 205713_s_at 5.662
hedgehog interacting protein HHIP 1556037_s_at 5.573
cyclic AMP-regulated phosphoprotein, 21 kD /// hypothetical protein LOC100130503 ARPP-21 /// LO 1556599_s_at 5.243
KIAA1128 KIAA1128 1554131_at 5.23
ribonuclease, RNase A family, 1 (pancreatic) RNASE1 201785_at 5.165
106 
 
Table S2.2 cont'd. 
 
SV2 related protein homolog (rat) SVOP 229818_at 5.14
coiled-coil domain containing 85A CCDC85A 235228_at 5.131
heat shock 70kDa protein 1A /// heat shock 70kDa protein 1B HSPA1A /// HSP202581_at 5.082
chromosome 14 open reading frame 81 C14orf81 1564499_at 5.047
LIM domain only 2 (rhombotin-like 1) LMO2 204249_s_at 4.971
keratin associated protein 19-3 KRTAP19-3 240967_at 4.965
retinol binding protein 2, cellular RBP2 231734_at 4.96
suppressor of cytokine signaling 2 SOCS2 203373_at 4.938
chromosome 1 open reading frame 14 C1orf14 220996_s_at 4.936
neuron navigator 2 NAV2 218330_s_at 4.868
Syntrophin, gamma 1 SNTG1 1562287_at 4.854
G protein-coupled receptor 83 GPR83 222953_at 4.849
doublecortin domain containing 5 DCDC5 232603_at 4.783
lin-7 homolog B (C. elegans) LIN7B 241957_x_at 4.773
acyl-CoA thioesterase 11 ACOT11 214763_at 4.76
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha AKR1C2 211653_x_at 4.759
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 B3GALT5 206947_at 4.757
crystallin, alpha B CRYAB 209283_at 4.708
tachykinin, precursor 1 TAC1 206552_s_at 4.698
msh homeobox 2 MSX2 205555_s_at 4.689
epiplakin 1 EPPK1 232165_at 4.664
paired related homeobox 2 PRRX2 219729_at 4.659
chromosome 10 open reading frame 126 C10orf126 1553915_at 4.65
Na+/H+ exchanger domain containing 2 NHEDC2 229491_at 4.648
complement component (3b/4b) receptor 1-like CR1L 239206_at 4.631
chromosome 12 open reading frame 59 C12orf59 236646_at 4.616
chromosome 12 open reading frame 47 C12orf47 212868_x_at 4.586
plexin A2 PLXNA2 213030_s_at 4.575
heparan sulfate 6-O-sulfotransferase 3 HS6ST3 232276_at 4.547
glutathione peroxidase 3 (plasma) GPX3 214091_s_at 4.534
neural cell adhesion molecule 1 NCAM1 209968_s_at 4.53
msh homeobox 2 MSX2 210319_x_at 4.527
pyruvate dehydrogenase kinase, isozyme 4 PDK4 1562321_at 4.525
G protein-coupled receptor 137C GPR137C 242592_at 4.515
mal, T-cell differentiation protein-like MALL 209373_at 4.481
phospholipase C, eta 1 PLCH1 216634_at 4.47
G protein-coupled receptor 158 GPR158 232195_at 4.448
kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) KMO 205306_x_at 4.438
fibrinogen C domain containing 1 FIBCD1 240042_at 4.389
uronyl-2-sulfotransferase UST 205138_s_at 4.359
Atonal homolog 8 (Drosophila) ATOH8 1558706_a_at 4.353
chromosome 13 open reading frame 38 C13orf38 234085_at 4.351
hypothetical protein LOC641364 LOC641364 1562253_at 4.35
transient receptor potential cation channel, subfamily C, member 3 TRPC3 210814_at 4.341
neurofilament, light polypeptide NEFL 221801_x_at 4.293
placenta-specific 1 PLAC1 219702_at 4.286
maestro MRO 224324_at 4.283
atonal homolog 8 (Drosophila) ATOH8 228890_at 4.266
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroi AKR1C1 204151_x_at 4.254
replication protein A4, 34kDa RPA4 221143_at 4.239
hypothetical protein LOC652821 /// variable charge, Y-linked /// variable charge, Y-linked 1B LOC652821 /// V206922_at 4.209
serpin peptidase inhibitor, clade B (ovalbumin), member 5 SERPINB5 1555551_at 4.159
hypothetical protein MGC16121 MGC16121 228235_at 4.159
par-3 partitioning defective 3 homolog B (C. elegans) PARD3B 1555113_at 4.144
slit homolog 3 (Drosophila) SLIT3 216216_at 4.107
caspase 12 (gene/pseudogene) CASP12 1564736_a_at 4.104
DnaJ (Hsp40) homolog, subfamily A, member 4 DNAJA4 225061_at 4.102
A kinase (PRKA) anchor protein 5 AKAP5 207800_at 4.1
activating transcription factor 3 ATF3 202672_s_at 4.099
TMF1-regulated nuclear protein 1 TRNP1 227862_at 4.095
arginine-glutamic acid dipeptide (RE) repeats RERE 200939_s_at 4.089
solute carrier family 23 (nucleobase transporters), member 3 SLC23A3 1553265_at 4.076
Cell division cycle 20 homolog B (S. cerevisiae) CDC20B 240161_s_at 4.069
coiled-coil domain containing 3 CCDC3 223316_at 4.062
THAP domain containing, apoptosis associated protein 2 THAP2 230380_at 4.04
calponin 1, basic, smooth muscle CNN1 203951_at 4.023
natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) NPR1 204648_at 4.018
glycoprotein V (platelet) GP5 211525_s_at 3.984
interleukin 8 IL8 211506_s_at 3.977
hypothetical LOC100268168 LOC100268168233491_at 3.975
placental growth factor PGF 209652_s_at 3.963
bone morphogenetic protein receptor, type IB BMPR1B 210523_at 3.961
immunoglobulin-like and fibronectin type III domain containing 1 IGFN1 229275_at 3.928
DnaJ (Hsp40) homolog, subfamily A, member 4 DNAJA4 1554334_a_at 3.921
parathyroid hormone-like hormone PTHLH 211756_at 3.915
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transducin-like enhancer of split 6 (E(sp1) homolog, Drosophila) TLE6 1553813_s_at 3.895
aggrecan ACAN 207692_s_at 3.883
protein phosphatase 1, regulatory (inhibitor) subunit 14C PPP1R14C 226907_at 3.88
similar to hCG41624 LOC1001280711556560_a_at 3.865
isopentenyl-diphosphate delta isomerase 2 IDI2 1552491_at 3.86
Triple functional domain (PTPRF interacting) TRIO 216700_at 3.845
discoidin, CUB and LCCL domain containing 2 DCBLD2 213873_at 3.841
cholecystokinin CCK 205827_at 3.831
T-box, brain, 1 TBR1 220025_at 3.801
Phospholamban PLN 228202_at 3.777
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha AKR1C2 209699_x_at 3.771
nescient helix loop helix 2 NHLH2 215228_at 3.765
AT rich interactive domain 1A (SWI-like) ARID1A 207591_s_at 3.739
hairy/enhancer-of-split related with YRPW motif 1 HEY1 44783_s_at 3.736
dynein, axonemal, heavy chain 1 DNAH1 239059_at 3.729
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroi AKR1C1 216594_x_at 3.725
DiGeorge syndrome critical region gene 12 DGCR12 1566235_at 3.722
frizzled homolog 8 (Drosophila) FZD8 227405_s_at 3.713
acid phosphatase 5, tartrate resistant ACP5 204638_at 3.709
frizzled homolog 8 (Drosophila) FZD8 224325_at 3.698
distal-less homeobox 3 DLX3 231778_at 3.698
cAMP responsive element binding protein 5 CREB5 229228_at 3.695
similar to hCG1815045 LOC100131781240320_at 3.694
epiplakin 1 EPPK1 208156_x_at 3.684
chromodomain helicase DNA binding protein 5 CHD5 213965_s_at 3.683
KH domain containing, RNA binding, signal transduction associated 2 KHDRBS2 215527_at 3.679
peptidase domain containing associated with muscle regeneration 1 PAMR1 213661_at 3.667
WNK lysine deficient protein kinase 2 WNK2 1557536_at 3.665
catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein) CTNND2 209617_s_at 3.665
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 232080_at 3.641
parathyroid hormone-like hormone PTHLH 206300_s_at 3.641
calsequestrin 1 (fast-twitch, skeletal muscle) CASQ1 219645_at 3.64
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203015_s_at 3.625
heat shock 70kDa protein 1A HSPA1A 200799_at 3.62
Hypothetical LOC150538 FLJ32063 235147_at 3.618
gap junction protein, gamma 1, 45kDa GJC1 228563_at 3.617
transmembrane protein 132E TMEM132E 243708_at 3.56
gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2 217077_s_at 3.544
microtubule-associated protein 1B MAP1B 226084_at 3.528
chromosome 1 open reading frame 129 C1orf129 221182_at 3.525
signal transducer and activator of transcription 3 (acute-phase response factor) STAT3 243213_at 3.509
insulin-like growth factor binding protein 5 IGFBP5 1555997_s_at 3.487
calmodulin binding transcription activator 1 CAMTA1 213268_at 3.465
chymotrypsin-like elastase family, member 3A CELA3A 210080_x_at 3.457
homeobox C13 HOXC13 219832_s_at 3.44
talin 2 TLN2 212701_at 3.438
chondroitin sulfate proteoglycan 4 CSPG4 214297_at 3.436
atlastin GTPase 2 ATL2 237968_at 3.429
elastin microfibril interfacer 2 EMILIN2 224374_s_at 3.429
ArfGAP with dual PH domains 1 ADAP1 219150_s_at 3.411
Neural cell adhesion molecule 1 NCAM1 231532_at 3.405
Kruppel-like factor 6 KLF6 208960_s_at 3.401
growth arrest and DNA-damage-inducible, beta GADD45B 209304_x_at 3.387
hypothetical protein LOC144481 LOC144481 1559315_s_at 3.383
UL16 binding protein 2 ULBP2 238542_at 3.378
oxytocin, prepropeptide OXT 207576_x_at 3.368
met proto-oncogene (hepatocyte growth factor receptor) MET 203510_at 3.364
copine IV CPNE4 231336_at 3.362
Na+/H+ exchanger domain containing 2 NHEDC2 1564746_at 3.347
makorin ring finger protein 2 MKRN2 216995_x_at 3.338
potassium voltage-gated channel, Shaw-related subfamily, member 4 KCNC4 208251_at 3.335
neuron navigator 2 NAV2 222598_s_at 3.326
hypothetical LOC100126784 LOC100126784240407_at 3.326
Fc receptor-like A FCRLA 235400_at 3.312
eukaryotic translation initiation factor 4A, isoform 2 EIF4A2 1556350_a_at 3.305
melanoma cell adhesion molecule MCAM 209087_x_at 3.3
dual specificity phosphatase 5 pseudogene DUSP5P 1553299_at 3.296
glycoprotein, alpha-galactosyltransferase 1 GGTA1 228376_at 3.291
Hypothetical protein LOC203274 LOC203274 232034_at 3.29
kazrin RP1-21O18.1 229144_at 3.286
brain-derived neurotrophic factor BDNF 206382_s_at 3.278
AF4/FMR2 family, member 2 AFF2 206105_at 3.267
ATPase type 13A3 ATP13A3 219558_at 3.262
GPRIN family member 3 GPRIN3 1556697_at 3.253
Atonal homolog 8 (Drosophila) ATOH8 1558705_at 3.247
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keratin 73 KRT73 1553537_at 3.238
adrenergic, beta-1-, receptor ADRB1 229309_at 3.225
tropomyosin 1 (alpha) TPM1 206117_at 3.223
kazrin RP1-21O18.1 213478_at 3.222
muscle RAS oncogene homolog MRAS 225185_at 3.218
hairy/enhancer-of-split related with YRPW motif 1 HEY1 218839_at 3.216
mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 214339_s_at 3.207
echinoderm microtubule associated protein like 2 EML2 204399_s_at 3.204
hyaluronoglucosaminidase 1 HYAL1 210619_s_at 3.197
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203019_x_at 3.195
stimulated by retinoic acid gene 6 homolog (mouse) STRA6 1569334_at 3.185
Kruppel-like factor 6 KLF6 208961_s_at 3.185
tripartite motif-containing 14 TRIM14 211044_at 3.184
SERTA domain containing 4 SERTAD4 229674_at 3.181
cAMP responsive element binding protein 5 CREB5 205931_s_at 3.167
histone cluster 1, H3g HIST1H3G 208496_x_at 3.156
cysteinyl-tRNA synthetase CARS 240982_at 3.155
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 210871_x_at 3.153
hypothetical protein LOC149086 LOC149086 1566647_s_at 3.152
hypothetical protein LOC731477 LOC731477 237312_at 3.146
Glycoprotein, synaptic 2 GPSN2 231556_at 3.146
growth arrest and DNA-damage-inducible, beta GADD45B 209305_s_at 3.14
cartilage acidic protein 1 CRTAC1 221204_s_at 3.131
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203018_s_at 3.122
msh homeobox 1 MSX1 205932_s_at 3.121
Hypothetical protein DKFZp686O24166 DKFZp686O241229715_at 3.115
SLAM family member 9 SLAMF9 1553770_a_at 3.113
keratin associated protein 2-4 KRTAP2-4 1555673_at 3.112
family with sequence similarity 83, member G FAM83G 228587_at 3.108
SMAD family member 9 SMAD9 227719_at 3.101
interleukin 1 family, member 5 (delta) IL1F5 222223_s_at 3.098
v-myb myeloblastosis viral oncogene homolog (avian) MYB 204798_at 3.094
natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) NPR1 32625_at 3.083
heat shock protein 90kDa alpha (cytosolic), class A member 1 HSP90AA1 211968_s_at 3.081
stimulated by retinoic acid gene 6 homolog (mouse) STRA6 221701_s_at 3.08
hypothetical protein MGC16121 MGC16121 227488_at 3.072
peptidylprolyl isomerase A (cyclophilin A)-like 4A /// peptidylprolyl isomerase A (cyclophilin A)-like 4B /// pePPIAL4A /// PP 217136_at 3.066
HHIP-like 2 HHIPL2 220283_at 3.056
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203016_s_at 3.056
microtubule-associated protein 1B MAP1B 212233_at 3.056
hypothetical protein LOC100132388 LOC100132388224241_s_at 3.045
phospholipase C, epsilon 1 PLCE1 205111_s_at 3.04
tousled-like kinase 2 TLK2 233349_at 3.038
leucine zipper protein 2 LUZP2 215323_at 3.034
GATA binding protein 3 GATA3 209602_s_at 3.034
Kruppel-like factor 4 (gut) KLF4 220266_s_at 3.033
solute carrier family 4, sodium bicarbonate cotransporter, member 7 SLC4A7 207604_s_at 3.033
kinesin family member 23 KIF23 204709_s_at 3.031
hypothetical gene supported by AK098783 FLJ25917 1564295_at 3.03
nuclear receptor interacting protein 3 NRIP3 222900_at 3.023
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolasMTHFD1 202309_at 3.005
dual specificity phosphatase 1 DUSP1 201044_x_at 2.985
gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 235504_at 2.982
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 9 (GalNAc-T9) /// simGALNT9 /// LOC229451_at 2.974
matrix metallopeptidase 25 MMP25 207890_s_at 2.973
growth arrest and DNA-damage-inducible, beta GADD45B 207574_s_at 2.973
ovo-like 1(Drosophila) OVOL1 229396_at 2.969
progesterone receptor PGR 228554_at 2.967
Kruppel-like factor 2 (lung) KLF2 219371_s_at 2.967
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) HMGCS1 205822_s_at 2.964
Kruppel-like factor 4 (gut) KLF4 221841_s_at 2.962
heat shock 27kDa protein 1 HSPB1 201841_s_at 2.961
interleukin 8 IL8 202859_x_at 2.956
glycerol kinase GK 215977_x_at 2.955
Kruppel-like factor 6 KLF6 1555832_s_at 2.953
secretogranin II (chromogranin C) SCG2 204035_at 2.94
plexin A2 PLXNA2 227032_at 2.938
pleckstrin homology-like domain, family A, member 1 PHLDA1 218000_s_at 2.933
somatostatin receptor 1 SSTR1 235591_at 2.932
chromosome 18 open reading frame 1 C18orf1 207996_s_at 2.927
brain-derived neurotrophic factor BDNF 239367_at 2.919
fibulin 2 FBLN2 203886_s_at 2.905
parathyroid hormone-like hormone PTHLH 210355_at 2.896
hairy and enhancer of split 6 (Drosophila) HES6 226446_at 2.89
ArfGAP with dual PH domains 1 ADAP1 90265_at 2.888
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poliovirus receptor PVR 212662_at 2.888
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 SLC25A15 222705_s_at 2.879
insulin-like 3 (Leydig cell) INSL3 1553594_a_at 2.875
similar to hCG2042915 LOC100129673236611_at 2.871
Collagen, type XXVII, alpha 1 COL27A1 1564008_at 2.87
adaptor-related protein complex 1, sigma 3 subunit AP1S3 1555731_a_at 2.866
prolactin receptor PRLR 216638_s_at 2.865
tubulin tyrosine ligase-like family, member 5 TTLL5 1566102_at 2.851
Threonyl-tRNA synthetase TARS 240206_at 2.847
glycine-N-acyltransferase-like 1 GLYATL1 227794_at 2.843
one cut homeobox 2 ONECUT2 233441_at 2.842
transient receptor potential cation channel, subfamily C, member 3 TRPC3 206425_s_at 2.834
F-box protein 27 FBXO27 235169_at 2.825
synaptotagmin XV SYT15 1560878_at 2.825
chromosome 17 open reading frame 53 C17orf53 219879_s_at 2.823
mucin 12, cell surface associated MUC12 226654_at 2.816
SMAD family member 7 SMAD7 204790_at 2.813
cysteine-rich, angiogenic inducer, 61 CYR61 210764_s_at 2.813
DnaJ (Hsp40) homolog, subfamily C, member 6 DNAJC6 204720_s_at 2.807
Kruppel-like factor 6 KLF6 224606_at 2.798
carbonic anhydrase II CA2 209301_at 2.796
TIMP metallopeptidase inhibitor 3 TIMP3 201150_s_at 2.787
scavenger receptor class A, member 5 (putative) SCARA5 235849_at 2.778
chimerin (chimaerin) 2 CHN2 213385_at 2.776
chromosome 1 open reading frame 114 C1orf114 1555112_a_at 2.774
discoidin, CUB and LCCL domain containing 2 DCBLD2 213865_at 2.769
SHC (Src homology 2 domain containing) family, member 4 SHC4 230538_at 2.765
aldehyde dehydrogenase 3 family, member B2 ALDH3B2 204941_s_at 2.76
PDZ and LIM domain 3 PDLIM3 238592_at 2.758
prostaglandin E synthase PTGES 207388_s_at 2.757
ubiquitin-like modifier activating enzyme 6 UBA6 1555441_at 2.756
sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and sSEMA5B 223610_at 2.752
KIAA1826 KIAA1826 223799_at 2.752
serine/threonine kinase 35 STK35 1553673_at 2.741
hairy and enhancer of split 4 (Drosophila) HES4 227347_x_at 2.737
fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) FABP3 214285_at 2.727
phosphatidylinositol transfer protein, cytoplasmic 1 PITPNC1 229414_at 2.725
brix domain containing 5 BXDC5 234243_at 2.718
echinoderm microtubule associated protein like 1 EML1 204797_s_at 2.712
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide YWHAH 201020_at 2.704
KIT ligand KITLG 226534_at 2.702
protein phosphatase 4, regulatory subunit 1-like PPP4R1L 223733_s_at 2.7
hyaluronan synthase 2 HAS2 206432_at 2.696
Similar to programmed cell death 6 interacting protein LOC731884 217520_x_at 2.689
mucin 17, cell surface associated MUC17 232321_at 2.688
chromosome 20 open reading frame 195 C20orf195 220426_at 2.685
tubulin, beta 2A TUBB2A 204141_at 2.682
poly(A) binding protein, cytoplasmic 1-like PABPC1L 233104_at 2.682
progestin and adipoQ receptor family member IX PAQR9 1558322_a_at 2.681
neuron navigator 2 NAV2 222599_s_at 2.678
interleukin 1 receptor accessory protein-like 1 IL1RAPL1 222963_s_at 2.666
heat shock 60kDa protein 1 (chaperonin) /// heat shock 60kDa protein 1 (chaperonin) pseudogene 4 HSPD1 /// HSP 243372_at 2.642
gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2 211679_x_at 2.641
actinin, alpha 2 ACTN2 203863_at 2.635
annexin A1 ANXA1 201012_at 2.631
NPC1 (Niemann-Pick disease, type C1, gene)-like 1 NPC1L1 220106_at 2.631
protocadherin 10 PCDH10 1552925_at 2.624
lin-7 homolog B (C. elegans) LIN7B 219760_at 2.621
aminolevulinate, delta-, synthase 2 ALAS2 244205_at 2.621
hypothetical protein LOC100132356 hCG_2039148 1558310_s_at 2.611
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN 202626_s_at 2.609
family with sequence similarity 84, member B FAM84B 225864_at 2.594
calpain 5 CAPN5 205166_at 2.584
glycerol kinase GK 207387_s_at 2.583
phosphatidylinositol transfer protein, membrane-associated 2 PITPNM2 1552924_a_at 2.579
leucine-rich repeat LGI family, member 2 LGI2 219699_at 2.579
oxidative stress induced growth inhibitor 1 OSGIN1 219475_at 2.578
serine incorporator 2 SERINC2 224762_at 2.578
KIAA2018 KIAA2018 242508_at 2.571
oxysterol binding protein-like 6 OSBPL6 238575_at 2.563
dual specificity phosphatase 26 (putative) DUSP26 219144_at 2.56
Kruppel-like factor 13 KLF13 219878_s_at 2.551
KIAA1310 KIAA1310 1558652_at 2.548
jagged 1 (Alagille syndrome) JAG1 209098_s_at 2.546
tubulin, beta 2A /// tubulin, beta 2B TUBB2A /// TUB209372_x_at 2.546
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deleted in liver cancer 1 DLC1 224822_at 2.543
UL16 binding protein 2 ULBP2 221291_at 2.537
cysteine and glycine-rich protein 2 CSRP2 207030_s_at 2.537
gremlin 2, cysteine knot superfamily, homolog (Xenopus laevis) GREM2 240509_s_at 2.535
hypothetical LOC401317 LOC401317 242329_at 2.533
protocadherin 9 PCDH9 219737_s_at 2.533
cysteine and glycine-rich protein 2 CSRP2 211126_s_at 2.532
lipopolysaccharide-induced TNF factor LITAF 200706_s_at 2.532
ADAM metallopeptidase domain 28 ADAM28 208269_s_at 2.531
vaccinia related kinase 3 VRK3 239190_at 2.523
zinc finger and BTB domain containing 1 ZBTB1 213376_at 2.516
Anthrax toxin receptor 1 ANTXR1 234832_at 2.512
armadillo repeat gene deletes in velocardiofacial syndrome ARVCF 217516_x_at 2.508
C-type lectin domain family 4, member E CLEC4E 222934_s_at 2.507
GATA binding protein 2 GATA2 209710_at 2.501
nuclear receptor interacting protein 3 NRIP3 219557_s_at 2.495
GINS complex subunit 3 (Psf3 homolog) GINS3 218719_s_at 2.481
family with sequence similarity 62 (C2 domain containing), member C FAM62C 239770_at 2.457
carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 CHST8 221065_s_at 2.451
gamma-aminobutyric acid (GABA) A receptor, beta 1 GABRB1 207010_at 2.448
stanniocalcin 2 STC2 203439_s_at 2.441
calmodulin binding transcription activator 1 CAMTA1 1555370_a_at 2.439
T cell receptor beta variable 27 TRBV27 241133_at 2.439
D-aspartate oxidase DDO 207418_s_at 2.435
Transforming, acidic coiled-coil containing protein 1 TACC1 1557305_at 2.433
GATA binding protein 5 GATA5 238095_at 2.432
insulin-like growth factor binding protein 5 IGFBP5 203424_s_at 2.423
spectrin, beta, non-erythrocytic 1 SPTBN1 226342_at 2.422
cancer susceptibility candidate 5 CASC5 1552680_a_at 2.42
phospholipase inhibitor LOC646627 238143_at 2.417
T-box 3 TBX3 229576_s_at 2.416
KN motif and ankyrin repeat domains 4 KANK4 229125_at 2.414
Norrie disease (pseudoglioma) NDP 206022_at 2.408
solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 SLC7A1 212290_at 2.408
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 SLC25A15 218653_at 2.4
MHC class I polypeptide-related sequence A MICA 205904_at 2.396
aquaporin 1 (Colton blood group) AQP1 209047_at 2.395
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT 202834_at 2.393
MAP/microtubule affinity-regulating kinase 1 MARK1 226653_at 2.386
schlafen family member 5 SLFN5 243999_at 2.384
semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) SEMA7A 230345_at 2.382
deleted in liver cancer 1 DLC1 220511_s_at 2.379
PDZ and LIM domain 3 PDLIM3 210170_at 2.378
mal, T-cell differentiation protein MAL 204777_s_at 2.376
zinc finger, MYM-type 2 ZMYM2 210281_s_at 2.375
ATPase, class V, type 10A ATP10A 214255_at 2.375
bone morphogenetic protein 7 BMP7 211259_s_at 2.374
glycine amidinotransferase (L-arginine:glycine amidinotransferase) GATM 216733_s_at 2.371
heat shock 70kD protein 12B HSPA12B 234610_at 2.371
mex-3 homolog C (C. elegans) MEX3C 1556874_a_at 2.37
tetraspanin 12 TSPAN12 219274_at 2.368
matrix metallopeptidase 7 (matrilysin, uterine) MMP7 204259_at 2.368
tetraspanin 10 TSPAN10 223795_at 2.366
insulin-like growth factor binding protein 5 IGFBP5 203426_s_at 2.363
cyclic nucleotide gated channel beta 1 CNGB1 207342_at 2.359
ChaC, cation transport regulator homolog 1 (E. coli) CHAC1 219270_at 2.358
RAB27B, member RAS oncogene family RAB27B 207017_at 2.357
spire homolog 2 (Drosophila) SPIRE2 227706_at 2.353
small VCP/p97-interacting protein SVIP 230285_at 2.353
phosphatidylinositol transfer protein, cytoplasmic 1 PITPNC1 238649_at 2.351
pyruvate dehydrogenase (lipoamide) alpha 2 PDHA2 214518_at 2.348
rhodopsin RHO 206454_s_at 2.344
glycerol kinase GK 217167_x_at 2.343
small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta SGTB 228745_at 2.342
N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits GNPTAB 220398_at 2.342
tubulin tyrosine ligase-like family, member 7 TTLL7 219882_at 2.339
PH domain and leucine rich repeat protein phosphatase-like PHLPPL 213407_at 2.337
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN 210754_s_at 2.337
chloride intracellular channel 3 CLIC3 219529_at 2.336
plasticity-related gene 2 PRG2 220798_x_at 2.336
microRNA host gene 1 (non-protein coding) MIRHG1 232291_at 2.334
Janus kinase 2 JAK2 205841_at 2.333
serine/threonine protein kinase MST4 RP6-213H19.1 224407_s_at 2.332
RAB27B, member RAS oncogene family RAB27B 207018_s_at 2.331
solute carrier family 14 (urea transporter), member 2 SLC14A2 208409_at 2.331
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phosphatidylinositol transfer protein, cytoplasmic 1 PITPNC1 219155_at 2.312
Tropomyosin 1 (alpha) TPM1 238688_at 2.312
methyl-CpG binding domain protein 2 MBD2 214397_at 2.31
T-box 2 TBX2 213417_at 2.309
Jagged 1 (Alagille syndrome) JAG1 231183_s_at 2.306
GATA binding protein 3 GATA3 209604_s_at 2.301
tensin 4 TNS4 230398_at 2.297
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN 202625_at 2.295
jumonji domain containing 4 JMJD4 230810_at 2.295
small VCP/p97-interacting protein SVIP 226278_at 2.293
chromosome 20 open reading frame 57 C20orf57 234829_at 2.293
contactin 3 (plasmacytoma associated) CNTN3 229831_at 2.292
jun D proto-oncogene JUND 203751_x_at 2.291
nuclear receptor subfamily 1, group D, member 1 /// thyroid hormone receptor, alpha (erythroblastic leukemNR1D1 /// THRA204760_s_at 2.291
chondroitin sulfate proteoglycan 4 CSPG4 204736_s_at 2.282
heparin-binding EGF-like growth factor HBEGF 38037_at 2.28
MHC class I polypeptide-related sequence A /// MHC class I polypeptide-related sequence B MICA /// MICB 205905_s_at 2.277
dishevelled associated activator of morphogenesis 1 DAAM1 244062_at 2.276
natural cytotoxicity triggering receptor 2 NCR2 217493_x_at 2.269
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein ID3 207826_s_at 2.269
acylphosphatase 1, erythrocyte (common) type ACYP1 205260_s_at 2.268
pleckstrin homology-like domain, family A, member 1 PHLDA1 217997_at 2.268
UDP glucuronosyltransferase 1 family, polypeptide A1 /// UDP glucuronosyltransferase 1 family, polypeptidUGT1A1 /// UGT208596_s_at 2.265
choroideremia-like (Rab escort protein 2) CHML 226350_at 2.262
echinoderm microtubule associated protein like 6 EML6 229656_s_at 2.261
prostaglandin I2 (prostacyclin) synthase PTGIS 211892_s_at 2.26
karyopherin alpha 4 (importin alpha 3) KPNA4 209653_at 2.259
ubiquitin specific peptidase 53 USP53 231817_at 2.258
blood vessel epicardial substance BVES 223853_at 2.256
tetratricopeptide repeat domain 32 TTC32 226838_at 2.25
glutamate receptor, ionotropic, kainate 2 GRIK2 1563754_at 2.25
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) ETS1 1555355_a_at 2.249
Hyaluronan synthase 2 HAS2 230372_at 2.244
syndecan 1 SDC1 201287_s_at 2.244
pleckstrin 2 PLEK2 218644_at 2.24
T-box 18 TBX18 1559840_s_at 2.238
fibroblast growth factor receptor 3 FGFR3 204379_s_at 2.227
myosin X MYO10 201976_s_at 2.225
kinesin family member 7 KIF7 229405_at 2.224
GNAS complex locus GNAS 217673_x_at 2.223
non imprinted in Prader-Willi/Angelman syndrome 1 NIPA1 225752_at 2.223
glycogen synthase kinase 3 alpha GSK3A 202210_x_at 2.22
radical S-adenosyl methionine domain containing 2 RSAD2 213797_at 2.22
peptidoglycan recognition protein 4 PGLYRP4 220944_at 2.218
WD repeat domain 69 WDR69 242162_at 2.215
ADP-ribosylarginine hydrolase ADPRH 228042_at 2.214
tight junction protein 2 (zona occludens 2) TJP2 202085_at 2.213
KIAA0182 KIAA0182 212056_at 2.209
tubulin, beta 3 TUBB3 202154_x_at 2.204
keratin 24 KRT24 220267_at 2.191
malic enzyme 2, NAD(+)-dependent, mitochondrial ME2 210154_at 2.187
abhydrolase domain containing 5 ABHD5 218739_at 2.185
T-box 3 TBX3 225544_at 2.183
cadherin-like 24 CDH24 1553166_at 2.181
cadherin 4, type 1, R-cadherin (retinal) CDH4 1563587_at 2.177
synovial sarcoma, X breakpoint 2 interacting protein SSX2IP 203017_s_at 2.175
blood vessel epicardial substance BVES 228783_at 2.173
similar to MCT /// solute carrier family 16, member 5 (monocarboxylic acid transporter 6) LOC100133772206600_s_at 2.166
transmembrane protein 70 TMEM70 219449_s_at 2.162
inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 209291_at 2.158
protein phosphatase 1, regulatory (inhibitor) subunit 15A PPP1R15A 202014_at 2.157
integrin, alpha 6 ITGA6 201656_at 2.155
synaptotagmin XI SYT11 209198_s_at 2.15
kelch domain containing 10 KLHDC10 209254_at 2.15
transient receptor potential cation channel, subfamily V, member 2 TRPV2 219282_s_at 2.149
tropomyosin 1 (alpha) TPM1 1558532_at 2.145
serine hydrolase-like 2 SERHL2 217276_x_at 2.144
beta-1,4-N-acetyl-galactosaminyl transferase 1 B4GALNT1 206435_at 2.14
dual specificity phosphatase 8 DUSP8 206374_at 2.133
progestin and adipoQ receptor family member V PAQR5 220333_at 2.132
hypothetical protein LOC149684 LOC149684 244231_at 2.132
stanniocalcin 2 STC2 203438_at 2.131
glutamate receptor interacting protein 2 GRIP2 216481_at 2.131
connective tissue growth factor CTGF 209101_at 2.131
glycophorin B (MNS blood group) GYPB 207459_x_at 2.121
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staufen, RNA binding protein, homolog 2 (Drosophila) STAU2 227179_at 2.119
zinc finger protein 83 ZNF83 236429_at 2.118
transmembrane protein 8 (five membrane-spanning domains) TMEM8 221882_s_at 2.118
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 MLLT11 211071_s_at 2.115
Rho-guanine nucleotide exchange factor RGNEF 1560348_at 2.112
ubiquilin 1 UBQLN1 222989_s_at 2.112
lipopolysaccharide-induced TNF factor LITAF 200704_at 2.11
zinc finger CCCH-type containing 12C ZC3H12C 231899_at 2.108
paternally expressed 10 PEG10 212092_at 2.108
Fraser syndrome 1 FRAS1 226145_s_at 2.106
WD repeat domain 64 WDR64 1553373_at 2.105
general transcription factor IIA, 1, 19/37kDa GTF2A1 206521_s_at 2.104
anoctamin 10 ANO10 218910_at 2.102
metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) MALAT1 224558_s_at 2.099
keratin 9 KRT9 208188_at 2.096
acyl-CoA thioesterase 9 ACOT9 221641_s_at 2.093
GA binding protein transcription factor, alpha subunit 60kDa GABPA 210188_at 2.091
thioredoxin-related transmembrane protein 3 TMX3 1552822_at 2.09
zinc finger and BTB domain containing 1 ZBTB1 205092_x_at 2.086
tropomyosin 1 (alpha) TPM1 206116_s_at 2.071
hypothetical LOC284837 LOC284837 1563088_a_at 2.069
coiled-coil domain containing 68 CCDC68 220180_at 2.067
olfactory receptor, family 51, subfamily J, member 1 (gene/pseudogene) OR51J1 233736_at 2.066
non imprinted in Prader-Willi/Angelman syndrome 1 NIPA1 1552696_at 2.065
hairy and enhancer of split 1, (Drosophila) HES1 203394_s_at 2.064
sprouty homolog 2 (Drosophila) SPRY2 204011_at 2.061
Strawberry notch homolog 1 (Drosophila) SBNO1 216162_at 2.056
nicalin homolog (zebrafish) NCLN 222206_s_at 2.055
cell division cycle 42 (GTP binding protein, 25kDa) CDC42 210232_at 2.055
wingless-type MMTV integration site family, member 4 WNT4 208606_s_at 2.054
forkhead box D1 FOXD1 206307_s_at 2.052
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 214352_s_at 2.05
erythrocyte membrane protein band 4.1 like 4B EPB41L4B 220161_s_at 2.049
chromosome 16 open reading frame 11 C16orf11 1553826_a_at 2.042
progestin and adipoQ receptor family member III PAQR3 213372_at 2.04
prefoldin subunit 2 PFDN2 218336_at 2.038
cerebellar degeneration-related protein 2-like CDR2L 213230_at 2.036
heat shock protein 90kDa alpha (cytosolic), class A member 1 HSP90AA1 211969_at 2.031
Kruppel-like factor 7 (ubiquitous) KLF7 204334_at 2.031
hypothetical protein KIAA1434 RP5-1022P6.2 224826_at 2.031
glycerol kinase 3 pseudogene GK3P 215966_x_at 2.025
pyruvate dehydrogenase kinase, isozyme 4 PDK4 205960_at 2.025
heat shock 22kDa protein 8 HSPB8 221667_s_at 2.025
zinc finger protein 606 ZNF606 229707_at 2.024
hypothetical protein FLJ23519 /// ribonuclease/angiogenin inhibitor 1 FLJ23519 /// RN216798_at 2.021
myosin X MYO10 244350_at 2.02
pregnancy specific beta-1-glycoprotein 6 PSG6 208106_x_at 2.017
Fraser syndrome 1 FRAS1 1560153_at 2.016
forkhead box F2 FOXF2 206377_at 2.013
BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) BAMBI 203304_at 2.011
ring finger protein 112 RNF112 223603_at 2.01
synaptotagmin XI SYT11 209197_at 2.007
similar to mCG134545 LOC342918 230814_at 2.006
myotubularin related protein 9 MTMR9 204837_at 2.006
KIAA0182 KIAA0182 212057_at 2.006
thrombospondin, type I, domain containing 4 THSD4 222835_at 2.003
Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 226933_s_at 2.003
aryl hydrocarbon receptor AHR 202820_at 2.002
splicing factor, arginine/serine-rich 15 SFRS15 233753_at 2.001
forkhead box C1 FOXC1 1553613_s_at 2.001
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Supplemental Table 3. Genes with decreased expression due to ALK3QD in adherent EOC cells
Gene Title Gene Symbol Probe Set ID Fold Change
RAP1A, member of RAS oncogene family RAP1A 1555340_x_at 1000.000
RAP1A, member of RAS oncogene family RAP1A 1555339_at 333.333
serum amyloid A1 /// serum amyloid A2 SAA1 /// SAA2 214456_x_at 25.000
chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 209396_s_at 23.810
major histocompatibility complex, class II, DR alpha HLA-DRA 210982_s_at 20.000
dipeptidyl-peptidase 6 DPP6 228546_at 19.231
protein kinase (cAMP-dependent, catalytic) inhibitor beta PKIB 231120_x_at 18.182
periplakin PPL 203407_at 15.152
chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 209395_at 14.085
chloride channel accessory 2 CLCA2 206165_s_at 13.699
serum amyloid A1 /// serum amyloid A2 SAA1 /// SAA2 208607_s_at 13.699
toll-like receptor 7 TLR7 220146_at 12.821
selenoprotein P, plasma, 1 SEPP1 201427_s_at 9.615
family with sequence similarity 5, member B FAM5B 214822_at 9.009
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 HSD3B2 206294_at 9.009
chloride channel accessory 2 CLCA2 217528_at 8.475
dipeptidyl-peptidase 6 DPP6 207789_s_at 8.333
alpha-2-macroglobulin A2M 217757_at 7.634
haptoglobin /// haptoglobin-related protein HP /// HPR 208470_s_at 7.463
chromosome 13 open reading frame 36 C13orf36 241672_at 6.536
complement component 8, alpha polypeptide C8A 206305_s_at 6.410
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) ASPM 232238_at 6.369
RALBP1 associated Eps domain containing 2 REPS2 227425_at 6.211
chromosome 9 open reading frame 38 C9orf38 208077_at 6.098
calbindin 1, 28kDa CALB1 205625_s_at 6.024
benzodiazapine receptor (peripheral) associated protein 1 BZRAP1 205839_s_at 5.988
podoplanin PDPN 221898_at 5.882
cadherin 1, type 1, E-cadherin (epithelial) CDH1 201131_s_at 5.814
immunoglobulin heavy constant delta IGHD 214973_x_at 5.714
serine PI Kazal type 5-like 3 SPINK5L3 233340_at 5.682
pyruvate carboxylase PC 204476_s_at 5.682
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) ASPM 219918_s_at 5.435
bone morphogenetic protein 7 BMP7 211259_s_at 5.376
netrin 3 NTN3 207640_x_at 5.319
insulin-like growth factor 1 receptor IGF1R 203628_at 5.181
piwi-like 1 (Drosophila) PIWIL1 214868_at 5.128
testicular cell adhesion molecule 1 homolog (mouse) TCAM1 233320_at 5.000
ATPase, class I, type 8B, member 4 ATP8B4 220416_at 4.902
keratin 36 KRT36 214576_at 4.785
calcium/calmodulin-dependent protein kinase II beta CAMK2B 210404_x_at 4.762
carboxylesterase 8 (putative) CES8 228903_at 4.739
thioredoxin interacting protein TXNIP 201010_s_at 4.739
chromosome 19 open reading frame 59 C19orf59 235568_at 4.717
keratin 20 KRT20 213953_at 4.695
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain SEMA4D 228891_at 4.673
solute carrier family 39 (zinc transporter), member 2 SLC39A2 220413_at 4.630
transmembrane and tetratricopeptide repeat containing 4 TMTC4 225666_at 4.630
RALBP1 associated Eps domain containing 2 REPS2 205645_at 4.608
haptoglobin /// haptoglobin-related protein HP /// HPR 206697_s_at 4.608
zinc finger protein 29 pseudogene ZNF29 1567856_x_at 4.587
WD repeat domain 41 WDR41 240637_at 4.545
platelet derived growth factor D PDGFD 219304_s_at 4.545
protein disulfide isomerase-like, testis expressed PDILT 1554970_at 4.505
retinoschisin 1 RS1 216937_s_at 4.484
aryl-hydrocarbon receptor nuclear translocator 2 ARNT2 202986_at 4.464
Oligodendrocyte myelin glycoprotein OMG 238720_at 4.444
heterogeneous nuclear ribonucleoprotein C (C1/C2) HNRNPC 235500_at 4.425
Immunoglobulin heavy constant gamma 1 (G1m marker) IGHG1 217320_at 4.367
potassium voltage-gated channel, subfamily H (eag-related), member 2 KCNH2 210036_s_at 4.367
solute carrier family 47, member 1 SLC47A1 219525_at 4.348
chromosome 2 open reading frame 58 C2orf58 1553829_at 4.348
hemoglobin, epsilon 1 HBE1 205919_at 4.348
insulin-like growth factor binding protein 2, 36kDa IGFBP2 202718_at 4.310
leucine-rich repeats and immunoglobulin-like domains 3 LRIG3 226908_at 4.310
brain peptide A1 BPA-1 1555547_at 4.292
chloride channel accessory 2 CLCA2 206166_s_at 4.255
interferon stimulated exonuclease gene 20kDa-like 2 ISG20L2 216502_at 4.167
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interleukin 18 (interferon-gamma-inducing factor) IL18 206295_at 4.167
chromosome 14 open reading frame 162 C14orf162 220887_at 4.149
transforming growth factor, beta receptor III TGFBR3 204731_at 4.132
solute carrier family 27 (fatty acid transporter), member 2 SLC27A2 205768_s_at 4.065
chromosome 14 open reading frame 83 C14orf83 227544_at 4.065
NEDD4 binding protein 2-like 1 N4BP2L1 213375_s_at 4.016
superoxide dismutase 2, mitochondrial SOD2 221477_s_at 4.016
Hypothetical protein LOC100130458 LOC100130458 239214_at 3.968
family with sequence similarity 84, member A FAM84A 234331_s_at 3.953
solute carrier family 4, sodium bicarbonate cotransporter, member 5 SLC4A5 221723_s_at 3.937
vascular cell adhesion molecule 1 VCAM1 203868_s_at 3.817
lysyl oxidase-like 4 LOXL4 227145_at 3.774
solute carrier family 46, member 3 SLC46A3 214719_at 3.774
Tripartite motif-containing 8 TRIM8 228015_s_at 3.731
discs, large (Drosophila) homolog-associated protein 1 DLGAP1 206490_at 3.690
CD28 molecule CD28 206545_at 3.690
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 221589_s_at 3.676
potassium voltage-gated channel, Shal-related subfamily, member 3 KCND3 213832_at 3.663
collagen, type XIV, alpha 1 COL14A1 216866_s_at 3.663
cytochrome P450, family 7, subfamily B, polypeptide 1 CYP7B1 207386_at 3.636
growth arrest-specific 7 GAS7 202191_s_at 3.636
angiopoietin-like 1 ANGPTL1 239183_at 3.636
vacuolar protein sorting 36 homolog (S. cerevisiae) VPS36 240086_at 3.623
complement component 1, s subcomponent C1S 1555229_a_at 3.623
potassium voltage-gated channel, Shal-related subfamily, member 3 KCND3 215014_at 3.623
synovial sarcoma, X breakpoint 3 SSX3 207666_x_at 3.623
hook homolog 1 (Drosophila) HOOK1 219976_at 3.597
chemokine (C-X-C motif) ligand 16 CXCL16 223454_at 3.571
family with sequence similarity 170, member B FAM170B 1559828_at 3.546
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain SEMA4D 203528_at 3.534
chromosome 13 open reading frame 31 C13orf31 1553142_at 3.521
vanin 1 VNN1 205844_at 3.484
endothelin 2 EDN2 206758_at 3.484
synaptopodin 2 SYNPO2 227662_at 3.472
cytochrome b5 type A (microsomal) CYB5A 217021_at 3.472
podoplanin PDPN 204879_at 3.460
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase-like 1 HMGCLL1 232305_at 3.413
major facilitator superfamily domain containing 4 MFSD4 229254_at 3.401
cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate monooxygen CMAH 205518_s_at 3.401
G protein-coupled receptor 112 GPR112 1553006_at 3.356
E74-like factor 3 (ets domain transcription factor, epithelial-specific ) ELF3 210827_s_at 3.344
cyclin-dependent kinase 2 CDK2 211803_at 3.322
KIAA1324 KIAA1324 226248_s_at 3.322
chromosome 5 open reading frame 4 C5orf4 220751_s_at 3.322
caspase 12 (gene/pseudogene) CASP12 1564736_a_at 3.322
complement factor H /// complement factor H-related 1 CFH /// CFHR1 215388_s_at 3.322
immunoglobulin kappa constant IGKC 214836_x_at 3.300
WW and C2 domain containing 1 WWC1 216074_x_at 3.300
CUG triplet repeat, RNA binding protein 2 CUGBP2 242268_at 3.289
vanin 1 VNN1 1558549_s_at 3.257
cytochrome b reductase 1 CYBRD1 222453_at 3.247
STEAP family member 4 STEAP4 220187_at 3.226
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 203153_at 3.195
phospholipid scramblase 4 PLSCR4 218901_at 3.175
baculoviral IAP repeat-containing 3 BIRC3 210538_s_at 3.175
hypothetical LOC728475 LOC728475 242010_at 3.165
interleukin-1 receptor-associated kinase 3 IRAK3 213817_at 3.165
discs, large (Drosophila) homolog-associated protein 1 /// hypothetical protein LOC284214 DLGAP1 /// LOC235527_at 3.145
chromosome X open reading frame 56 CXorf56 239444_at 3.145
ring finger protein 125 RNF125 235199_at 3.135
hypothetical LOC653602 LOC653602 229546_at 3.115
B-cell CLL/lymphoma 8 BCL8 1560683_at 3.086
nuclear factor (erythroid-derived 2)-like 3 NFE2L3 204702_s_at 3.058
tescalcin TESC 218872_at 3.040
myosin VB MYO5B 225299_at 3.040
myosin VB MYO5B 225301_s_at 3.040
sprouty homolog 1, antagonist of FGF signaling (Drosophila) SPRY1 212558_at 3.021
hypothetical LOC401312 LOC401312 1560520_at 3.012
golgi phosphoprotein 3-like GOLPH3L 218361_at 3.012
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SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 SMARCA4 213719_s_at 3.003
coiled-coil domain containing 80 CCDC80 225241_at 3.003
chromobox homolog 2 (Pc class homolog, Drosophila) CBX2 224138_at 2.994
interferon, alpha-inducible protein 6 IFI6 204415_at 2.985
BCL2-interacting killer (apoptosis-inducing) BIK 205780_at 2.976
myelin basic protein MBP 210136_at 2.967
solute carrier family 44, member 3 SLC44A3 228221_at 2.967
hypothetical protein LOC100129827 LOC100129827 231595_at 2.950
calcyphosine CAPS 226424_at 2.941
calbindin 2 CALB2 205428_s_at 2.941
OTU domain containing 1 OTUD1 226140_s_at 2.924
WW and C2 domain containing 1 WWC1 229180_at 2.924
armadillo repeat containing, X-linked 4 ARMCX4 1552327_at 2.924
chromosome 13 open reading frame 31 C13orf31 228937_at 2.915
Fc fragment of IgA, receptor for FCAR 211816_x_at 2.915
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) SMPD3 231732_at 2.915
superoxide dismutase 2, mitochondrial SOD2 215223_s_at 2.915
EPH receptor B3 EPHB3 204600_at 2.907
potassium voltage-gated channel, subfamily H (eag-related), member 6 KCNH6 211045_s_at 2.899
tumor necrosis factor, alpha-induced protein 2 TNFAIP2 202510_s_at 2.890
plasticity related gene 3 RP11-35N6.1 1570250_at 2.890
chromosome 5 open reading frame 4 C5orf4 48031_r_at 2.890
E74-like factor 3 (ets domain transcription factor, epithelial-specific ) ELF3 201510_at 2.874
olfactory receptor, family 7, subfamily E, member 47 pseudogene OR7E47P 222304_x_at 2.874
cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate monooxygen CMAH 210571_s_at 2.874
chromosome 13 open reading frame 31 C13orf31 1553141_at 2.865
par-6 partitioning defective 6 homolog beta (C. elegans) PARD6B 235165_at 2.857
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 221588_x_at 2.841
sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 SVEP1 219552_at 2.817
synaptotagmin III SYT3 223901_at 2.817
phospholipid scramblase 1 PLSCR1 202430_s_at 2.809
Hypothetical protein LOC100128484 LOC100128484 239308_at 2.809
solute carrier family 22 (organic cation transporter), member 2 SLC22A2 207429_at 2.809
interleukin 23 receptor IL23R 1561853_a_at 2.801
glutamate receptor, ionotropic, N-methyl D-aspartate 2A GRIN2A 206534_at 2.793
EF-hand domain (C-terminal) containing 2 EFHC2 220591_s_at 2.770
par-3 partitioning defective 3 homolog B (C. elegans) PARD3B 1553188_s_at 2.762
Solute carrier family 25, member 29 SLC25A29 232280_at 2.762
E74-like factor 3 (ets domain transcription factor, epithelial-specific ) ELF3 229842_at 2.762
furry homolog (Drosophila) FRY 204072_s_at 2.755
transmembrane protein 140 TMEM140 218999_at 2.755
collectin sub-family member 12 COLEC12 221019_s_at 2.740
cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39A1 1553977_a_at 2.732
transforming growth factor, beta 3 TGFB3 209747_at 2.732
solute carrier family 22, member 23 SLC22A23 223194_s_at 2.717
KIAA1462 KIAA1462 213316_at 2.717
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) /// hypothetical protein CSF2RA /// LOC210340_s_at 2.710
annexin A4 ANXA4 201302_at 2.703
glutaminase GLS 203157_s_at 2.688
interferon-induced protein with tetratricopeptide repeats 2 IFIT2 226757_at 2.688
chromosome 10 open reading frame 11 C10orf11 223703_at 2.688
ERO1-like beta (S. cerevisiae) ERO1LB 231944_at 2.688
transmembrane protein 37 TMEM37 227190_at 2.681
T-cell activation RhoGTPase activating protein TAGAP 1552541_at 2.674
vitronectin VTN 204534_at 2.674
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF OBSCN 229854_at 2.674
vav 3 guanine nucleotide exchange factor VAV3 218807_at 2.667
islet cell autoantigen 1,69kDa-like ICA1L 223881_at 2.660
PTPRF interacting protein, binding protein 2 (liprin beta 2) PPFIBP2 212841_s_at 2.660
histone cluster 1, H2bc HIST1H2BC 236193_at 2.660
prostaglandin F2 receptor negative regulator PTGFRN 224937_at 2.660
cytochrome P450, family 27, subfamily A, polypeptide 1 CYP27A1 203979_at 2.639
spectrin, beta, non-erythrocytic 4 SPTBN4 224297_s_at 2.632
mesoderm specific transcript homolog (mouse) MEST 202016_at 2.604
chromosome 9 open reading frame 125 C9orf125 224458_at 2.597
ferritin, heavy polypeptide 1 FTH1 214211_at 2.591
ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABCB1 209993_at 2.584
Mannosidase, alpha, class 1A, member 1 MAN1A1 221760_at 2.577
family with sequence similarity 38, member B FAM38B 219602_s_at 2.571
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MACRO domain containing 2 MACROD2 235278_at 2.564
myelin basic protein MBP 1554544_a_at 2.558
cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 219534_x_at 2.551
RAB7B, member RAS oncogene family RAB7B 1553982_a_at 2.551
ubiquitin protein ligase E3 component n-recognin 4 UBR4 231889_at 2.551
hypothetical LOC151658 LOC151658 238283_at 2.545
tensin 3 TNS3 217853_at 2.545
calcium/calmodulin-dependent protein kinase kinase 2, beta CAMKK2 207359_at 2.538
dymeclin DYM 220774_at 2.538
unc-51-like kinase 2 (C. elegans) ULK2 215154_at 2.538
ATP/GTP binding protein-like 2 AGBL2 220390_at 2.538
discs, large (Drosophila) homolog-associated protein 1 DLGAP1 206489_s_at 2.538
hypothetical LOC100129550 LOC100129550 229699_at 2.532
low density lipoprotein-related protein 2 LRP2 205710_at 2.525
TAP binding protein (tapasin) TAPBP 210294_at 2.525
transmembrane protein 163 TMEM163 1552626_a_at 2.519
chromosome 11 open reading frame 35 C11orf35 236050_at 2.519
tumor necrosis factor receptor superfamily, member 21 TNFRSF21 214581_x_at 2.519
potassium inwardly-rectifying channel, subfamily J, member 12 KCNJ12 232289_at 2.513
chromosome 17 open reading frame 103 C17orf103 226657_at 2.513
cathepsin F CTSF 203657_s_at 2.506
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 204290_s_at 2.506
4-hydroxyphenylpyruvate dioxygenase HPD 206024_at 2.500
Mov10l1, Moloney leukemia virus 10-like 1, homolog (mouse) MOV10L1 239257_at 2.500
potassium inwardly-rectifying channel, subfamily J, member 12 KCNJ12 207110_at 2.500
LRRN4 C-terminal like LRRN4CL 1556427_s_at 2.500
microtubule-associated protein 7 MAP7 202890_at 2.500
WW and C2 domain containing 1 WWC1 213085_s_at 2.494
spermatid perinuclear RNA binding protein STRBP 223246_s_at 2.494
chromosome 8 open reading frame 83 C8orf83 224158_s_at 2.494
growth arrest-specific 7 GAS7 202192_s_at 2.488
paired box 8 PAX8 221990_at 2.488
glutamate decarboxylase 1 (brain, 67kDa) GAD1 205278_at 2.481
ATP-binding cassette, sub-family A (ABC1), member 9 ABCA9 235335_at 2.481
hypothetical gene supported by AK026416 FLJ22763 233604_at 2.475
complement component 1, s subcomponent C1S 208747_s_at 2.475
ets variant 4 ETV4 1554576_a_at 2.463
collagen, type XVI, alpha 1 COL16A1 204345_at 2.457
acyl-CoA thioesterase 4 ACOT4 229534_at 2.457
Kallmann syndrome 1 sequence KAL1 205206_at 2.457
carboxymethylenebutenolidase homolog (Pseudomonas) CMBL 227522_at 2.457
chromosome 5 open reading frame 13 C5orf13 201310_s_at 2.457
phospholipase A2, group X PLA2G10 207222_at 2.451
CD6 molecule CD6 213958_at 2.445
proprotein convertase subtilisin/kexin type 6 PCSK6 211262_at 2.445
GM2 ganglioside activator GM2A 209727_at 2.439
caspase 10, apoptosis-related cysteine peptidase CASP10 205467_at 2.433
receptor tyrosine kinase-like orphan receptor 1 ROR1 232060_at 2.433
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 /// hydroxy-delta-5-steroidHSD3B1 /// HSD215665_at 2.433
ureidopropionase, beta UPB1 220507_s_at 2.433
C-terminal binding protein 1 CTBP1 1557714_at 2.427
glutaminase GLS 203159_at 2.421
chromosome 10 open reading frame 54 C10orf54 225372_at 2.415
family with sequence similarity 38, member B FAM38B 222908_at 2.410
ring finger protein 144B RNF144B 228153_at 2.398
keratinocyte growth factor-like protein 2 KGFLP2 231031_at 2.398
cell adhesion molecule 4 CADM4 222293_at 2.398
K(lysine) acetyltransferase 2B KAT2B 203845_at 2.392
aldehyde oxidase 1 AOX1 205082_s_at 2.392
ubiquitin specific peptidase 2 USP2 229337_at 2.392
chromosome 6 open reading frame 123 C6orf123 207698_at 2.387
tumor necrosis factor receptor superfamily, member 21 TNFRSF21 218856_at 2.387
ADAM metallopeptidase domain 12 ADAM12 215613_at 2.387
phosphoinositide-3-kinase, regulatory subunit 3 (gamma) PIK3R3 202743_at 2.381
solute carrier family 39 (metal ion transporter), member 11 SLC39A11 227046_at 2.381
myelin-associated oligodendrocyte basic protein MOBP 242765_at 2.375
chromosome 18 open reading frame 2 C18orf2 224045_x_at 2.375
superoxide dismutase 2, mitochondrial SOD2 216841_s_at 2.375
coiled-coil domain containing 80 CCDC80 225242_s_at 2.375
117 
 
Table S2.3 cont'd. 
 
programmed cell death 4 (neoplastic transformation inhibitor) PDCD4 212594_at 2.370
dual adaptor of phosphotyrosine and 3-phosphoinositides DAPP1 219290_x_at 2.370
synovial sarcoma, X breakpoint 4 /// synovial sarcoma, X breakpoint 4B SSX4 /// SSX4B 211425_x_at 2.364
syndecan 4 SDC4 202071_at 2.358
signal-regulatory protein gamma SIRPG 220485_s_at 2.358
palmdelphin PALMD 218736_s_at 2.358
par-3 partitioning defective 3 homolog B (C. elegans) PARD3B 228411_at 2.353
hyaluronan and proteoglycan link protein 1 HAPLN1 230204_at 2.353
mannosidase, alpha, class 1A, member 1 MAN1A1 208116_s_at 2.342
chromosome 12 open reading frame 35 C12orf35 227152_at 2.342
family with sequence similarity 35, member A FAM35A 233048_at 2.336
endoplasmic reticulum metallopeptidase 1 ERMP1 222603_at 2.331
ribosomal modification protein rimK-like family member A RIMKLA 241075_at 2.331
mitogen-activated protein kinase kinase kinase 7 interacting protein 3 MAP3K7IP3 1558518_at 2.326
hypothetical LOC79150 MGC4859 207775_at 2.326
chromosome 5 open reading frame 13 C5orf13 201309_x_at 2.320
ADAM metallopeptidase domain 12 ADAM12 213790_at 2.315
cyclin-dependent kinase-like 2 (CDC2-related kinase) CDKL2 236331_at 2.309
dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) DCT 205338_s_at 2.304
yippee-like 3 (Drosophila) YPEL3 223179_at 2.304
phospholipid scramblase 1 PLSCR1 202446_s_at 2.299
histone cluster 1, H2bc HIST1H2BC 214455_at 2.294
serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 242814_at 2.294
FERM domain containing 4B FRMD4B 213056_at 2.294
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 PCMTD1 232382_s_at 2.288
copine VIII CPNE8 243727_at 2.288
KIAA0247 KIAA0247 202181_at 2.288
glutaminase GLS 203158_s_at 2.288
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 ST3GAL5 203217_s_at 2.283
ectonucleotide pyrophosphatase/phosphodiesterase 3 ENPP3 232737_s_at 2.283
phospholipase D1, phosphatidylcholine-specific PLD1 226636_at 2.278
endoplasmic reticulum metallopeptidase 1 ERMP1 218342_s_at 2.278
KIAA0895 KIAA0895 213424_at 2.278
aldehyde oxidase 1 AOX1 205083_at 2.278
unc-51-like kinase 2 (C. elegans) ULK2 1554112_a_at 2.268
transmembrane protein 151A TMEM151A 235614_at 2.268
six transmembrane epithelial antigen of the prostate 2 STEAP2 225871_at 2.262
solute carrier family 27 (fatty acid transporter), member 2 SLC27A2 205769_at 2.262
growth arrest-specific 6 /// similar to growth arrest-specific 6 GAS6 /// LOC101598_g_at 2.262
interleukin 1 receptor, type I IL1R1 202948_at 2.262
Hypothetical protein LOC100130353 LOC100130353 1564449_at 2.262
Family with sequence similarity 92, member A1 FAM92A1 237910_x_at 2.257
MAX dimerization protein 4 MXD4 210778_s_at 2.257
mal, T-cell differentiation protein 2 MAL2 224650_at 2.257
poly (ADP-ribose) polymerase family, member 14 PARP14 224701_at 2.252
zinc finger and BTB domain containing 44 ZBTB44 225845_at 2.252
annexin A4 ANXA4 201301_s_at 2.252
myelin basic protein MBP 225408_at 2.247
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) GALNT1 201724_s_at 2.242
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked UTY 210322_x_at 2.242
G protein-coupled receptor 87 GPR87 219936_s_at 2.237
Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) TFPI 215447_at 2.232
macrophage stimulating 1 receptor (c-met-related tyrosine kinase) MST1R 205455_at 2.232
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 DDX60 218986_s_at 2.232
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) CDKN2B 236313_at 2.222
post-GPI attachment to proteins 1 PGAP1 220576_at 2.217
engulfment and cell motility 1 ELMO1 204513_s_at 2.217
actin-like 8 ACTL8 214957_at 2.217
TP53 target 1 (non-protein coding) TP53TG1 210241_s_at 2.212
macrophage stimulating 1 (hepatocyte growth factor-like) MST1 205614_x_at 2.212
secretory leukocyte peptidase inhibitor SLPI 203021_at 2.212
solute carrier family 15, member 3 SLC15A3 219593_at 2.212
integrin, beta 8 ITGB8 226189_at 2.208
hypothetical LOC541472 LOC541472 243977_at 2.208
aquaporin 2 (collecting duct) AQP2 206672_at 2.203
solute carrier family 27 (fatty acid transporter), member 1 SLC27A1 226728_at 2.203
fibroblast growth factor 7 (keratinocyte growth factor) FGF7 205782_at 2.203
neuroblastoma, suppression of tumorigenicity 1 NBL1 201621_at 2.203
cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 216894_x_at 2.203
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fibulin 1 FBLN1 207835_at 2.198
peroxisome proliferator-activated receptor gamma, coactivator 1 beta PPARGC1B 1553639_a_at 2.193
Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3 218501_at 2.193
ciliary neurotrophic factor receptor CNTFR 205723_at 2.188
SH3 domain binding glutamic acid-rich protein like 2 SH3BGRL2 225354_s_at 2.188
TNFSF12-TNFSF13 readthrough transcript /// tumor necrosis factor (ligand) superfamily, member 13 TNFSF12-TNFS209500_x_at 2.188
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) H6PD 221892_at 2.188
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E SEMA3E 206941_x_at 2.183
guanine nucleotide binding protein (G protein), gamma 7 GNG7 228831_s_at 2.183
endothelin receptor type A EDNRA 204464_s_at 2.183
CD40 molecule, TNF receptor superfamily member 5 CD40 222292_at 2.179
chromosome 9 open reading frame 126 C9orf126 228174_at 2.174
solute carrier family 25, member 27 SLC25A27 1554161_at 2.174
collagen, type XXII, alpha 1 COL22A1 228873_at 2.169
pre T-cell antigen receptor alpha PTCRA 211837_s_at 2.169
mannosidase, alpha, class 2A, member 2 MAN2A2 219999_at 2.169
interferon regulatory factor 1 IRF1 238725_at 2.169
interleukin 16 (lymphocyte chemoattractant factor) IL16 1555016_at 2.169
sortilin 1 SORT1 224818_at 2.169
pleckstrin homology domain containing, family G (with RhoGef domain) member 1 PLEKHG1 226122_at 2.155
phosphoinositide-3-kinase interacting protein 1 PIK3IP1 221757_at 2.155
hypothetical LOC729970 LOC729970 230433_at 2.155
leucine rich repeat containing 1 LRRC1 218816_at 2.146
2-5-oligoadenylate synthetase 3, 100kDa OAS3 218400_at 2.146
zinc finger and BTB domain containing 44 ZBTB44 226148_at 2.146
furry homolog (Drosophila) FRY 214318_s_at 2.141
zinc finger, FYVE domain containing 16 ZFYVE16 1555982_at 2.141
growth arrest-specific 6 /// similar to growth arrest-specific 6 GAS6 /// LOC10202177_at 2.137
chromosome 12 open reading frame 35 C12orf35 218614_at 2.132
interleukin 20 IL20 224071_at 2.132
Transcription factor Dp-2 (E2F dimerization partner 2) TFDP2 226157_at 2.132
plexin B1 PLXNB1 215807_s_at 2.132
phosphoinositide-3-kinase, catalytic, delta polypeptide PIK3CD 203879_at 2.128
thioredoxin-related transmembrane protein 4 TMX4 201580_s_at 2.123
complement factor H CFH 213800_at 2.119
T-cell lymphoma invasion and metastasis 2 TIAM2 222942_s_at 2.114
hypothetical LOC283070 LOC283070 226382_at 2.114
ezrin EZR 208621_s_at 2.114
ribonuclease T2 RNASET2 217984_at 2.114
islet cell autoantigen 1,69kDa-like ICA1L 230454_at 2.105
transmembrane phosphatase with tensin homology TPTE 220205_at 2.105
basonuclin 1 BNC1 1552487_a_at 2.101
cordon-bleu homolog (mouse) COBL 213050_at 2.101
ATPase, Cu++ transporting, beta polypeptide ATP7B 204624_at 2.101
mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) MASP1 210680_s_at 2.096
chromosome 6 open reading frame 170 C6orf170 232038_at 2.096
regulator of calcineurin 1 RCAN1 215253_s_at 2.092
chromosome 1 open reading frame 133 C1orf133 230121_at 2.092
Spermatid perinuclear RNA binding protein STRBP 229513_at 2.092
hypothetical protein DKFZp586I1420 DKFZP586I1420213546_at 2.092
C-terminal binding protein 2 CTBP2 215377_at 2.079
serpin peptidase inhibitor, clade B (ovalbumin), member 3 SERPINB3 209719_x_at 2.079
KIAA1217 KIAA1217 231807_at 2.079
tumor necrosis factor receptor superfamily, member 8 TNFRSF8 206729_at 2.079
prostaglandin F2 receptor negative regulator PTGFRN 224950_at 2.079
WD repeat and SOCS box-containing 1 WSB1 201295_s_at 2.075
hypothetical protein LOC283867 LOC283867 231518_at 2.075
KIAA1324 KIAA1324 221874_at 2.075
protocadherin alpha 1 /// protocadherin alpha 10 /// protocadherin alpha 11 /// protocadherin alpha 12 /// PCDHA1 /// PCD224212_s_at 2.075
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 B3GNT1 203188_at 2.075
hemoglobin, alpha 1 /// hemoglobin, alpha 2 HBA1 /// HBA2 209458_x_at 2.070
Ral GEF with PH domain and SH3 binding motif 1 RALGPS1 204199_at 2.070
gastrokine 1 GKN1 220191_at 2.066
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6 B4GALT6 235333_at 2.066
pre-B-cell leukemia homeobox 1 PBX1 212148_at 2.066
HBV preS1-transactivated protein 4 PS1TP4 226381_at 2.062
thioredoxin-related transmembrane protein 4 TMX4 201581_at 2.058
salt-inducible kinase 2 SIK2 213221_s_at 2.058
StAR-related lipid transfer (START) domain containing 10 STARD10 232322_x_at 2.058
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protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 PCMTD1 226119_at 2.053
RUN domain containing 3B RUNDC3B 241703_at 2.053
major facilitator superfamily domain containing 6 MFSD6 225325_at 2.049
phospholipase A2 receptor 1, 180kDa PLA2R1 210194_at 2.049
SPARC related modular calcium binding 2 SMOC2 243946_at 2.049
hypothetical protein LOC90246 LOC90246 233830_at 2.049
transient receptor potential cation channel, subfamily M, member 3 TRPM3 216452_at 2.049
caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 206011_at 2.045
complement component 3 C3 217767_at 2.045
family with sequence similarity 53, member A FAM53A 1569139_s_at 2.041
cyclin D2 CCND2 200953_s_at 2.041
progesterone receptor membrane component 2 PGRMC2 213227_at 2.037
chromosome 12 open reading frame 26 C12orf26 229018_at 2.037
isochorismatase domain containing 1 ISOC1 218170_at 2.037
programmed cell death 4 (neoplastic transformation inhibitor) PDCD4 202731_at 2.033
MU-2/AP1M2 domain containing, death-inducing MUDENG 232156_at 2.033
CCAAT/enhancer binding protein (C/EBP), delta CEBPD 203973_s_at 2.033
fibroblast growth factor receptor substrate 2 FRS2 226045_at 2.033
KIAA0146 KIAA0146 228325_at 2.028
phospholipase C, delta 3 PLCD3 234971_x_at 2.028
family with sequence similarity 111, member A FAM111A 218248_at 2.024
regulator of calcineurin 1 RCAN1 215254_at 2.024
dishevelled associated activator of morphogenesis 1 DAAM1 216060_s_at 2.024
chromosome 11 open reading frame 54 C11orf54 223268_at 2.020
hyaluronan synthase 3 HAS3 223541_at 2.020
chromosome 8 open reading frame 68 C8orf68 1557679_at 2.016
Cyclin E1 CCNE1 242105_at 2.016
fucosidase, alpha-L- 1, tissue FUCA1 202838_at 2.016
LAG1 homolog, ceramide synthase 6 LASS6 212446_s_at 2.012
zinc finger protein 720 ZNF720 242091_at 2.012
interleukin 2 receptor, gamma (severe combined immunodeficiency) IL2RG 204116_at 2.012
chromosome 10 open reading frame 4 C10orf4 238596_at 2.012
chromosome 9 open reading frame 125 C9orf125 213386_at 2.008
hypothetical LOC651250 LOC651250 1566987_s_at 2.004
MAX dimerization protein 4 MXD4 212346_s_at 2.004
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Supplemental Table 4. Genes with decreased expression due to ALK3QD in EOC spheroids
Gene Title Gene Symbol Probe Set ID Fold Change
RAP1A, member of RAS oncogene family RAP1A 1555340_x_at 333.333
RAP1A, member of RAS oncogene family RAP1A 1555339_at 333.333
centromere protein I CENPI 1555046_at 10.870
glutamate receptor, metabotropic 1 GRM1 207299_s_at 9.709
interferon stimulated exonuclease gene 20kDa ISG20 204698_at 9.346
chromosome 4 open reading frame 37 C4orf37 1555096_at 8.547
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like GALNTL6 1555273_at 8.065
platelet-derived growth factor receptor-like PDGFRL 205226_at 7.752
hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse) HSD17B6 205700_at 7.576
folate hydrolase (prostate-specific membrane antigen) 1 FOLH1 215363_x_at 7.407
hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse) HSD17B6 37512_at 7.194
tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 202687_s_at 6.667
tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 202688_at 6.452
folate hydrolase (prostate-specific membrane antigen) 1 FOLH1 205860_x_at 6.289
aldehyde oxidase 1 AOX1 205083_at 6.250
EPH receptor B3 EPHB3 204600_at 5.952
ATP-binding cassette, sub-family A (ABC1), member 9 ABCA9 242541_at 5.882
similar to hCG2041313 LOC100128178235891_at 5.814
tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 214329_x_at 5.714
SH3 domain containing ring finger 2 SH3RF2 228892_at 5.587
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) BBOX1 205363_at 5.435
transmembrane protein 170B TMEM170B 235798_at 5.376
ankyrin 1, erythrocytic ANK1 205390_s_at 5.155
chromosome 18 open reading frame 20 C18orf20 1553934_at 5.128
RALBP1 associated Eps domain containing 2 REPS2 227425_at 5.076
actin filament associated protein 1-like 2 AFAP1L2 226829_at 4.902
transmembrane protein 176B TMEM176B 220532_s_at 4.878
PRP18 pre-mRNA processing factor 18 homolog (S. cerevisiae) PRPF18 232473_at 4.854
pre-B-cell leukemia homeobox 1 PBX1 205253_at 4.831
protein kinase (cAMP-dependent, catalytic) inhibitor beta PKIB 223551_at 4.762
Hypothetical protein LOC650392 LOC650392 1558463_s_at 4.762
signal transducer and activator of transcription 5B STAT5B 1555088_x_at 4.717
sperm protein associated with the nucleus, X-linked, family member A1 /// SPANX family, SPANXA1 /// SP224032_x_at 4.673
MAM domain containing glycosylphosphatidylinositol anchor 1 MDGA1 238543_x_at 4.608
katanin p60 subunit A-like 2 KATNAL2 1554234_at 4.608
transmembrane protein 176A TMEM176A 218345_at 4.608
interferon-induced protein 44-like IFI44L 204439_at 4.587
wingless-type MMTV integration site family, member 6 WNT6 221608_at 4.587
Protein tyrosine phosphatase, non-receptor type 9 PTPN9 230140_at 4.545
plasticity related gene 3 RP11-35N6.1 219732_at 4.525
periplakin PPL 203407_at 4.425
G0/G1switch 2 G0S2 213524_s_at 4.386
dedicator of cytokinesis 2 DOCK2 213160_at 4.348
chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 209396_s_at 4.348
phosphatase and actin regulator 3 PHACTR3 227949_at 4.329
family with sequence similarity 20, member A FAM20A 226804_at 4.237
immunoglobulin heavy locus /// immunoglobulin heavy constant gamma 1 (G1m marker) //IGH@ /// IGHG 211430_s_at 4.237
hypothetical LOC154872 LOC154872 237271_at 4.237
MYC induced nuclear antigen MINA 229675_at 4.219
Rho GTPase activating protein 25 ARHGAP25 204882_at 4.202
phosphodiesterase 3B, cGMP-inhibited PDE3B 214582_at 4.202
hypothetical LOC79100 MGC4473 224020_at 4.098
protein tyrosine phosphatase, receptor type, F PTPRF 215066_at 4.082
lipocalin-like 1 LCNL1 1564431_a_at 3.984
ATP-binding cassette, sub-family B (MDR/TAP), member 6 ABCB6 203191_at 3.968
neuropeptide Y receptor Y1 NPY1R 205440_s_at 3.937
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) PTPN22 206060_s_at 3.906
aquaporin 3 (Gill blood group) AQP3 39248_at 3.861
calcitonin receptor-like CALCRL 206331_at 3.846
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postmeiotic segregation increased 2-like 5-like /// PMS2 postmeiotic segregation increase LOC100132832216039_at 3.831
RIMS binding protein 2 RIMBP2 214811_at 3.817
thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog THRB 207044_at 3.817
ATP-binding cassette, sub-family A (ABC1), member 6 ABCA6 217504_at 3.817
prematurely terminated mRNA decay factor-like LOC91431 1565935_at 3.802
DNA-damage-inducible transcript 4-like DDIT4L 228057_at 3.802
ring finger protein 8 RNF8 203161_s_at 3.774
protogenin homolog (Gallus gallus) PRTG 229073_at 3.759
decorin DCN 209335_at 3.745
IKAROS family zinc finger 2 (Helios) IKZF2 231929_at 3.731
vanin 1 VNN1 205844_at 3.717
myosin VB MYO5B 225301_s_at 3.704
zinc finger protein 224 ZNF224 216991_at 3.690
leucine-rich repeats and immunoglobulin-like domains 3 LRIG3 226908_at 3.650
podoplanin PDPN 221898_at 3.636
prostaglandin F receptor (FP) PTGFR 207177_at 3.571
Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) binding proteinMTBP 233436_at 3.559
SH3 domain containing ring finger 2 SH3RF2 243582_at 3.472
Hypothetical gene supported by BC008048 LOC440934 244159_at 3.460
A kinase (PRKA) anchor protein 13 AKAP13 232188_at 3.436
spastic paraplegia 11 (autosomal recessive) SPG11 1559747_at 3.436
vascular cell adhesion molecule 1 VCAM1 203868_s_at 3.378
dpy-19-like 2 (C. elegans) DPY19L2 230158_at 3.378
odontogenic, ameloblast asssociated ODAM 220133_at 3.378
casein alpha s1 CSN1S1 208350_at 3.367
proteasome (prosome, macropain) subunit, alpha type, 3 PSMA3 232648_at 3.356
laminin, beta 4 LAMB4 215516_at 3.356
prostaglandin D2 synthase 21kDa (brain) PTGDS 211663_x_at 3.356
cyclin-dependent kinase-like 2 (CDC2-related kinase) CDKL2 207073_at 3.344
formin-like 1 FMNL1 204789_at 3.333
potassium voltage-gated channel, KQT-like subfamily, member 4 KCNQ4 243209_at 3.322
baculoviral IAP repeat-containing 5 BIRC5 202095_s_at 3.322
v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) MAF 209347_s_at 3.311
DENN/MADD domain containing 2A DENND2A 221886_at 3.311
platelet derived growth factor D PDGFD 219304_s_at 3.300
homeobox D1 HOXD1 205974_at 3.289
coiled-coil domain containing 80 CCDC80 225241_at 3.268
chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 209395_at 3.247
protein kinase (cAMP-dependent, catalytic) inhibitor beta PKIB 231120_x_at 3.226
extracellular matrix protein 2, female organ and adipocyte specific ECM2 206101_at 3.215
KIAA0644 gene product KIAA0644 205151_s_at 3.205
potassium voltage-gated channel, subfamily H (eag-related), member 2 KCNH2 210036_s_at 3.205
RALBP1 associated Eps domain containing 2 REPS2 205645_at 3.195
TBC1 domain family, member 8 (with GRAM domain) TBC1D8 204526_s_at 3.175
lipoprotein lipase LPL 203549_s_at 3.155
myelin basic protein MBP 1554544_a_at 3.155
heparan sulfate 6-O-sulfotransferase 2 HS6ST2 230030_at 3.125
GTPase, IMAP family member 2 GIMAP2 232024_at 3.106
kelch repeat and BTB (POZ) domain containing 10 KBTBD10 219106_s_at 3.106
synaptotagmin XVII SYT17 205613_at 3.096
myosin VB MYO5B 225299_at 3.096
V-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 241193_at 3.086
decorin DCN 211896_s_at 3.067
phosphodiesterase 1A, calmodulin-dependent PDE1A 233547_x_at 3.040
myosin light chain kinase family, member 4 MYLK4 1556136_at 3.030
T-box 1 TBX1 236926_at 3.021
teratocarcinoma-derived growth factor 1 /// teratocarcinoma-derived growth factor 3, pseu TDGF1 /// TDG 206286_s_at 3.021
coxsackie virus and adenovirus receptor CXADR 203917_at 3.012
GABA(A) receptors associated protein like 3 (pseudogene) GABARAPL3 211457_at 3.012
chromosome 9 open reading frame 100 C9orf100 230521_at 3.003
phosphorylase kinase, alpha 1 (muscle) PHKA1 229876_at 3.003
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KIAA1409 KIAA1409 229550_at 2.985
hypothetical LOC100192378 LOC1001923781559965_at 2.976
WD repeat domain 91 WDR91 222799_at 2.967
protein tyrosine phosphatase, receptor type, N polypeptide 2 PTPRN2 203029_s_at 2.959
carboxypeptidase A4 CPA4 205832_at 2.950
chromosome 1 open reading frame 88 C1orf88 228100_at 2.950
dpy-19-like 2 pseudogene 2 (C. elegans) DPY19L2P2 215143_at 2.941
potassium channel tetramerisation domain containing 12 KCTD12 212192_at 2.933
coiled-coil domain containing 102B CCDC102B 220301_at 2.933
complement component 5 C5 205500_at 2.924
dipeptidyl-peptidase 4 DPP4 203717_at 2.915
protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phospPTPN13 204201_s_at 2.915
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 B3GNT1 203188_at 2.915
ADAMTS-like 1 ADAMTSL1 224371_at 2.899
hypothetical LOC285780 RP3-398D13.1 1553428_at 2.890
regulator of G-protein signaling 2, 24kDa RGS2 202388_at 2.890
hypothetical protein FLJ10489 FLJ10489 1562433_at 2.890
phosphodiesterase 7A PDE7A 1552343_s_at 2.882
epoxide hydrolase 2, cytoplasmic EPHX2 209368_at 2.865
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 221589_s_at 2.857
Carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 226372_at 2.857
chemokine (C-X-C motif) ligand 16 CXCL16 223454_at 2.849
Collagen, type III, alpha 1 COL3A1 232458_at 2.833
family with sequence similarity 111, member B FAM111B 1557129_a_at 2.825
retinoic acid receptor responder (tazarotene induced) 3 RARRES3 204070_at 2.817
ATP-binding cassette, sub-family A (ABC1), member 8 ABCA8 204719_at 2.817
complement component 2 /// complement factor B C2 /// CFB 202357_s_at 2.801
tudor domain containing 6 TDRD6 232692_at 2.801
ATP/GTP binding protein-like 3 AGBL3 220649_at 2.801
podoplanin PDPN 226658_at 2.793
matrix metallopeptidase 8 (neutrophil collagenase) MMP8 207329_at 2.793
dehydrogenase/reductase (SDR family) member 2 DHRS2 214079_at 2.778
CD36 molecule (thrombospondin receptor) CD36 206488_s_at 2.770
inter-alpha (globulin) inhibitor H5 ITIH5 219064_at 2.755
K(lysine) acetyltransferase 2B KAT2B 203845_at 2.755
dihydropyrimidine dehydrogenase DPYD 204646_at 2.747
CD9 molecule CD9 233322_at 2.747
1-acylglycerol-3-phosphate O-acyltransferase 3 AGPAT3 224282_s_at 2.747
carboxymethylenebutenolidase homolog (Pseudomonas) CMBL 227522_at 2.740
podocan-like 1 PODNL1 220411_x_at 2.740
thyroglobulin TG 203673_at 2.732
sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) SPAM1 216989_at 2.725
RAB26, member RAS oncogene family RAB26 50965_at 2.725
tumor necrosis factor receptor superfamily, member 21 TNFRSF21 218856_at 2.717
podoplanin PDPN 204879_at 2.717
coiled-coil domain containing 80 CCDC80 225242_s_at 2.717
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase COLQ 206073_at 2.717
fin bud initiation factor homolog (zebrafish) FIBIN 226769_at 2.710
coiled-coil domain-containing-like hCG_29977 227043_at 2.703
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 203153_at 2.703
G protein-coupled receptor 115 GPR115 237690_at 2.695
phospholipase C, beta 4 PLCB4 203896_s_at 2.688
chromosome 14 open reading frame 143 C14orf143 210525_x_at 2.688
neural precursor cell expressed, developmentally down-regulated 4-like NEDD4L 241396_at 2.681
BTG family, member 3 BTG3 215425_at 2.681
similar to hCG2041586 LOC730124 231337_at 2.674
mucin 12, cell surface associated MUC12 1557906_at 2.674
DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 DDX50 1568814_at 2.667
formin-like 1 FMNL1 1569257_at 2.667
paired immunoglobin-like type 2 receptor alpha PILRA 219788_at 2.667
cytochrome P450, family 7, subfamily B, polypeptide 1 CYP7B1 207386_at 2.667
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zinc finger protein 3 ZNF3 232497_at 2.667
heat shock 70kDa protein 12A HSPA12A 214434_at 2.660
protocadherin 18 PCDH18 225975_at 2.660
Phospholipase C, beta 4 PLCB4 240728_at 2.646
myosin light chain kinase MYLK 202555_s_at 2.639
myosin light chain kinase MYLK 224823_at 2.632
obscurin-like 1 OBSL1 227573_s_at 2.625
cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39A1 220432_s_at 2.618
collagen, type I, alpha 2 COL1A2 229218_at 2.611
platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homPDGFB 216055_at 2.611
zinc finger, matrin type 1 ZMAT1 226344_at 2.611
chromosome 3 open reading frame 65 C3orf65 1563207_at 2.591
ribonucleotide reductase M2 polypeptide RRM2 209773_s_at 2.591
sortilin 1 SORT1 224818_at 2.571
CAP, adenylate cyclase-associated protein, 2 (yeast) CAP2 212554_at 2.571
JMJD7-PLA2G4B readthrough transcript /// phospholipase A2, group IVB (cytosolic) JMJD7-PLA2G4219095_at 2.564
nicotinamide N-methyltransferase NNMT 202237_at 2.558
cholinergic receptor, nicotinic, alpha 6 CHRNA6 207568_at 2.558
coiled-coil domain containing 69 CCDC69 1553102_a_at 2.551
cysteine conjugate-beta lyase 2 /// similar to RNA binding motif protein, X-linked /// RNA b CCBL2 /// LOC11556336_at 2.545
coiled-coil domain containing 69 CCDC69 212886_at 2.538
Zinc finger protein 64 homolog (mouse) ZFP64 229186_s_at 2.538
BCL2-like 11 (apoptosis facilitator) BCL2L11 225606_at 2.538
ribonuclease H2, subunit B RNASEH2B 229210_at 2.525
chromosome 18 open reading frame 24 C18orf24 217640_x_at 2.525
hypothetical protein LOC284898 LOC284898 1562030_at 2.513
myelin basic protein MBP 210136_at 2.506
pyridine nucleotide-disulphide oxidoreductase domain 2 PYROXD2 228384_s_at 2.506
SH3-domain GRB2-like 3 SH3GL3 211565_at 2.506
ets variant 3 ETV3 214480_at 2.506
frizzled homolog 7 (Drosophila) FZD7 203706_s_at 2.500
ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function) ENPP5 237054_at 2.494
hypothetical protein LOC100129444 LOC100129444236272_at 2.488
cation channel, sperm-associated, beta CATSPERB 1570470_at 2.481
hypothetical LOC653602 LOC653602 229546_at 2.475
chromosome 9 open reading frame 126 C9orf126 228174_at 2.463
ADAMTS-like 1 ADAMTSL1 1552808_at 2.463
fin bud initiation factor homolog (zebrafish) FIBIN 231001_at 2.457
Rho GTPase activating protein 18 ARHGAP18 225171_at 2.445
family with sequence similarity 65, member C FAM65C 227654_at 2.439
prostaglandin F2 receptor negative regulator PTGFRN 224937_at 2.433
MANSC domain containing 1 MANSC1 220945_x_at 2.427
phospholipid scramblase 4 PLSCR4 218901_at 2.427
chromosome 11 open reading frame 21 C11orf21 220560_at 2.421
mitogen-activated protein kinase kinase 6 MAP2K6 205698_s_at 2.421
arsenic (+3 oxidation state) methyltransferase AS3MT 223652_at 2.415
Parkinson disease (autosomal recessive, juvenile) 2, parkin PARK2 207058_s_at 2.415
coiled-coil domain containing 138 CCDC138 235644_at 2.415
glycosyltransferase 8 domain containing 2 GLT8D2 221447_s_at 2.415
glycosyltransferase 8 domain containing 2 GLT8D2 227070_at 2.415
integrin, beta 8 ITGB8 226189_at 2.410
P antigen family, member 1 (prostate associated) PAGE1 206897_at 2.404
hypothetical FLJ13197 FLJ13197 219871_at 2.392
zinc finger protein 541 ZNF541 232604_at 2.392
V-set and transmembrane domain containing 2A VSTM2A 230117_at 2.392
microtubule-associated protein 7 MAP7 202890_at 2.392
Synaptotagmin XVII SYT17 229053_at 2.392
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 221588_x_at 2.387
BRF1 homolog, subunit of RNA polymerase III transcription initiation factor IIIB (S. cerevisBRF1 215676_at 2.381
paraneoplastic antigen MA2 PNMA2 209598_at 2.381
GLE1 RNA export mediator homolog (yeast) GLE1 206920_s_at 2.381
124 
 
Table S2.4 cont'd. 
 
 
synaptotagmin XII SYT12 228072_at 2.375
MOCO sulphurase C-terminal domain containing 2 MOSC2 227417_at 2.370
ribosomal protein L13 RPL13 229590_at 2.364
dehydrogenase/reductase (SDR family) member 2 DHRS2 206463_s_at 2.358
chromosome 4 open reading frame 23 C4orf23 220891_at 2.358
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 ELOVL3 234513_at 2.358
testis specific, 14 TSGA14 215637_at 2.353
gap junction protein, alpha 3, 46kDa GJA3 239572_at 2.353
hypothetical protein LOC100130506 LOC100130506236656_s_at 2.353
integrin, beta 4 ITGB4 204990_s_at 2.353
phospholipase C, beta 4 PLCB4 203895_at 2.353
hypothetical LOC401052 LOC401052 232812_at 2.353
Fanconi anemia, complementation group D2 FANCD2 242560_at 2.353
hypothetical LOC346547 FLJ42291 238648_at 2.347
SEC31 homolog B (S. cerevisiae) SEC31B 209889_at 2.347
sphingomyelin synthase 2 SGMS2 227038_at 2.347
chromosome 14 open reading frame 147 C14orf147 213508_at 2.342
SEC16 homolog B (S. cerevisiae) SEC16B 228150_at 2.342
chromosome 11 open reading frame 54 C11orf54 223268_at 2.342
transmembrane protein 190 TMEM190 1552594_at 2.342
non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) NME5 206197_at 2.336
chromosome 4 open reading frame 12 C4orf12 241401_at 2.331
Spectrin, beta, non-erythrocytic 1 SPTBN1 213914_s_at 2.331
2,5-oligoadenylate synthetase 1, 40/46kDa OAS1 205552_s_at 2.331
KIAA1652 protein KIAA1652 1560671_at 2.326
toll-interleukin 1 receptor (TIR) domain containing adaptor protein TIRAP 1552804_a_at 2.326
chromosome 6 open reading frame 64 C6orf64 218784_s_at 2.326
progesterone receptor membrane component 2 PGRMC2 213227_at 2.320
5-nucleotidase domain containing 1 NT5DC1 223178_s_at 2.315
Protein kinase (cAMP-dependent, catalytic) inhibitor alpha PKIA 226864_at 2.315
aldehyde dehydrogenase 6 family, member A1 ALDH6A1 204290_s_at 2.309
solute carrier family 25, member 27 SLC25A27 230624_at 2.304
solute carrier family 39 (zinc transporter), member 8 SLC39A8 209267_s_at 2.304
chromosome 10 open reading frame 11 C10orf11 223703_at 2.294
phospholipase C, beta 1 (phosphoinositide-specific) PLCB1 215687_x_at 2.283
EF-hand calcium binding domain 3 /// similar to hypoxia-inducible protein 2 EFCAB3 /// LOC1553392_at 2.283
SLIT and NTRK-like family, member 4 SLITRK4 232636_at 2.283
LIM and cysteine-rich domains 1 LMCD1 218574_s_at 2.283
caspase 10, apoptosis-related cysteine peptidase CASP10 205467_at 2.278
tensin like C1 domain containing phosphatase (tensin 2) TENC1 212494_at 2.278
hypothetical LOC151162 /// mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaLOC151162 /// 212098_at 2.278
CAP, adenylate cyclase-associated protein, 2 (yeast) CAP2 212551_at 2.273
ephrin-A5 EFNA5 227955_s_at 2.268
phosphoinositide-3-kinase interacting protein 1 PIK3IP1 221756_at 2.262
CD302 molecule CD302 203799_at 2.262
coxsackie virus and adenovirus receptor pseudogene 1 CXADRP1 239155_at 2.262
spermatogenesis associated 6 SPATA6 238459_x_at 2.252
nucleoredoxin NXN 219489_s_at 2.252
mucin 1, cell surface associated MUC1 213693_s_at 2.252
decorin DCN 211813_x_at 2.252
neuropeptide Y receptor Y5 NPY5R 207400_at 2.252
septin 8 08-Sep 226627_at 2.252
nicotinamide N-methyltransferase NNMT 202238_s_at 2.247
chromosome 1 open reading frame 53 C1orf53 1558507_at 2.247
mucin 1, cell surface associated MUC1 207847_s_at 2.242
carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 219634_at 2.242
dipeptidyl-peptidase 4 DPP4 203716_s_at 2.232
ELL associated factor 2 EAF2 219551_at 2.232
transducin (beta)-like 1X-linked TBL1X 201868_s_at 2.232
OMA1 homolog, zinc metallopeptidase (S. cerevisiae) OMA1 226019_at 2.232
retinoic acid receptor responder (tazarotene induced) 2 RARRES2 209496_at 2.232
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NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa NDUFB6 1559042_at 2.227
solute carrier family 46, member 3 SLC46A3 214719_at 2.222
glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase) GCAT 205164_at 2.222
similar to pM5 (3 partial) /// NODAL modulator 1 /// NODAL modulator 2 /// NODAL modulaLOC100133864242922_at 2.222
sidekick homolog 1, cell adhesion molecule (chicken) SDK1 229912_at 2.217
SIX homeobox 4 SIX4 229796_at 2.212
cell cycle progression 1 CCPG1 221511_x_at 2.212
metallothionein 1M MT1M 217546_at 2.203
potassium channel tetramerisation domain containing 12 KCTD12 212188_at 2.203
basonuclin 1 BNC1 1552487_a_at 2.198
basic helix-loop-helix family, member e41 BHLHE41 221530_s_at 2.193
zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 1 ZRSR1 206512_at 2.193
nuclear factor (erythroid-derived 2)-like 3 NFE2L3 204702_s_at 2.193
prostaglandin D2 synthase 21kDa (brain) PTGDS 211748_x_at 2.188
chromosome 12 open reading frame 35 C12orf35 218614_at 2.188
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3 SEMA3A 206805_at 2.174
hypothetical protein LOC100131731 LOC1001317311557263_s_at 2.169
arachidonate 5-lipoxygenase-activating protein ALOX5AP 204174_at 2.165
Rho GTPase activating protein 18 ARHGAP18 225173_at 2.165
methylcrotonoyl-Coenzyme A carboxylase 2 (beta) MCCC2 1560033_at 2.165
bestrophin 4 BEST4 1552296_at 2.160
ferritin, heavy polypeptide 1 FTH1 214211_at 2.160
dipeptidyl-peptidase 4 DPP4 211478_s_at 2.160
ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit ATP5D 203926_x_at 2.155
frizzled homolog 2 (Drosophila) FZD2 210220_at 2.151
runt-related transcription factor 1 RUNX1 209360_s_at 2.151
engulfment and cell motility 1 ELMO1 204513_s_at 2.151
solute carrier family 27 (fatty acid transporter), member 1 SLC27A1 226728_at 2.151
flavin containing monooxygenase 4 FMO4 206263_at 2.151
RAB40B, member RAS oncogene family RAB40B 204547_at 2.141
similar to Six transmembrane epithelial antigen of prostate MGC87042 217553_at 2.141
zinc finger, FYVE domain containing 16 ZFYVE16 1555982_at 2.141
chromosome 12 open reading frame 72 C12orf72 1563474_at 2.137
smoothened homolog (Drosophila) SMO 218629_at 2.132
V-set and immunoglobulin domain containing 1 VSIG1 243764_at 2.128
cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39A1 1553977_a_at 2.123
hypothetical protein LOC283658 LOC283658 239741_at 2.123
intraflagellar transport 122 homolog (Chlamydomonas) IFT122 220744_s_at 2.119
cell cycle progression 1 CCPG1 214151_s_at 2.114
transcription elongation factor A (SII), 3 TCEA3 226388_at 2.110
polymerase (DNA directed), mu POLM 222238_s_at 2.110
Chromosome 12 open reading frame 32 C12orf32 241074_at 2.105
LIM domains containing 1 LIMD1 222762_x_at 2.105
von Willebrand factor A domain containing 5A VWA5A 205011_at 2.105
spermatogenesis associated 17 SPATA17 230763_at 2.101
NHL repeat containing 3 NHLRC3 227040_at 2.096
Hypothetical LOC645513 LOC645513 1561761_x_at 2.096
C-type lectin domain family 7, member A CLEC7A 1555213_a_at 2.096
phospholipid scramblase 1 PLSCR1 202430_s_at 2.096
syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) SNTB1 226438_at 2.092
ubiquitin-like modifier activating enzyme 7 UBA7 203281_s_at 2.088
phosphoribosyl pyrophosphate synthetase 2 PRPS2 203401_at 2.083
SATB homeobox 1 SATB1 203408_s_at 2.083
Carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 226368_at 2.083
formin binding protein 1 FNBP1 230389_at 2.083
prostaglandin D2 synthase 21kDa (brain) PTGDS 212187_x_at 2.079
inhibin, alpha INHA 210141_s_at 2.079
zinc finger protein 853 ZNF853 232884_s_at 2.079
chromosome 5 open reading frame 4 C5orf4 220751_s_at 2.075
nei endonuclease VIII-like 1 (E. coli) NEIL1 219396_s_at 2.075
coiled-coil domain containing 82 CCDC82 220693_at 2.070
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zinc finger protein 658 ZNF658 231950_at 2.070
coiled-coil domain containing 109B CCDC109B 218802_at 2.066
peroxisomal biogenesis factor 1 PEX1 204873_at 2.066
ERO1-like beta (S. cerevisiae) ERO1LB 231944_at 2.062
fucosidase, alpha-L- 1, tissue FUCA1 202838_at 2.062
cell division cycle associated 7-like CDCA7L 225081_s_at 2.058
cancer susceptibility candidate 5 CASC5 228323_at 2.053
Hypothetical gene supported by BC043549; BX648102 DKFZp686O132216874_at 2.053
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) TGM2 201042_at 2.053
glutamate receptor, ionotrophic, AMPA 3 GRIA3 208032_s_at 2.049
RNA binding motif, single stranded interacting protein 2 RBMS2 225778_at 2.041
LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) LSM5 202903_at 2.041
phytanoyl-CoA dioxygenase domain containing 1 PHYHD1 226846_at 2.037
Nuclear autoantigenic sperm protein (histone-binding) NASP 242918_at 2.037
HBV preS1-transactivated protein 4 PS1TP4 226381_at 2.037
hypothetical locus LOC401237 FLJ22536 229280_s_at 2.037
CUG triplet repeat, RNA binding protein 2 CUGBP2 227178_at 2.033
syndecan 3 SDC3 202898_at 2.033
cold inducible RNA binding protein CIRBP 225191_at 2.024
elastin microfibril interfacer 1 EMILIN1 204163_at 2.020
melanoma associated antigen (mutated) 1-like 1 MUM1L1 229160_at 2.020
adaptor-related protein complex 2, alpha 1 subunit AP2A1 223237_x_at 2.016
potassium inwardly-rectifying channel, subfamily J, member 12 KCNJ12 207110_at 2.008
ribonuclease H2, subunit B RNASEH2B 219056_at 2.008
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-likeCTDSPL 201906_s_at 2.008
myotubularin related protein 3 MTMR3 202198_s_at 2.008
Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3 218501_at 2.008
nuclear receptor subfamily 1, group H, member 3 NR1H3 203920_at 2.008
ATP-binding cassette, sub-family A (ABC1), member 5 ABCA5 213353_at 2.008
carbonic anhydrase XII CA12 204509_at 2.008
cytochrome b5 type B (outer mitochondrial membrane) CYB5B 227382_at 2.008
potassium inwardly-rectifying channel, subfamily J, member 12 KCNJ12 232289_at 2.000
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Chapter 3 
3 LKB1 signalling protects dormant ovarian cancer 
spheroids from cell death in an AMPK-independent 
manner 
3.1 Introduction 
Ovarian cancer is the most lethal gynecologic malignancy in the western world, the 
overall survival of which has remained unchanged for more than 50 years1,2. Models that 
can be used to uncover the molecular events important for disease dissemination are 
crucial since the majority of women with ovarian cancer  (over 75%) are diagnosed at 
advanced stage3. Intraperitoneal implants identified in these patients with advanced-stage 
disease are the result of single cells and multicellular aggregates, or spheroids, that 
adhere to the mesothelial lining of various abdominal organs to establish secondary 
lesions4-6. In many cases, this is accompanied by accumulation of ascites fluid within the 
peritoneal cavity, where cells in suspension are exposed to a unique set of 
microenvironmental cues, allowing this population of cells to form secondary 
metastases3-5,7. These non-adherent metastatic cells provide unique therapeutic challenges 
for treatment of ovarian cancer3.  
 The biological significance and clinical relevance of multicellular spheroids has 
been documented in many different tumour types8-14. It is well accepted that spheroids 
more closely mimic the cell-cell, cell-matrix interactions, metabolic gradients, cellular 
viability and differentiation of malignant cells within a solid tumour than do conventional 
monolayer cultures15. We have shown that ascites-derived ovarian cancer cells in 
suspension form dormant multicellular aggregates characterized by quiescence and 
decreased Akt activity16. These dormant cells are subsequently able to re-enter the cell 
cycle and grow when they reach an adherent substratum.16. Ovarian cancer cells that are 
able to resist anoikis and survive within ascitic fluid most likely have uniquely adapted 
key cell survival pathways to meet the nutrient and energy demands of this particular 
microenvironment. 
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A fundamental requirement of all cells is the ability to respond to various forms of 
metabolic stress and balance ATP consumption and generation in response. Under 
conditions where nutrients are low, AMPK acts as a metabolic checkpoint by activating 
catabolic processes and inhibiting anabolic metabolism17,18. AMPK is a heterotrimeric 
complex containing a catalytic α-subunit and two regulatory subunits, β and γ. When 
intracellular ATP levels are low, AMP or ADP directly bind to the γ regulatory subunits. 
This causes a conformation change in the complex that allows AMPK to be 
phosphorylated at threonine 172 on the α subunit17. The primary kinase responsible for 
phosphorylation at this site is LKB119-21. 
It has been suggested that AMPK may function as a context-dependent tumour 
suppressor or oncogene22. Modest activation of AMPK may be cell protective, but 
prolonged or enhanced activation can be detrimental and result in growth arrest or cell 
death18.  The most thoroughly characterized mechanism through which the LKB1/AMPK 
pathway regulates cell growth is by suppression of mTORC1 signalling. LKB1, on the 
other hand, is commonly regarded as a tumour suppressor, and is mutated in the rare 
hereditary autosomal dominant Peutz Jeghers Syndrome. These patients experience 
benign intestinal hamartomatous polyps and have an increased risk of developing 
malignant tumours23. Despite this, LKB1 mutations have been identified in relatively few 
sporadic cancers.  
Previous studies have shown that metabolic stress is induced when normal 
epithelial cells lose ECM attachment, resulting in a decreased ATP:ADP ratio and 
subsequent activation of AMPK24-26. However, this suspension-induced AMPK activation 
has yet to be examined in tumour spheroids. In our study, we use a disease-relevant 
spheroid model to interrogate the function of the LKB1/AMPK pathway in ovarian 
cancer cells. Our results indicate that LKB1 and AMPK serve distinct functions in 
ovarian cancer cells and spheroids to promote dormancy and anoikis-resistance. 
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3.2 Materials and Methods 
3.2.1  Culture of cell lines, ascites-derived cells and isolation of 
native ascites spheroids 
Ascites fluid from patients diagnosed with advanced stage (II-IV), high-grade 
serous epithelial ovarian cancer (Table S1) was used to establish primary cell cultures as 
previously described27. The iOvCa147-E2 and iOvCa198 cell line were isolated from the 
EOC147 and EOC 198 ascites samples respectively. All work with patient materials has 
been approved by The University of Western Ontario Health Sciences Research Ethics 
Board (Protocol # 12668E and 16391E; Appendix B). Spheroids were isolated directly 
from ascites fluid by filtration through a 40 µm cell strainer (Becton Dickinson), washed 
with phosphate-buffered saline (PBS) into a collection tube with protein lysis buffer for 
immunoblot or embedded directly in OCT to obtain fresh frozen sections.  
3.2.2  TCGA Analysis 
Datasets from The Cancer Genome Atlas analysis of ovarian serous 
cystadenocarcinoma samples were downloaded from the University of California Santa 
Cruz Cancer Genomics Browser (https://genome- cancer.ucsc.edu)28 and from the 
Memorial Sloan-Kettering Cancer Center’s cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/)29. Array comparative genomic hybridization data was 
acquired at the Broad TCGA genome characterization center using the Affymetrix 
Genome-Wide Human SNP Array 6.0 platform. Raw data was analyzed using the 
GISTIC2 method to generate gene-level copy-number variation (CNV) estimates and 
downloaded as either thresholded copy-number calls or as log2-transformed CNV values. 
Protein expression data was generated and processed at the MD Anderson Cancer Center 
TCGA proteome characterization center using reverse-phase protein array (RPPA) 
technology as described30 and downloaded either natural log-transformed values or as z-
scores. 
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3.2.3  Immunoblotting and Immunofluorescence 
Whole cell protein lysates were generated from cell lines and ascites-derived cells in 
adherent and spheroid culture as previously described31. Antibodies used for immunoblot 
against p-AMPKα Thr172 (#2535), AMPKα (#5832), p-LKB1 Ser428 (#3482), LKB1 
(#3050), p-p70S6K1 Thr 389 (#9234), p-ACC (#3661), ACC (#3676) and p70S6K1 
(#2708) were obtained from Cell Signaling Technology (Danvers, MA). Anti-Tubulin 
antibody was obtained from Sigma. AICAR was purchased from Caymen Chemical 
Company (Ann Arbor, MI) and A-769662 from Tocris Bioscience (Bristol, UK).  
Immunofluorescent (IF) analysis was performed on fresh frozen sections that were fixed 
(4% formaldehyde), permeabilized (0.1% Triton X-100 in PBS), and blocked (5% BSA 
in 0.1% Triton X-100) before incubation with p-AMPKα antibody (#ab51110) from 
abcam® Inc. (Cambridge, MA). Following primary antibody incubation and PBS washes, 
sections were incubated for 1 hour with anti-rabbit FITC secondary antibody (1:250; 
Sigma-Aldrich). After further washing, sections were incubated with 4',6-diamidino-2-
phenylindole (DAPI; 1:1000) and slides were mounted with Vectashield (Vector 
Laboratories, Burlingame CA, USA). Fluorescence images were captured using an 
Olympus AX70 upright microscope and ImagePro image capture software. 
3.2.4  Cell Viability and ATP assays 
Cells were seeded to either 24-well tissue culture plastic or ultra-low attachment (ULA) 
plates at a density of 1.0x104 to form adherent cultures or 5.0x104 per well to form 
spheroids, respectively.. Treatment was initiated at time of seeding for cells in suspension 
while cells under adherent conditions were given 12 hours to adhere prior to commencing 
treatment. CellTiter-Glo® reagent (Promega, Madison, WI) was prepared according to 
manufacturer’s instructions. At 72h post-treatment, spheroids were collected, pelleted and 
left in a minimal volume of media (100 µL), at which point CellTiter-Glo® reagent was 
added in a 1:1 volume ratio. Under adherent conditions, cells were harvested directly in 
CellTiter-Glo® reagent (1:1 reagent/media) after a 20 minute incubation period. All 
samples were subject to a freeze/thaw cycle prior to analysis. Approximately 200µL of 
the mixture was added to a white-walled 96-well micro-plate and luminescence signal 
was detected using a microplate spectrophotometer (Wallac 1420 Victor 2; Perkin-Elmer, 
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Waltham, MA). Treatments were conducted in at least duplicate wells and luminescence 
readings normalized to cells treated with vehicle control.  
3.2.5  siRNA transfections 
All siRNA transfections were performed in a 6-well format. The day prior to 
transfection, cells were plated at a density of approximately 1 × 105 cells per well in 
antibiotic-free media. The next day, DharmaFECT transfection reagent (DharmaFECT1 
for OVCA429 and iOVCA147-E2 and DharmaFECT3 for SKOV3) was used to transfect 
cells, as per manufactures protocol. Briefly, 1 µl of DharmaFECT1 or 4 µl of 
DharmaFECT3 was combined with 10nM siRNA in a volume of 1mL of media (Wisent) 
and incubated for 20 min; the complexes of DharmaFECT and siRNAs were then added 
directly to each well. Media was removed 24 hours following transfection and replaced 
with fresh antibiotic-free growth media.  At this point, the cells were incubated until 
nearly confluent, approximately 72 hours following transfection. PRKAA1 and STK11 
siRNAs (M-005027-02 and M-005035-02 respectively) were obtained from Dharmacon 
(Thermo Fisher Scientific Inc., Waltham, MA). All siRNAs used were siGENOME 
SMARTpool predesigned pools of four oligos. 
3.2.6  Graphing and Statistical Analysis 
All graphs were generated using GraphPad Prism 5 (GraphPad Software, San Diego, 
CA). Data were expressed as Mean ± SEM, as indicated. All statistical analysis 
(Student’s t-test and Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison 
Test) was performed using GraphPad Prism 5.  Tests of significance were set at p < 0.05. 
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3.3 Results 
3.3.1  AMPKα1 is expressed in metastatic ovarian tumour samples 
and is associated with a high frequency of copy-number 
gains and amplifications.  
AMPK has been described in many instances to serve as a tumour suppressor 
despite the lack of genetic evidence to demonstrate a loss of AMPK function in cancer18. 
In order to assess AMPK activity in a large number of serous ovarian tumours, the 
majority of which (91.1%) are from metastatic, stage III-IV cases, we made use of level 3 
array comparative genomic hybridization (aCGH) and reverse phase protein array 
(RPPA) data from The Cancer Genome Atlas (TCGA). This analysis revealed copy-
number gain of the PRKAA1 gene (encoding AMPKα1) in 36% (111/311) of samples 
(Figure 3.1A). To determine whether PRKAA1 copy-number correlated with protein 
expression, we plotted RPPA data against copy-number calls for both phosphorylated 
(T172) and total AMPKα1. This demonstrated a significant increase in both 
phosphorylated (Figure 3.1B) and total AMPKα1 (Figure 3.1C) in samples with copy-
number gain. Using log2-transformed copy-number data, we also performed regression 
analysis to measure the correlation between PRKAA1 copy-number and protein 
expression. This revealed a positive correlation between copy-number and AMPKα1 
protein expression (both phosphorylated and total; Figure 3.1D&E). In addition, we also 
noted a positive correlation between AMPKα1 protein expression and activity (Figure 
3.1F). To verify AMPKα1 expression and activity in fresh tumour specimens, we 
performed western blots on lysates harvested from metastatic tumour samples obtained 
by our lab (Figure 3.1G). Indeed, our direct results demonstrate that AMPKα1 is 
expressed and active in metastatic ovarian tumours. 
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Figure 3.1: The AMPK pathway is active in mestatic ovarian tumour samples. 
(A) Gene copy-number calls at the PRKAA1 locus are depicted for 311 ovarian serous 
cystadenocarcinoma tumors (red & pink = high-level & low-level amplification, 
respectively; teal &blue = heterozygous & homozygous deletion, respectively). 
OncoPrint obtained from cBioPortal.org. (B,C) Phosphorylated and total AMPKα1 
protein (quantitative RPPA; n=398) expression data were transformed to z-scores and 
depicted as functions of copy-number. One-way ANOVA with Tukey’s Test was 
performed (*p<0.05; ***p<0.001). (D,E) ln-transformed protein expression (n=397;re-
transformed to log2 values) data depicted as a function of log2-transformed copy number 
values. (F) Phosphorylated AMPKα1 protein expression depicted as a function of total 
protein. Correlation and linear regression analysis performed: line of best fit, Pearson’s r, 
Goodness-of-fit R2, and p values all reported. (G) Lysates were generated from metastatic 
tumour samples from seven ovarian cancer patients and immunoblot was performed to 
examine AMPK activity in these samples.  
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3.3.2  Multicellular aggregates filtered from patient ascites fluid 
exhibit enhanced AMPK activity. 
Our lab has previously demonstrated that ovarian cancer cells which form 
multicellular aggregates in vitro enter a dormant state, a process which is aided by 
decreased AKT activity16. Herein, we postulate that the AMPK pathway is another 
pathway, that mediates spheroid formation-induced dormancy. due to its unique ability to 
respond to stresses, such as nutrient deprivation and hypoxia. In order to evaluate this, we 
analyzed AMPK activity in native ascites spheroids filtered directly from patient ascites 
fluid by western blot and immunofluorescence. Lysates generated from ascites spheroids 
filtered directly from a number of different patient ascites samples revealed a significant 
increase in AMPK activity in spheroids compared to matched adherent samples from the 
same patient (Figure 3.2A). Additionally, immunofluorescence on ascites-derived 
spheroids revealed intense expression of phosphorylated AMPKα1 in the cytoplasm and 
along the cell membrane (Figure 3.2B). These data indicate that AMPK activity is 
enhanced is actively metastatic cells in spheroids within malignant ascites fluid. 
3.3.3  Ovarian cancer cell lines and ascites-derived cells in 
suspension exhibit decreased levels of ATP and enhanced 
AMPK activity. 
Following our observation that AMPK activity is enhanced in native ascites 
spheroids, we sought to investigate regulation of this phenomenon further using spheroids 
formed in vitro. We hypothesized that as a result of spheroid formation induced-
dormancy, the metabolic state of cells within these multicellular aggregates is decreased. 
To assess this, we used Cell Titer Glo® luminescence-based ATP assay to determine 
levels of intracellular ATP in ovarian cancer cells in adherent and spheroid form. Indeed, 
ATP levels were significantly lower in spheroids compared to their adherent counterparts 
(Figure 3.3A). Correspondingly, western blot analysis of adherent and spheroid ovarian 
cancer cells revealed a significant increase in AMPK activity associated with spheroid 
formation (Figure 3.3B,C). Taken together, these data demonstrate decreased ATP levels 
that are associated with increased AMPK activity when ovarian cancer cells aggregate to 
form multicellular clusters or spheroids.  
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Figure 3.2: Native ascites spheroids have enhanced AMPK activity compared to 
adherent cells. 
(A) Lysates were prepared from filtered spheroids [S] and passage 0 adherent cells [A] 
from 5 independent patient ascites samples. Immunoblot (shown representative image 
from two samples) and subsequent densitometry were performed to determine levels of 
phosphorylated AMPKα1 compared to total protein. Bars: Mean ± SEM. Levels of 
phosphorylated AMPKα1 were compared using Student’s t-test (*p<0.05). (B) Spheroids 
filtered from patient ascites fluid for immunofluorescence analysis compared to early 
passage adherent cells from the same patient [EOC 169]. Nuclei (blue) and pAMPKα1 
(green) are visible. Scale bar: 100µm. 
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Figure 3.3: Spheroids formed from EOC cell lines and ascites-derived cells have 
decreased levels of ATP and corresponding increases in AMPK activity. 
(A) Quantification of ATP levels in EOC cell lines cultured in both adherent and spheroid 
conditions using luminescence-based ATP assay CellTiter Glo®. Difference in viable 
cells between each culture condition was accounted for by normalizing results to total 
protein levels for each sample.  Bars: Mean ± SEM. Student’s t-test was used to compare 
levels of ATP between culture conditions (***p<0.001). (B) Immunoblot performed on 
EOC cell lines and ascites-derived EOC cells to determine levels of phosphorylated and 
total AMPKα1 protein. (C) Densitometry was performed on cell lines and primary EOC 
cells (n=14) to compare levels of phosphorylated AMPKα1 between adherent and 
spheroid cultured cells. Bars: Mean ± SEM. Student’s t-test was used to determine 
statistical significance (*p<0.05).  
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3.3.4  LKB1 protein is expressed in metastatic ovarian tumour 
samples. 
Activity of the key upstream AMPK kinase LKB1 is commonly thought to be 
tumour suppressive32. Multiple studies have suggested that single allelic inactivation of 
the STK11 gene encoding LKB1 is sufficient to promote tumorigenesis, while other data 
suggests that biallelic loss may be required33-36.  In order to examine status of LKB1 in 
serous ovarian tumours we again made use of data from the TCGA. Whereas copy-
number gain was common for PRKAA1, heterozygous deletion of STK11 was detected in 
84% of samples (262/311; Figure 3.4A). This single allelic loss correlated with decreased 
protein expression compared to samples with normal copy-number (Figure 3.4B), and a 
positive correlation between STK11 copy-number and LKB1 protein expression when we 
performed regression analysis on log2-transformed copy-number data (Figure 3.4C). 
When we sought to determine LKB1 expression in metastatic tumour samples obtained 
by our lab, however, we consistently observed expression of phosphorylated and total 
LKB1 (Figure 3.4D). Therefore, despite single allele loss of STK11, LKB1 protein 
expression is maintained in metastatic ovarian cancer cells and may in fact serve an 
important function in late-stage disease. 
3.3.5  Suspension-induced activation of AMPK signalling is 
accompanied by enhanced LKB1 signalling and inhibition of 
mTORC1. 
 We next wanted to determine the specific components of the AMPK pathway that 
may also be altered when ovarian cancer cells are put in suspension. We first focused on 
LKB1 as a critical upstream activator of AMPK signalling. Immunoblot revealed 
increased phosphorylation of LKB1 at Serine 428 in spheroids formed from a number of 
ovarian cancer cell lines and ascites-derived cells compared to cells grown under 
adherent conditions (Figure 3.5A,B). Although its phosphorylation state does not affect 
its catalytic activity, phosphorylation at Ser428 has been shown to be important for the 
tumour suppressive functions of LKB137. LKB1 can be localized to the nucleus or 
cytoplasm, and the cytoplasmic pool of LKB1 has been shown to contribute to the 
tumour suppressive function of this kinase32. We determined by cellular fractionation and 
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immunoblotting that LKB1protein in adherent and spheroid-cultured cells is located in 
the cytoplasm (Figure S3.1).  
Since the LKB1/AMPK signalling pathway has been identified as a key negative 
regulator of mTORC1 signalling, we next focused on this pathway as a downstream 
readout for AMPK’s ability to rewire cellular metabolism in these clusters of cells. 
Immunoblot performed on spheroids from cell lines and ascites-derived cells revealed a 
significant decrease in mTORC1 activity as determined by p70S6K1 phosphorylation 
(Figure 3.5C). Taken together, these results provide additional evidence for decreased 
anabolic metabolism that occurs when cells detach into suspension and form spheroids, 
indicating that the LKB1/AMPK/mTORC1 signalling axis may be a crucial mediator of 
cell survival in this context.  
3.3.6  Spheroids are much less sensitive to further activation of the 
AMPK pathway than adherent ovarian cancer cells. 
It has been previously demonstrated that treatment of ovarian cancer cells with 
AMP mimetic AICAR results in increased AMPK activity and decreased viability of 
adherent cells38,39. Similarly, in our study, we demonstrate robust activation of AMPK 
after treatment of ovarian cancer cells with 1 mM AICAR, which corresponds with 
decreased mTORC1 activity (Figure 3.6A). In addition, AICAR treatment of various 
ovarian cancer cell lines and ascites-derived cells results in decreased viability in cells 
cultured under both adherent and suspension conditions. Importantly, the detrimental 
effects of AICAR treatment on spheroid cell viability are not observed until later time 
points compared to their adherent counterparts (Figure 3.6B).  When spheroids are treated 
with AICAR during reattachment, however, a significant reduction in dispersion area was 
observed highlighting the detrimental effect that AMPK activation has on cell 
proliferation (Figure 3.6C).  
To further explore mechanisms of AMPK activation, we also tested a more 
specific allosteric AMPK activator, A-769662, which stimulates AMPK directly without 
affecting the kinase domain40. Treatment of ovarian cancer cells with A-769662 (100µM) 
results in activation of AMPK as indicated by enhanced phosphorylation of ACC (Figure  
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Figure 3.4: Despite heterozygous deletion, LKB1 protein is expressed in metastatic 
ovarian tumour samples. 
(A) Gene copy-number calls at the STK11 locus are depicted for 311 ovarian serous 
cystadenocarcinoma tumors (red & pink = high-level & low-level amplification, 
respectively; teal &blue = heterozygous & homozygous deletion, respectively). 
OncoPrint obtained from cBioPortal.org.  (B) STK11 protein (quantitative RPPA; n=398) 
expression data was transformed to z-scores and depicted as functions of copy-number. 
One-way ANOVA with Tukey’s Test was performed (***p<0.001). (C) ln-transformed 
protein expression (n=397;re-transformed to log2 values) data depicted as a function of 
log2-transformed copy number values. Correlation and linear regression analysis 
performed: line of best fit, Pearson’s r, Goodness-of-fit R2, and p values all reported. (D) 
Lysates were generated from metastatic tumour samples from seven ovarian cancer 
patients and immunoblot was performed to examine LKB1 expression in these samples. 
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Figure 3.5: Spheroids formed from EOC cell lines and ascites-derived cells express 
LKB1 protein and have decreased levels of mTORC1 signalling. 
(A) Immunoblot performed on EOC cell lines and ascites-derived EOC cells to determine 
levels of phosphorylated and total LKB1 protein. (B) Densitometry was performed on 
cell lines and primary EOC cells (n=16) to compare levels of phosphorylated and total 
LKB1 between adherent and spheroid cultured cells. Bars: Mean ± SEM. Student’s t-test 
was used to determine statistical significance (*p<0.05). (C) Immunoblot performed on 
EOC cell lines and ascites-derived EOC cells to determine levels of phosphorylated and 
total p70S6K1 protein as a read-out of mTORC1 activity.  
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Figure 3.6: AICAR treatment of EOC cell lines and ascites-derived cells decreases 
cell viability in adherent and spheroid cells. 
(A) Immunoblot performed on EOC cells treated for 24 hours with various doses of 
AICAR as indicated. (B) Viability of ovarian cancer cell lines and ascites-derived cells 
following 3 and 6 days of AICAR (1mM) treatment in adherent and spheroid culture 
conditions. Bars: Mean ± SEM. Effect of treatment at each timepoint was determined 
using Student’s t-test. Results are significant (p<0.05) unless otherwise indicated. (C) 
Reattachment of spheroids (72h) formed from ascites-derived cells (n=9) treated with 
AICAR (1mM) at time of seeding to suspension culture. Quantifications performed using 
ImageJ and Student’s t-test used to compare areas between groups (***p<0.001). 
Representative image of one patient sample (EOC154) depicted. Scale bar: 100µm. 
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3.7A). Similarly to AICAR treatment, this compound also reduces viability of ovarian 
cancer cells in adherent culture. However, there is no effect of A-769662 treatment on 
viability of cells in spheroids (Figure 3.7B). These results suggest that actively 
proliferating, adherent ovarian cancer cells are more sensitive to AMPK activation, but 
quiescent cells in multicellular spheroids are less impacted by a further increase in the 
activation state of this pathway.  
 Following the observation that both AICAR and A-769662 have detrimental 
effects on ovarian cancer cells in adherent culture, we further characterized this reduced 
viability by determining whether cells were undergoing apoptosis or arresting in a 
particular phase of the cell cycle. Both compounds result in a decreased proportion of 
cells in the S-phase of the cell cycle as early as 24 hours after treatment. The effect 
observed with AICAR treatment is more robust across different cell lines than that 
observed with A-769662 (Figure S3.2). We also used Caspase-Glo® luminescence-based 
assay which uses caspase 3/7 activity as a read-out for apoptosis. We found that 72 hours 
following treatment with AICAR (1mM), there was a significant induction of apoptosis, 
an effect which was not observed in A-769662-treated cells (Figure S3.2). These results 
suggest that these two compounds have different mechanisms of action in ovarian cancer 
cells:  AICAR decreases ovarian cancer cell viability largely by apoptosis, whereas A-
769662 elicits a cytostatic response thereby blocking ovarian cancer cell growth.  
3.3.7  LKB1, but not AMPK, is required for ovarian cancer cell 
survival in suspension. 
 Given the relative insensitivity of ovarian cancer cells in suspension to further 
activation of AMPK, we assessed the functional impact of attenuation of the 
LKB1/AMPK pathway in spheroids. In order to do this we transfected ovarian cancer cell 
lines with siRNAs targeting either PRKAA1 (AMPKα1) or STK11 (LKB1). A number of 
established ovarian cancer cell lines were screened for LKB1 and AMPK expression and 
activity in adherent culture (Figure S3.3) and those with the highest activity were used in 
knockdown experiments. Effective knockdown of STK11 and PRKAA1 was achieved in 
cells in both adherent (Figure 3.8A) and suspension (Figure 3.8B) cultures. Cells in 
adherent culture were not sensitive to knockdown of either AMPKα1 or LKB1 with 
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respect to cell viability, most likely since these cells are proliferating and not under 
metabolic stress, therefore not requiring this pathway. Surprisingly, knockdown of 
AMPKα1 had no impact on the survival of cells in suspension, while loss of LKB1 
significantly reduced viability of cells in spheroids (Figure 3.8C). These results point to 
AMPK-independent LKB1 signalling as an important stress adaptation used by ovarian 
cancer cells in suspension in order to avoid anoikis.   
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Figure 3.7: Allosteric AMPK activator A-769662 decreases viability of EOC cells in 
a context-dependent manner. 
(A) Immunoblot performed on EOC cells treated for 24 hours with various doses of A-
769662 as indicated. AMPK activation determined by levels of phosphorylated ACC. (B) 
Viability of ovarian cancer cell lines following 3 and 6 days of A-769662 (100µM) 
treatment in adherent and spheroid culture conditions. Bars: Mean ± SEM. Effect of 
treatment at each timepoint was determined using Student’s t-test. Results are significant 
(p<0.05) unless otherwise indicated. 
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Figure 3.8: siRNA-mediated knockdown of STK11 but not PRKAA1 results in a 
decrease in viability of ovarian cancer spheroids. 
(A,B) Immunoblot performed for proteins as indicated on adherent and spheroid ovarian 
cancer cells 72 hours after transfection or 3 days after spheroid formation respectively. 
(C,D) Cell viability as determined by Cell Titer Glo® assay on ovarian cancer cell lines 
in adherent or suspension culture respectively after three days (seeded to these conditions 
72 hours after transfection). (E) Images of day 3 OVCA429 spheroids following siRNA 
knockdown as indicated. Scale Bar: 100µm. 
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3.4 Discussion 
The distinct mode of metastatic spread whereby EOC cells transit the peritoneal 
cavity in suspension, presents unique therapeutic challenges for treatment of advanced-
stage ovarian cancer. Characterization of this unique population of non-adherent cells 
will provide insights into novel targets for treatment of this deadly disease. Our 
laboratory has previously shown that ovarian cancer cells in suspension have a propensity 
to aggregate and form dormant multicellular clusters or spheroids. This dormancy is 
reversible upon reattachment to an adherent substratum, a process that is dependent upon 
AKT16.  Following up on this observation, we show in this report that cells in dormant 
EOC spheroids have reduced metabolic activity and as such induce the LKB1/AMPK 
metabolic stress response pathway. Indeed, we demonstrate that AMPK activity is 
enhanced in quiescent ovarian cancer spheroids. Also, direct pharmacologic activation of 
AMPK in proliferating adherent ovarian cancer cells to leads to cytostasis and ultimately 
a decrease in cell viability. Our surprising new result, however, is that where maintenance 
of LKB1 expression is required for ovarian cancer cell survival in suspension, AMPK is 
not necessary. This implies an AMPK-independent role for LKB1 in mediating anoikis-
resistance in ovarian cancer cells.  This is the first study to demonstrate a pro-survival 
function for LKB1, a kinase that has been traditionally considered to be a tumour 
suppressor. 
Expansive tumour growth is typically dependent on over-proliferative malignant cells 
that lack the normal response to induce protective growth arrest. Under nutrient-rich 
conditions, proliferative cancer cells should have low to absent levels of active AMPK 
signalling. Indeed, we show that expression of phosphorylated AMPKα is marginal in the 
majority of cultured EOC cells assessed; however, AMPK activity is significantly 
elevated upon spheroid formation. Ectopic activation of this pathway in proliferating cells 
using the AMP mimetic AICAR or an allosteric AMPKα activator A-769662 result in 
decreased viability. These agents most likely produce this effect through different 
mechanisms. Although both compounds induce a potent cytostatic response, AICAR 
treatment eventually results in significant cell death due to induction of apoptosis 
whereas A-769662 does not. A recent report highlighted the difference between these two 
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compounds, demonstrating that the growth-suppressive effects of AICAR are actually 
independent of AMPK in a glioma model41. Thus, the decreased viability observed in 
ovarian cancer spheroids treated with AICAR may in fact occur via AMPK-independent 
mechanisms. Taken together, this indicates that suppressed AMPK signalling is required 
to sustain active tumour growth, and supports a general idea that this pathway possesses 
classical tumour suppressor function under these conditions. However, when cells are in 
suspension AMPK is activated to facilitate cellular quiescence, and further activation is 
of lesser consequence on viability. These results indicate that AMPK acts like a typical 
tumour suppressor, yet its function may be utilized to promote protection from apoptosis 
during later stages of ovarian cancer progression.  
Along this same reasoning, it is not unreasonable to postulate that LKB1 function 
may be context-specific during ovarian cancer progression given its array of downstream 
targets. A recent report of a conditional mouse model for serous ovarian carcinoma 
determined that loss of one Stk11 allele in the context of Pten loss within the OSE leads 
to the development of high-grade papillary serous ovarian carcinomas42. This is not the 
first study to demonstrate synergism between LKB1 and other tumour suppressors or 
oncogenes. In fact, LKB1 has been shown to accelerate tumorigenesis in conjunction 
with p5343, Kras44, and c-myc45. This provides additional support for the complex 
function of this important kinase. Indeed, the molecular signature of a particular tumour 
is likely another factor that impacts the operational role of LKB1 in a particular type or 
stage of cancer18. Although the study by Tanwar and colleagues42 implicates loss of 
LKB1 function in the initiation of ovarian cancer, knockout is performed in the ovarian 
surface epithelium and not the secretory epithelium of oviduct; the secretory epithelial 
cells of the distal fallopian tube is now considered the site of origin for high-grade serous 
ovarian cancer46-48. Since loss of STK11 in premalignant serous tubal intraepithelial 
carcinoma lesions in humans has not yet been documented, studies in this regard would 
provide additional insight into the role of LKB1 in ovarian cancer initiation.  
In this report, we show that analysis of the serous ovarian cancer provisional dataset 
from cBioPortal indicated that 84% of tumours exhibit heterozygous loss of STK11 the 
gene encoding LKB129.  Despite this, we show that numerous EOC solid tumour 
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specimens, as well as established ovarian cancer cell lines, express LKB1 protein. 
Interestingly, we also show copy number gains or amplifications in PRKAA1, which 
encodes AMPKα1, in 36% of samples. This suggests that there may be compensatory 
mechanisms to upregulate AMPK activity in late-stage ovarian tumours which harbour 
reduced LKB1 in order to maintain a functional pathway for tumour cell survival during 
metastasis. It is also possible that this discordance in LKB1 and AMPK copy number 
variations indicates that these kinases may not necessarily be acting in concert in 
advanced-stage ovarian cancer. Our data imply that although STK11 haploinsufficiency 
may occur and predispose to ovarian cancer initiation, maintenance of functional LKB1 
signalling pathway is likely essential during metastatic progression particularly to fuel 
recurrence of chemoresistant ovarian cancer. 
The LKB1/AMPK signalling pathway represents an immediate response to metabolic 
stress and reduced energy supply to downregulate anabolic metabolism and shunt 
pathways to utilize alternative energy substrates18. Previous data from our laboratory has 
shown a decrease in AKT activity upon spheroid formation and an accompanying 
induction of dormancy16 and autophagy (Correa, Shepherd, DiMattia, unpublished). We 
now show that the LKB1/AMPK pathway is induced in EOC spheroids, which has 
opposing regulatory effects on mTORC1 compared with what would be observed by 
AKT. Indeed, we show that mTORC1 activity is reduced in spheroids. This result 
indicates that the LKB1/AMPK signalling cascade acts to reduce protein translation and 
induce autophagy, likely in concert with downregulated AKT activity.  
It has been shown in other cell systems that LKB1/AMPK is an important mediator of 
protecting detached epithelial cells from anoikis24,26. Interestingly, targeted knockdown 
of STK11 (LKB1) in our study demonstrated a significant reduction in spheroid cell 
viability yet there was no effect when AMPKα1 activity was reduced.  We confirmed that 
there was no compensatory effect of AMPKα2 expression in PRKAA1-knockdown 
spheroid cells that could explain this lack of effect (Appendix A). This implies that LKB1 
plays an important role in mediating anoikis-resistance and dormancy in EOC spheroids 
independent of AMPK.  AMPK is the most studied downstream target of LKB1. 
However, LKB1 has been called a “master kinase” given its ability to phosphorylate at 
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least 12 other downstream proteins, referred to as AMPK-related kinases (ARKs: 
MARK1, MARK2, MARK3, MARK4, SIK1, SIK2, SIK3, BRSK1, BRSK2, SNRK, 
NUAK1, NUAK2)49. The ARKs have been shown to play roles in many important 
aspects of cell function including cell polarity (MARK, BRSK)50,51, cell proliferation 
(NUAKs)52,53 and CREB-regulated gene transcription (SIKs)54-56. It seems likely that one 
or more of these ARKs are important downstream mediators of the LKB1-dependent 
decrease in cell viability we observe in ovarian cancer spheroids. One likely candidate, 
microtubule affinity-regulating kinase 4 (MARK4), is able to phosphorylate Raptor on 
the same residue as AMPK, resulting in inhibition of mTORC1 signalling57. Another of 
these kinases, NUAK1 may also be an interesting target to investigate in our system, as it 
is able to promote cell survival during periods of nutrient deprivation58. Further studies 
are needed to determine which of the numerous substrates downstream from LKB1 are 
mediating this requirement to maintain cell viability in ovarian cancer spheroids. 
Although literature supports the idea that STK11 acts as a tumour suppressor during 
early steps of tumorigenesis, our STK11 knockdown results provide yet another example 
of a protein, in this case LKB1, exhibiting an important reciprocal metastasis-promoting 
function during late-stage disease. EOC spheroids have the capacity to harbour a niche of 
chemotherapy-resistant cells. Our data supports this idea, and importantly we provide the 
first evidence that AMPK-independent LKB1 signalling may play a significant role in 
adaptive resistance mechanisms in these metastasis-promoting structures.  
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Figure S3.1: LKB1 is located in the cytoplasm in adherent and spheroid EOC cells. 
Immunoblot performed on whole-cell (T), cytoplasmic (C), and nuclear (N) protein 
extracts isolated from ovarian cancer cell lines to determine subcellular localization of 
LKB1 protein.  Lamin A/C and tubulin used as nuclear and cytoplasmic loading controls, 
respectively. 
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Figure S3.2: AICAR and A-769662 have different effects on cell cycle progression 
and apoptosis in adherent ovarian cancer cells. 
(A) Cell cycle analysis (BrdU and PI) by flow cytometry on ovarian cancer cells 
following 24 and 72 hours of treatment with either AICAR or A-769662 (n=2 for each 
cell line). (B) Caspase 3/7 activity 72 hours following treatment with either AICAR or A-
769662 as determined by Caspase-Glo®. Bars: Mean ± SEM. Effect of treatment 
determined by One-way ANOVA (*p<0.05; **p<0.01; ***p<0.001). 
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Figure S3.3: LKB1 and AMPK are expressed in EOC cell lines under adherent 
conditions but activity is low. 
(A, B) Immunoblot performed on a number of ovarian cancer cell lines cultured under 
adherent conditions in order to determine levels of phosphorylated and total LKB1 and 
AMPK as indicated. 
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Chapter 4 
4 Discussion 
4.1 Summary of findings 
 The high level of a mortality associated with high-grade serous ovarian cancer has 
been directly attributed to intra-abdominal metastases, which recur despite aggressive 
surgical and chemotherapeutic interventions. The presence of microscopic disease and 
dormant, chemotherapy-resistant cancer cells is likely the cause of these recurrences. 
Therefore, experimental models that allow us to better understand the biology and 
pathogenesis of dormant high-grade ovarian cancer cells are crucial to uncover more 
effective treatment options for patients with advanced-stage disease. Our studies use a 
highly-relevant, tractable, non-adherent culture system to examine the molecular 
underpinnings of multicellular spheroid formation and subsequent reattachment to an 
adherent substratum. These structures induce dormancy and mimic the spheroid state of 
ovarian cancer cells in ascites, which facilitates the spread of this cancer. 
 I focused on two distinct cellular signalling systems and discovered in the first 
instance that BMP signalling is decreased upon spheroid formation, a process that is 
reversed when these clusters reattach to an adherent substratum (Chapter 2). To examine 
the functional implications of this dynamic regulation, I constitutively activated BMP 
signalling and discovered a detrimental effect on spheroid formation, resulting in smaller, 
more loosely aggregated clusters. Activation of this pathway during spheroid 
reattachment on the other hand, resulted in increased cellular dispersion. These 
phenotypic alterations in spheroid formation and reattachment observed in response to 
BMP signalling, were shown to be mediated, in part, by interaction with the PI3K/AKT 
signalling pathway. Specifically, constitutive activation of BMP signalling resulted in 
enhanced AKT activity, which was shown to contribute to increased spheroid 
reattachment observed as a result of overactive BMP signalling. 
 Given the ability of the PI3K/AKT and BMP signalling pathways to act together 
to alter spheroid formation and reattachment, I chose to examine other key cell survival 
pathways, which might act in concert with AKT in EOC cells. The objective was to 
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identify signalling pathways that may interact to maintain the viability of ovarian cancer 
cells and allow seeding of recurrent disease. In doing so, we expect to identify new 
potential therapeutic targets for which drugs may already exist or lay the ground work for 
use of specific combinatorial treatments. Additional rationale for this route of 
investigation was provided by other work in our laboratory demonstrating an AKT-
dependent induction of dormancy and autophagy in EOC spheroids1. Investigating this 
area of research revealed number of studies that reported AMPK-dependent induction of 
autophagy under conditions of stress such as glucose deprivation and hypoxia2,3. 
Therefore, I hypothesized that, in addition to the AKT pathway, the LKB1/AMPK 
signalling cascade would be an important contributor to spheroid-formation induced 
dormancy.  
AMPK has a unique ability integrate extracellular nutrient and energy signals in 
order to control the metabolic function of cells. I discovered that AMPK activity is 
greatly enhanced in ovarian cancer spheroids and this is associated with enhanced 
phosphorylation of its upstream kinase, LKB1 (Chapter 3). Activation of AMPK is 
detrimental in adherent, proliferating cells but has little effect on dormant, multicellular 
spheroids. On the other hand, targeted knockdown experiments highlight an AMPK-
independent role for LKB1 in survival of cells in suspension. This is the first 
demonstration of a pro-survival function for LKB1, a kinase that has been primarily 
considered to be a tumour suppressor. 
 The data presented in this thesis discusses two signalling pathways that play 
distinct roles in EOC spheroid formation and survival. Both pathways however, present 
potential therapeutic targets for the unique population of non-adherent ovarian cancer 
cells within ascites fluid.  
4.2 BMP signalling plays context-specific roles during 
ovarian cancer spheroid formation and reattachment 
  Although a dichotomous role for TGF-β in carcinogenesis is well-established, 
this is not the case for BMP signalling. More in vitro and in vivo evidence is required to 
determine whether this pathway is indeed oncogenic or tumour suppressive and in which 
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types and stages of cancers this is true. BMP signalling is generally considered a critical 
pathway during development controlling cell differentiation. Therefore, it is reasonable to 
suppose that induction of BMP signalling in cancer cells might be anti-oncogenic causing 
a differentiation-related program to force cancer cells out of the cell cycle. It is also 
possible that BMP signalling has been co-opted by cancer cells in a pro-oncogenic 
manner to facilitate maintenance of the cancer cell phenotype.  
Our study focused on dissecting the contribution of the BMP signalling cascade 
during the various phases of ovarian cancer progression using a biologically-relevant, 
tractable in vitro model system. This model takes into account the unique mode of 
ovarian cancer metastasis, whereby multicellular spheroids represent an important 
conduit through which cells are able to survive until they reach a mesothelial surface 
where re-implantation and invasion are possible.  It has been suggested that ovarian 
cancer cells within multicellular aggregates or spheroids undergo EMT, acquiring more 
mesenchymal characteristics, preparing them to reattach and invade, forming secondary 
metastases when conditions are favourable4,5.  
 The data presented in Chapter 2 confirms that spheroids formed from primary 
ovarian cancer cells undergo EMT, characterized by decreased expression of the E-
cadherin gene. This is supported by previous evidence that E-cadherin expression is 
reduced in cells isolated from ascites compared to their solid tumour counterparts6 as well 
as other studies demonstrating that ovarian cancer cell lines with more mesenchymal 
characteristics have an increased propensity for compact spheroid formation5.  The 
autonomous down-regulation of BMP signalling during spheroid formation and the 
decreased propensity for compact spheroid formation when this pathway is activated 
suggests that BMP signalling may in fact be opposing the natural EMT response of EOC 
spheroids. This is concordance with a study published in 2011 by the Weinburg lab in 
which they documented that the BMP pathway had the ability to antagonize TGF-β-
induced EMT in mammary epithelial cells7. Indeed, activation of BMP signalling within 
EOC spheroids results in increased E-cadherin expression when compared to controls, 
suggesting that inhibition of EMT could be a potential mechanism through which BMP 
signalling decreases spheroid compaction. 
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Although activated BMP signalling in spheroids results in smaller, more loosely 
aggregated clusters this does not result in an overall decrease in cell viability. Therefore, 
it should not be assumed that activation of this pathway is detrimental. Rather, it may 
‘prime’ cells within these aggregates to more readily attach and disperse. Indeed, when 
spheroids with constitutively active BMP signalling are exposed to an adherent 
substratum, they have an increased propensity for reattachment and dispersion. This is 
supported by previous work demonstrating that BMP4 has the ability to enhance motility 
and invasion of adherent primary ovarian cancer cells8,9.  
 Taken together, these findings suggest that inhibition of BMP signalling may in 
fact be a viable therapeutic target through which to prevent EOC spheroid reattachment 
and formation of secondary metastatic lesions. We show that inhibition of the BMP 
pathway using a small molecule inhibitor as well as BMP antagonist, noggin, does in fact 
decrease the ability of cells to disperse from a spheroid following re-introduction to an 
adherent substratum. Since this does not completely prevent spheroids from reattaching, 
it is likely that the BMP signalling pathway acts in conjunction with other pathways 
during this process. 
 Our studies uncovered an interaction between the BMP and AKT signalling 
cascades and demonstrated that these two pathways act in concert to promote EOC 
spheroid reattachment. This finding is supported by other reports demonstrating that the 
PI3K/AKT pathway is required for BMP-induced migration and invasion in gastric, colon 
and pancreatic cancer cells10,11. This highlights the potential for targeting these pathways 
in combination for treatment of metastatic ovarian cancer.  Xenograft models will be 
important to determine whether this interaction is translatable in an in vivo setting. 
Weroha and colleagues recently published elegant work validating the use of a novel 
‘tumourgraft’ model whereby ovarian cancer patient tumour material is minced and 
intraperitoneally injected into immune-compromised mice12. The tumours formed in mice 
recapitulate the clinical and molecular characteristics of the patient tumour but also 
mimic the patient’s clinical response to chemotherapeutic treatment. This is an extremely 
exciting, highly translatable in vivo model with which to test the potential response of an 
patient’s tumour to a targeted therapeutic. Using this model, we would be able to test the 
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therapeutic response of a number of ovarian cancer tumour specimens to treatment with 
the small molecule inhibitors of BMP and AKT signalling that I have in the studies 
described in this thesis. Molecular analysis of these ‘tumourgrafts’ would allow us to 
determine patient-specific responses to modulation of these two signalling pathways prior 
to and following treatment.  
 This work highlights the fact that the BMP signalling pathway exerts the majority 
of its effects during spheroid reattachment and dispersion. Therefore, it would be interest 
to examine the contribution of tumour-stroma interactions in this process and the role that 
the BMP signalling pathway plays in mediating these interactions. Carcinoma-associated 
fibroblasts (CAFs) have become increasingly recognized as important components of the 
tumour microenvironment that can aid in the initiation and progression of a number of 
different cancers including breast, prostate and ovarian13-16. Interestingly, normal 
fibroblasts co-cultured with carcinoma cells results in an irreversible conversion to a CAF 
phenotype, suggesting that fibroblasts exposed to cancer cells exhibit permanent, 
heritable changes13,14,16. Recent studies in ovarian cancer have demonstrated that the 
presence of CAFs can contribute to tumour progression, omental and lymph node 
metastases, in addition to being associated with poor patient prognosis17,18. Fu and 
colleagues were able to obtain primary cultures of CAFs from ovarian cancer patients and 
co-culture these with EOC cells19. Analysis of conditioned medium from this co-culture 
system revealed the presence of number of soluble factors including TGF-β and a number 
of BMPs. Using our in vitro system, it would be of interest to determine the effects of this 
co-culture media on spheroid reattachment both under ambient conditions as well in 
spheroids with constitutively activated BMP signalling and those treated with noggin. 
These studies would provide an additional layer of complexity to our model system, 
allowing us to not only determine the contribution of CAFs to spheroid reattachment and 
dispersion but also allow us to determine the interaction between the BMP signalling 
pathway and this population of cells (Figure 4.1).  
 The results presented in this thesis have uncovered an important role for BMP 
signalling in cellular cohesion and EMT during spheroid formation and cellular motility 
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during reattachment. This has laid the groundwork for preclinical models to investigate 
the utility of targeting this pathway for treatment of advanced-stage ovarian cancer.  
4.3  LKB1 has AMPK-independent effects on cellular 
viability in ovarian cancer spheroids 
 Given the important roles that the AKT signalling pathway plays in EOC 
spheroids both in mediating responses to BMP signalling but also in contributing to 
spheroid formation-induced dormancy, I wanted to identify other candidate pathways 
known to interact with the PI3K/AKT pathway. Taking into account the dormant state of 
the cells within spheroids and their decreased metabolism an obvious candidate for 
investigation was the AMPK signalling cascade given its unique ability to respond to 
changes in extracellular energy and nutrient supply. The AMPK and PI3K/AKT 
signalling pathways converge on mTORC1 and have opposing regulatory effects on this 
complex20. We have demonstrated that in ovarian cancer spheroids decreased AKT 
activity and induction of cellular dormancy is associated with enhanced and sustained 
AMPK activity (Figure 4.1).  
 Other studies in our laboratory have linked cellular dormancy and quiescence 
within multicellular spheroids with induction of autophagy (Correa, DiMattia, and 
Shepherd, unpublished data). AMPK has the ability to directly induce autophagy by 
phosphorylating and positively regulating ULK1, a critical protein for autophagy 
initiation21-23. AMPK can also indirectly induce autophagy through its ability to inhibit 
mTORC1 by phosphorylation of TSC2 and Raptor. A study by Avivar-Valderas and 
colleagues in 2012 highlighted the potential for interaction between mTORC1, AMPK 
and a member of the unfolded protein response (UPR) pathway, protein kinase (PKR)-
like endoplasmic reticulum kinase (PERK) in autophagy induction and anoikis-resistance 
in mammary epithelial cells24. It was noted that in response to loss of ECM attachment 
PERK was able to activate AMPK through its upstream kinase, LKB1 although the 
precise mechanism through which this occurs remains unclear. This suspension-induced 
AMPK activity was required for inhibition of mTORC1 and induction of autophagy. This 
was the first study to implicate the LKB1/AMPK/mTORC1 signalling cascade as a key 
regulator of anoikis in epithelial cells.  
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Figure 4.1: Contribution of BMP and LKB1/AMPK signalling pathways to ovarian 
cancer metastasis. 
A number of pathways and processes are uniquely altered in ovarian cancer spheroids, 
aiding in cellular aggregation and induction of dormancy. Specifically, the BMP 
signalling pathway is down-regulated during ovarian cancer spheroid formation and aids 
in cellular aggregation and cohesion. Alternatively, the LKB1/AMPK signalling cascade 
is up-regulated during spheroid formation and contributes to spheroid formation-induced 
dormancy. Many of these signalling aberrations are reversed during spheroid 
reattachment. We propose that upon spheroid reattachment to serosal surfaces of various 
peritoneal organs (omentum, appendix, intestine), carcinoma-associated fibroblasts 
(CAFs) secrete a number of cytokines, such as BMPs and TGF-βs, to enhance 
proliferation, motility and invasion.  
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Applying these findings to our system, I chose to focus on LKB1 and mTORC1 
as critical upstream and downstream mediators of AMPK signalling in EOC spheroids. 
As discussed in this thesis, suspension-induced AMPK activation in ovarian cancer cells 
is in fact associated with enhanced phosphorylation of its upstream kinase LKB1 and 
decreased activity of mTORC1. Surprisingly, targeted knockdown of AMPK did not have 
any effect on viability of cells within ovarian cancer spheroids. This was unexpected 
given the important role AMPK is known to play in cell survival under nutrient replete 
conditions. However, targeted knockdown of LKB1 results in significant reduction in 
viability of cells within multicellular aggregates, indicating an important role for this 
kinase in anoikis-resistance of ovarian cancer cells independent of AMPK.  
 As described in the introduction to this thesis, LKB1 phosphorylates 12 other 
kinases in addition to AMPK, termed the AMPK-related kinases (ARKs). Interestingly, 
one of these kinases, microtubule affinity-regulating kinase 4 (MARK4) has very recently 
been shown to phosphorylate Raptor on the same residue as AMPK, resulting in 
inhibition of mTORC1 signalling25 (Figure 4.2). Another of these kinases, NUAK1 may 
also be an interesting target to investigate in our system as it has been shown to be a 
target of AKT in addition to LKB126. Similar to AMPK, NUAK1 is able to promote cell 
survival during times of nutrient deprivation27. Although their functions are not as well 
characterized as AMPK, it is likely that one or more of the ARKs may be important 
mediators of the pro-survival functions of LKB1 in our system. Targeted knockdown of 
each of these ARKs (MARK1-4, NUAK1, NUAK2, SIK 1-3, SNRK, BRSK1, BRSK2) 
and assessment of cell viability in suspension would be the most effective method 
through which to determine our target(s) of interest.  
 These studies are the first to identify a pro-survival function for the tumour 
suppressor LKB1 in a metastatic cancer setting. Further studies will focus on examining 
the effect that LKB1 loss has on cellular quiescence and autophagy induction in ovarian 
cancer spheroids, as well as determining downstream mediators of LKB1 in our system. 
Perhaps we have uncovered a unique LKB1 signalling axis crucial in mediating anoikis-
resistance in ovarian cancer cells.   
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Figure 4.2: Proposed mechanisms of dormancy induction in ovarian cancer 
spheroids. 
AMPK and AKT have opposing regulatory effects on mTORC1 via phosphorylation of 
TSC2. mTORC1 activity is decreased in multicellular spheroids and this corresponds 
with decreased AKT activity and enhanced AMPK activation. LKB1 not only functions 
as an upstream kinase for AMPK but also for a number of AMPK-related kinases 
(ARKs). One of these ARKs, MARK4, phosphorylates Raptor leading to inhibition of 
mTORC1. This is another potential kinase with elevated activity in dormant ovarian 
cancer spheroids. We propose that LKB1 is an important mediator of spheroid-formation 
induced dormancy independent of AMPK.  
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4.4 BMP and LKB1 signalling: Is there a connection? 
 The ability to avoid anoikis is an adaptation that is afforded to all metastatic 
ovarian cancer cells. In fact this biologic phenomenon is probably important in a variety 
of cancers that induce ascites formation or pleural effusions including mesothelioma28, 
gastric cancer29 and pancreatic cancer30. We have shown that under non-adherent 
conditions these cells have a propensity to aggregate and form multicellular clusters or 
spheroids, conferring them with a survival advantage. Therapeutic targeting of this 
population of cells while they are suspended within the peritoneal cavity or at the point of 
reattachment to form secondary metastatic lesions would be beneficial since the majority 
of ovarian cancer patients succumb to recurrent, metastatic disease.  In this thesis I have 
specifically focused on two signalling pathways with diverse functions in ovarian cancer 
spheroid biology.  
One of the few studies linking LKB1 to the TGF-β/BMP signalling pathway 
demonstrated that LKB1 is able to phosphorylate Smad4, preventing it from binding 
DNA, resulting in inhibition of both TGF-β and BMP signalling cascades31. Future 
studies could focus on examining potential interaction between these two signalling 
cascades through Smad4 or other transcriptional targets. It would also be important to 
determine whether there may be a functional link between these pathways. Perhaps 
decreased cellular cohesion that occurs as a result of activated BMP signalling will render 
cells in suspension even more susceptible to knockdown of LKB1. It would also be 
interesting to determine the activity of the TGF-β/BMP pathways in cells that have LKB1 
knocked down. This may provide additional mechanistic evidence for the AMPK-
independent effects of LKB1 in our system.  
Both studies discussed in Chapter 2 and 3 of this thesis could be expanded with 
the use of the recent Pax8-Cre p53mut/PTEN-/-/BRCA1/2-/- mouse model of high grade 
serous cancer (HGSC)32. In this model, disease begins in the fallopian tube secretory 
epithelium with the development of STIC lesions which progress to HGSC, which 
metastasizes throughout the peritoneum, similar to the human disease. This is an 
extremely relevant model, as it highly resembles the progression of human ovarian cancer 
and provides opportunities to study the earliest events in initiation of HGSC.  
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 The majority of studies to date have focused on BMPs in the ovary and OSE. 
However, now that it is clear the OSE is not the origin of high-grade serous ovarian 
cancer, it would be of interest to determine the role that the BMP signalling pathway 
plays in the fallopian tube. To set the stage it will be relevant to determine the expression 
of various BMPs and their receptors by IHC in STIC lesions from human and mouse 
fallopian tube. Based on the expression levels, knockout of these specific components of 
the pathway using the aforementioned mouse model would provide insight into the role 
of this pathway in initiation and early pathogenesis of high-grade serous ovarian cancer. 
This would nicely complement the studies presented in this thesis where we demonstrate 
a role for this pathway in advanced-stage HGSC.  
 Very little is known about the role of LKB1 in ovarian cancer pathogenesis. 
However, recent studies from the Teixeria lab demonstrate that loss of Pten and STK11 in 
the OSE results in formation of high-grade papillary serous carcinomas33. This suggests 
that loss of LKB1 may be important in tumour establishment, but based on the findings 
presented in this thesis, LKB1 also aids in cell survival during later metastatic stages. 
However, the transgenic mouse model of high-grade serous ovarian cancer discussed 
above is a more relevant model with which to test this hypothesis since it provides a more 
accurate representation of disease initiation. Knockout of STK11 in addition to Pten Tp53 
and Brca1/2 specifically in the secretory epithelium of the fallopian tube may in fact 
result in more rapid disease progression in this model. Ideally, all combinations of this 
knockouts focusing on this gene set would provide the most relevant information 
regarding the importance of LKB1 in the initiation and progression of HGSC. These 
mouse models would indicate which genes, in combination with homozygous or 
heterozygous loss of LKB1 activity might predispose secretory epithelial cells to 
transformation and metastasis to the ovary and peritoneal cavity.  These studies would 
help to determine at which stage of disease progression LKB1 activity is important for 
either disease progression or inhibition, providing additional support for the findings 
discussed in Chapter 3. 
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4.5 Synthesis 
 The goal of this thesis was to contribute to our knowledge of ovarian cancer 
metastasis, particularly focusing on multicellular spheroids as major contributors to 
formation of secondary metastatic lesions. The data presented in Chapters 2 and 3 
characterizes two signalling pathways that are dysregulated in EOC spheroids and 
discusses the potential for targeting these pathways therapeutically. Overall, this body of 
work has contributed to the field of ovarian cancer metastasis by uncovering unique and 
complex interactions between a number of signalling cascades and provided rationale for 
investigating these pathways further in preclinical models. Understanding the unique 
characteristics afforded to non-adherent ovarian cancer cells is critical for the 
identification of more effective treatment regimes particularly for late-stage recurrent 
disease. 
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Appendix A: Additional Figures 
 
 
Figure 1: siRNA-mediated knockdown of PRKAA2 does not affect levels of AMPKα. 
Immunoblot performed on proteins as indicated 72 hours after transfection  of adherent 
EOC cells with siRNA. AMPKα expression and activity is decreased by PRKAA1 
knockdown but not PRKAA2. 
  
172 
 
Appendix B: Ethics Approval 
 
173 
 
 
 
 
 
 
 
 
174 
 
Appendix C: Summary of Clinical Data for EOCs 
 
  
Sample Age Histological Subtype Grade Stage 
EOC57 46 Serous adenocarcinoma 3 IIIC 
EOC61 78 Serous adenocarcinoma 3 IIIC 
EOC63 70 Carcinosarcoma 3 (High) IIIC 
EOC116 64 Papillary serous 2 IIIC 
EOC120 70 Goblet cell carcinoma n.a. n.a. 
EOC122 56 Serous carcinoma High IIIC 
EOC129 74 Serous carcinoma High IIIC 
EOC132 59 Serous Adenocarcinoma High IIIC 
EOC136 42 Serous ovarian carcinoma High IV 
EOC137 77 Serous Carcinoma High IIIC 
EOC140 76 poorly differentiated carcinoma High IIIC 
EOC148 67 Bilateral ovarian serous carcinoma High IC* 
EOC149 69 Serous adenocarcinoma High IIIC 
EOC153 48 Serous (60%) and endometriod (40%) High IIA 
EOC154 66 Serous intra-abdominal carcinomatosis High IIIC 
EOC155 66 Serous adenocarcinoma (poorly-differentiated) High IIIC 
EOC156 67 Serous High IIIC 
EOC158   45 Papillary serous 2/3 IIIC 
EOC159 57 Serous adenocarcinoma High n.a. 
EOC160 47 Cystadenofibroma (benign) n.a. n.a. 
EOC171 65 Serous carcinoma High IIIC 
iOVCA130 59 Serous Carcinoma High IIIC 
iOVCA147-E2 43 Serous (70%) and clear cell (30%) adenocarcinoma 2 IIC 
iOVCA198 65 serous adenocarcinoma High n.a. 
*, stage was defined as at least IC for this patient. 
n.a., not available 
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  for	  keeping	  accurate	  laboratory	  records	  
• Presented	  findings	  in	  two	  conferences	  	  
	  
TEACHING	  EXPERIENCE	  	  
Undergraduate	  Teaching	  assistant,	  Medical	  Science	  4461,	  University	  of	  
Western	  Ontario	  
	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Jan	  2012-­‐Aptil	  2012	  
Undergraduate	  Teaching	  assistant,	  Medical	  Science	  4900,	  University	  of	  
Western	  Ontario	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sept	  2011-­‐present	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Honours	  Student	  Mentorship	  Arlan	  Walsh,	  Department	  of	  Biochemistry,	  University	  of	  Western	  Ontario	  	  Sept	  2010-­‐April	  2011	  
• Responsible	  for	  training	  student	  in	  proper	  laboratory	  techniques,	  overseeing	  daily	  experiments	  as	  well	  as	  providing	  expertise	  crucial	  for	  project	  completion	  	  Anton	  Shimanovsky,	  Department	  of	  Biology,	  McMaster	  University	  	  Sept	  2009-­‐Aug	  2010	  
• Responsible	  for	  training	  student	  in	  proper	  laboratory	  techniques	  as	  well	  as	  overseeing	  daily	  experiments	  Dominik	  Dobransky,	  Department	  of	  Biochemistry,	  University	  of	  Western	  Ontario	  Sept	  2009-­‐April	  2010	  
• Responsible	  for	  training	  student	  in	  proper	  laboratory	  techniques,	  overseeing	  daily	  experiments	  as	  well	  as	  providing	  expertise	  crucial	  for	  project	  completion	  
	  
Undergraduate	  Teaching	  assistant,	  Anatomy	  and	  Cell	  Biology	  3319,	  University	  
of	  Western	  Ontario	  	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  Sept	  2008-­‐April	  2009	  	  
SCHOLARSHIPS	  
	  
Ontario	  Graduate	  Scholarship	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sept.	  2012-­‐Sept.	  2013	  	  
CIHR	  student	  training	  program	  in	  Cancer	  Research	   	  	  	  	  	  	  	  	  	  	  	  Sept.	  2009-­‐Sept.	  2013	  
	  
PUBLICATIONS	  
	  
	  
Peer-­‐Reviewed	  Publications	  Correa	  RJ,	  Ramos	  Valdes	  Y,	  Peart	  TM,	  Fazio	  EN,	  Bertrand	  M,	  McGee	  J,	  Préfontaine	  M,	  Sugimoto	  A,	  Dimattia	  GE,	  Shepherd	  TG	  (2014).	  Combination	  of	  AKT	  inhibition	  with	  autophagy	  blockade	  effectively	  reduces	  ascites-­‐derived	  ovarian	  cancer	  cell	  viability.	  
Carcinogenesis.	  
	  
Peart	  T,	  Correa	  R,	  DiMattia	  GE,	  Shepherd	  TG	  (2012).	  BMP	  signalling	  controls	  the	  malignant	  potential	  of	  ascites-­‐derived	  human	  epithelial	  ovarian	  cancer	  cells	  via	  Akt	  kinase	  activation	  in	  an	  in	  vitro	  metastasis	  model.	  Clinical	  and	  Experimental	  
Metastasis	  	  	  Correa	  R,	  Peart	  T,	  Ramos-­‐Valdes	  Y,	  DiMattia	  GE,	  Shepherd	  TG	  (2011).	  Modulation	  of	  AKT	  activity	  is	  associated	  with	  reversible	  dormancy	  in	  ascites-­‐derived	  epithelial	  ovarian	  cancer	  spheroids.	  Carcinogenesis.	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  model	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  Research	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Peart	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  Bertrand	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  Sugimoto	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  Prefontaine	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  DiMattia	  GE	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  protein	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Research	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  London,	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  GE	  and	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  prize	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  oral	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Peart	  T,	  Bertrand	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  Sugimoto	  AK,	  Prefontaine	  M,	  DiMattia	  GE	  and	  Shepherd	  TG	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  protein	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  (AMPK)	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  upregulated	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